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ABSTRACT

The present invention concerns compounds, compositions
containing these compounds, and methods of using these
compounds and compositions as inhibitors ofStat3 signaling,
Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding,
and/or aberrant cell growth in vitro or in vivo, e.g., as anticancer agents for treatment of cancer, such as breast cancer.
The compounds of the invention include, but are not limited
to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC
75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
Other non-malignant diseases characterized by proliferation
of cells that may be treated using the compounds of the
invention, but are not limited to, cirrhosis of the liver; graft
rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1
diabetes, lupus and multiple sclerosis. The invention further
includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying
inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a
method of identifying anti-cancer agents.
16 Claims, 28 Drawing Sheets
(1 of28 Drawing Sheet(s) Filed in Color)
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SMALL MOLECULE INHIBITORS OF STAT3
WITH ANTI-TUMOR ACTIVITY

disruptors of Stat3 :Stat3 dimers (Shao, H. et al. J Biol. Chem.,
2004, 279:18967-18973; Song, H. et al. Proc Natl Acad Sci
USA, 2005, 102:4700-4705).

CROSS-REFERENCE TO RELATED
APPLICATION
The present application claims the benefit of U.S. Provisional Application Ser. No. 60/801,750, filed May 19, 2006,
which is hereby incorporated by reference herein in its
entirety, including any figures, tables, nucleic acid sequences,
amino acid sequences, and drawings.
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BACKGROUND OF THE INVENTION
Signal transduction proteins important in carcinogenesis
and cancer progression present attractive targets forthe development of novel anticancer therapeutics. The family of proteins, Signal Transducer and Activator of Transcription
(STAT), are activated in response to cytokines and growth
factors and promote proliferation, survival, and other biological processes (Bromberg, J. Breast Cancer Res., 2000, 2:8690; Darnell, J.E., Jr. Nat. Rev. Cancer, 2002, 2:740-749; Yu,
H. and Jove, R.Nat. Rev. Cancer, 2004, 4:97-105). STATs are
activated by phosphorylation of a critical tyrosine residue,
which is mediated by growth factor receptor tyrosine kinases,
Janus kinases or the Src family kinases. Upon tyrosine phosphorylation, dimers ofSTATs formed between two phosphorylated monomers translocate to the nucleus, bind to specific
DNA-response elements in the promoters of target genes, and
induce gene expression. Aberrant activity of one of the family
members, Stat3, contributes to carcinogenesis and tumor progression by upregulating gene expression and promoting dysregulated growth, survival, and angiogenesis, and modulating
immune responses (Darnell, J.E., Jr. Nat. Rev. Cancer, 2002,
2:740-749; Yu, H. and Jove, R. Nat. Rev. Cancer, 2004, 4:97105; Bromberg, J. and Darnell, J. E., Jr. Oncogene, 2000,
19:2468-2473; Bowman, T. et al. Oncogene, 2000, 19:24742488; Turkson, J. and Jove, R. Oncogene, 2000, 19:66136626; Buettner, R. et al. Clin. Cancer Res., 2002, 8:945-954;
Turkson, J. Expert Opin Ther Targets, 2004, 8:409-422; Darnell, J. E. Nat. Med., 2005, 11 :595-596).
As a critical step in STAT activation (Shuai, K. et al. Cell,
1994, 76:821-828), the dimerization between two STAT
monomers presents an attractive target to abolish Stat3 DNAbinding and transcriptional activity and inhibit Stat3 biological functions (Turkson, J. et al. J. Biol. Chem., 2001, 276:
45443-45455; Turkson, J. et al. Mal Cancer Ther, 2004,
3:261-269). Stat3 dimerization relies on the reciprocal binding of the SH2 domain of one monomer to the pTyr peptide
containingAPY*LKT (Ala-Pro-pTyr-Leu-Lys-Thr) (SEQ ID
NO: 1) sequence of the other Stat3 monomer. To pursue the
development of inhibitors of Stat3 signaling, key structural
information gleaned from the X-ray crystal structure of the
Stat3~ homodimer (Becker, S. et al. Nature, 1998, 394:145151) was used in the computational modeling and automated
docking of small-molecules into the SH2 domain of a Stat3
monomer, relative to the bound native pTyr peptide, in order
to identify binders of the Stat3 SH2 domain, and potentially
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Structure-based high throughput virtual screening of the
National Cancer Institute (NCI) Chemical libraries identified
three compounds that selectively inhibit Stat3 DNA-binding
activity in vitro, with IC 50 values of 65-86 µM, namely NSC
74859, NSC 59263, and NSC 42067. The highest scoring
compound, NSC 7 4859 (re-synthesized as a pure sample and
named S3I-201), selectively inhibits Stat3 DNA-binding
activity in vitro with an IC 50 value of 86±33 µM. Furthermore, S3I-201 induces growth inhibition and apoptosis of
malignant cells in part by inhibiting constitutively-active
Stat3, and induces human breast tumor regression in
xenograft models. These findings support the therapeutic
potential of S3I-201 and other Stat3 inhibitors against tumors
harboring aberrant Stat3 activity.
The present invention concerns isolated compounds, compositions containing these compounds, and methods of using
these compounds and compositions as inhibitors of Stat3
and/or as inhibitors of aberrant cell growth, e.g., as anticancer agents. In one embodiment, the compound has a structure described by Formula A, B, C, D, E, or Fin FIG. 10, 11,
or 12A-D, respectively, or a pharmaceutically acceptable salt
or analog thereof. In another embodiment, the compound is
NSC 74859 (S3I-201; shown in FIG. 7), NSC 59263 (shown
in FIG. 8), NSC42067 (shown in FIG. 9), NSC 75912 (shown
in FIG. 50), NSC 11421 (shown in FIG. 49), NSC 91529
(shown in FIG. 51), NSC 263435 (shown in FIG. 48), or a
pharmaceutically acceptable salt or analog of any of the foregoing. In another embodiment, the compound is an analog of
S3I-201 shown in FIGS. 13-47, i.e., a compound selected
from the group consisting of HL2-006-l, HL2-006-2, HL2006-3, HL2-006-4, HL2-006-5, HL2-011-1, HL2-0ll-2,
HL2-011-3, HL2-011-4, HL2-0ll-5, BG2069-l, HL2-0ll6, HL2-0ll-7, HL2-005, HL2-003, BG2066, BG2074,
BG3004, BG3006A, BG3006B, BG3006D, BG3009,
RPM381, RPM384, RPM385, RPM405, RPM411, RPM407,
RPM412, RPM408, RPM410, RPM415, RPM416, RPM418,
RPM418-A, RPM427, RPM431, RPM432, RPM444,
RPM448, RPM445, RPM447, RPM452, RPM202, or a pharmaceutically acceptable salt or analog of any of the foregoing. In another embodiment, the compound is one listed in
Table 4, or a pharmaceutically acceptable salt or analog
thereof.
One aspect of the invention concerns a method of treating
a proliferation disorder in a subject, comprising administering an effective amount of at least one compound of the
invention to the subject. In one embodiment, the disorder is
mediated by cells harboring constitutively-active Stat3.
Another aspect of the invention concerns a method of suppressing the growth of malignant cells, comprising contacting
the cells in vitro or in vivo with an effective amount of at least
one compound of the invention. In one embodiment, the
malignant cells harbor constitutively-active Stat3.
Another aspect of the invention concerns a method of
inducing apoptosis in malignant cells, comprising contacting
the cells in vitro or in vivo with an effective amount of at least
one compound of the invention. In one embodiment, the
malignant cells harbor constitutively-active Stat3.
Another aspect of the invention concerns a method of
inhibiting constitutive activation ofStat3 in cells, comprising
contacting the cells in vitro or in vivo with an effective
amount of at least one compound of the invention.
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Another aspect of the invention concerns a method of preventing Stat3 dimerization in a mammalian cell, the method
comprising contacting the cell in vitro or in vivo with an
effective amount of at least compound of the invention.
Another aspect of the invention concerns a method of disrupting Stat3-DNA binding, the method comprising contacting the Stat3 with an effective amount of at least one compound of the invention.
Another aspect of the invention concerns a method of disrupting Stat5-DNA binding, the method comprising contacting the Stat5 with an effective amount of at least one compound of the invention.
Another aspect of the invention concerns an in-vitro
screening test for the presence of malignant cells in a mammalian tissue, the test including: obtaining a sample containing viable cells of the tissue; culturing the sample under
conditions promoting growth of the viable cells contained
therein; treating the cultured sample with a compound of the
invention; and analyzing the treated sample by a method
effective to determine percent apoptosis of cells as an indicator of presence of malignant cells in the sample.
Another aspect of the invention concerns a method ofidentifying inhibitors of constitutive Stat3 activation, Stat3-DNA
binding, Stat5-DNA binding, and/or Stat3 dimerization, the
method comprising selecting a compound having a structure
of Formula A, B, C, D, E, or F (shown in FIGS. 10-12A-D);
and determining whether the compound inhibits constitutive
Stat3 activation, disrupts Stat3-DNA binding, disrupts Stat5DNA binding, prevents (e.g., reduces incidence of) Stat3
dimerization, or determining two or more of the foregoing.
Another aspect of the invention concerns a method ofidentifying anti-cancer agents, the method comprising selecting a
compound having a structure of Formula A, B, C, D, E, or F
(shown in FIGS. 10-12A-D); and determining whether the
compound inhibits the growth of cancer cells in vitro or in
vivo (e.g., in an animal model).

incubated withS3I-201 or without (control, 0.05% DMSO) in
the presence or absence of increasing amount of cell lysates
containing inactive Stat3 protein (monomer), inactive Stat!
protein (monomer), inactive Stat5 protein (monomer), or Src
protein prior to incubation with radio labeled hSIE probe and
subjecting to EMSA analysis. FIG. 2B-2 shows SDS-PAGE
and Western blot analysis of cell lysate preparations of equal
total protein containing inactive Stat3 (monomer), Stat!
(monomer), or Stat5 (monomer), or Src protein probing with
anti-Stat3, anti-Stat!, anti-Stat5, or anti-Src antibody. FIG.
2C-l shows SDS-PAGE and Western blot analysis of Stat3YFP immunoprecipitates (i.p. YFP, left panels) probing for
FLAG-Stat3 (anti-FLAG, upper panel) or Stat3-YFP (antiYFP, lower panel), or of FLAG-Stat3 immunoprecipitates
(i.p. FLAG, right panels) probing for Stat3-YFP (anti-YFP,
lower panel) or FLAG-Stat3 (anti-FLAG, upper panel). FIG.
2C-2 shows SDS-PAGE and Western blot analysis ofwholecelllysates from FLAG-ST3-transiently-transfected cells (input) treated with S3I-201 or untreated (control) probing for
FLAG. FIG. 2D shows in vitro ELISA for the binding of
Lck-SH2-GST to the conjugate biotinylated pTyr-peptide
(EPQpYEEIEL (wherepY represents pTyr)) (SEQ ID N0:2),
and effects of increasing concentration of S3I-201. FIG. 2E
shows EMSA analysis of nuclear extract preparations from
v-Src-transformed mouse fibroblasts (NIH3 T3/v-Src) treated
for the indicated times or from the human breast cancer
MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells
treated for 48 hours with 100 µM S3I-201 and incubated with
radiolabeled hSIE probe. FIG. 2F shows SDS-PAGE and
Western blot analysis ofwhole-cell lysates from NIH3T3/vSrc fibroblasts untreated (control) or treated with S3I-201
(100 µM, 24 hours) probing with anti-pTyr705 Stat3 or antiStat3 antibody. FIGS. 2G-l, 2G-2, 2G-3, and 2G-4 show
SDS-PAGE and Western blot analysis of cell lysates prepared
from NIH3T3/v-Src or EGF-stimulated NIH3T3/hEGFR
untreated (control) or treated with S3I-201 (100 µM, 24
hours) probing with antibodies against pShc (FIG. 2G-l),
pErkl/2 (pp42/pp44), Erkl/2 (FIG. 2G-2), pSrc (FIG. 2G-3),
or ~-actin, or anti-phosphoTyr antibody, clone 4G10 (FIG.
2G-4). Positions of STATs:DNA complexes or proteins in gel
are labeled; control lanes represent nuclear extracts treated
with 0.05% DMSO, and nuclear extracts or cell lysates prepared from 0.05% DMSO-treated cells; asterisks (*) indicates supershifted complexes ofSTAT:probe:antibody in the
presence of anti-Stat!, anti-Stat3 or anti-Stat5 antibody; values are the mean and S.D. of three independent determinations.
FIGS. 3A-3C show that S3I-201 suppresses Stat3-dependent but not Stat3-independent transcriptional activity.
Luciferase reporter activities in cytosolic extracts prepared
from normal mouse fibroblasts (NIH3T3) transiently
co-transfected with the Stat3-dependent (pLucTKS3 [FIG.
3A]), or the Stat3-independent (pLucSRE [FIG. 3B] or
~-Casein promoter-driven Luc [FIG. 3C]) luciferase reporters together with a plasmid expressing the v-Src oncoprotein
that activates all three reporters, and untreated (0.05%
DMSO, control) or treated with 100 µM S3I-201 for 24.
Values are the mean and S.D. of three independent determinations.
FIGS. 4A-4G show that S3I-201 inhibits anchorage-dependent and-independent growth only of cells that contain
persistently-active Stat3. Normal mouse fibroblasts
(NIH3T3) (FIG. 4A) and v-Src transformed counterparts
(NIH3T3/v-Src) (FIG. 4B), as well as the human breast carcinoma cells (MDA-MB-453 [FIG. 4C]), MDA-MB-435
[FIG. 4D], MDA-MB-231 [FIG. 4E], or MDA-MB-468 [FIG.
4F]) were untreated (0.05% DMSO, control) or treated with
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BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawing(s) will be provided by the
Office upon request and payment of the necessary fee.
FIGS. lA-lB showdockingofS3I-201(NSC74859)tothe
SH2 domain ofStat3. FIG. lA depicts S3I-201 docked to the
SH2 domain of Stat3; a solvent accessible surface of the
protein (rendered on a 6 A shell of residues surrounding the
ligand) is shown. It is color coded according to the electrostatic potential. Hydrogen bonding to Lys 591, Ser 611, Ser
613, and Arg 609 is shown by white dashed lines. Carbon
atoms of S3I-201 are shown in green. FIG. lB depicts S3I201 docked to the SH2 domain of Stat3 along with pTyr
peptide. Coloring for pTyr peptide is as follows: (P: red, Y*:
pink; L: orange; K: green).
FIGS. 2A-1, 2A-2, 2B-1, 2B-2, 2C-l, 2C-2, 2D, 2E, 2F,
2G-l, 2G-2, 2G-3, and 2G-4 show the effects ofS3I-201 on
STATs, She, Src, and Erks activation, and on Lck-SH2
domain-phosphopeptide binding. In FIGS. 2A-1 and 2A-2,
nuclear extracts containing activated Stat!, Stat3, and/or
Stat5 proteins were pre-incubated with or without S3I-201 for
30 minutes at room temperature prior to incubation with
radiolabeled hSIE probe that binds Stat! and Stat3 or MGFe
probe that binds Stat! and Stat5, or nuclear extracts were
incubated with anti-Stat!, anti-Stat3, or anti-Stat5A antibody
for 30 minutes at room temperature prior to incubation with
radiolabeled probes, and subjecting to EMSA analysis. In
FIG. 2B-1, cell lysates containing activated Stat3 were pre-
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100 µM S3I-201 and counted by trypan blue exclusion on
each of four days for viable cell number. In FIG. 4G, v-Src
transformed mouse fibroblasts (NIH3T3/v-Src) and their
v-Ras transformed counterparts (NIH3 T3/v-Ras) were grown
in soft-agar suspension and untreated (0.05% DMSO, control) or treated with 100 µM S3I-201 every 3 days until large
colonies were visible, which were enumerated. Values are the
mean and S.D. of3-4 independent determinations.
FIGS. SA-SC show that S3I-201 inhibits Cyclin Dl, BclxL and Survivin expression and induces apoptosis in a Stat3dependent manner. In FIG. SA, normal NIH3T3 mouse fibroblasts and their v-Src transformed counterparts (NIH3T3/vSrc ), and the human breast carcinoma MDA-MB-453 and
MDA-MB-435 cell lines were untreated (0.05% DMSO) or
treated with 100-300 µM S3I-201 for 48 hours and subjected
to Annexin V staining and Flow Cytometry. In FIG. 4B,
human breast carcinoma MDA-MB-231 cells were transfected with pcDNA3 (mock), Stat3C or untransfected (Non),
or the v-Src transformed mouse fibroblasts (NIH3 T3/v-Src)
were transfected with pcDNA3 (mock), N-terminus ofStat3
(ST3-NT) or the Stat3 SH2 domain (ST3-SH2) for 4 hours.
Twenty four hours after transfection, cells were untreated
(0.05% DMSO, (-))or treated(+) with 100 µM S3I-201 for
an additional 24 hours and subjected to Annexin V staining
and Flow Cytometry. FIG. SC shows SDS-PAGE and Western
blot analysis ofwhole-cell lysates prepared from the v-Srctransformed mouse fibroblasts (NIH3 T3/v-Src) or the human
breast cancer MDA-MB-231 cells untreated (DMSO, control) or treated with 100 µM S3I-201 for 48 hours probing
with anti-Cyclin Dl, Bcl-xL and Survivin antibodies. Values
are the mean and S.D. of six independent determinations.
Western blot data are representative of3 independent analyses.
FIGS. 6A-6C show tumor growth inhibition by S3I-201. In
FIG. 6A, human breast (MDA-MB-231) tumor-bearing mice
were given S3I-201 (5 mg/kg) i.v. every 2 or every 3 days.
Tumor sizes were monitored every 2 to 3 days, converted to
tumor volumes, and plotted. In FIG. 6B, upon completion of
study 3 days after the last S3I-201 injection, animals were
sacrificed and tumor from one control animal (DMSOtreated) or residual tumor tissue from S3I-201 treated (T 1 and
T2) mice were extracted and lysate preparations of equal total
proteins were analyzed for Stat3 activation by incubating
withradiolabeled hSIE probe and subjecting to EMSA analysis (lanes 1 to 3 ), or lysates from control tumor tissue of equal
protein were pre-incubated with or without increasing concentration of S3I-201 prior to incubation with radiolabeled
hSIE probe and subjecting to EMSA analysis (lanes 1, 4, 5
and 6). In FIG. 6C, lysate preparations from extracted tumor
tissue in control or treated (Tl and T2) were subjected to
SDS-PAGE and Western blot analysis for pTyr Stat3 (pYStat3, upper panel) and total Stat3 (lower panel). Values are the
mean and S.D. of eight tumor-bearing mice each. Positions of
Stat3:DNA complexes are shown.
FIG. 7 shows the chemical structure ofNSC-74859 (also
referred to herein as S3I-201).
FIG. 8 shows the chemical structure ofNSC-59263.
FIG. 9 shows the chemical structure ofNSC-42067.
FIG. 10 shows the chemical structure of formula A, encompassing some embodiments of the invention. R, if present
=Hor OH; Y=O, NH, NR, CH 2 , CHR, or CR2 ; and X, if
present=a phosphate mimic, e.g., C0 2 H, S03 H, P0 3 H, N0 2 ,
CH 2 C0 2 H, or CF 2 C0 2 H, CF(C0 2 H) 2 tetrazole.
FIG. 11 shows the chemical structure of formula B, encompassing some embodiments of the invention. R, if present

=H or OH; X, if present=phosphate mimic, e.g., C0 2 H,
S03 H, P0 3 H, N0 2 , CH 2 C0 2 H, or CF 2 C0 2 H, CF(C0 2 H) 2
tetrazole.
FIGS. 12A-12D show the structures ofT-shapedmolecules
(Formulas C, D, E, and F, respectively) that bind in the SH2
binding groove. The hydrophobic group containing R 2 binds
in a STAT3 hydrophobic pocket formed from Ile634, Ile597,
Lys591, and Arg595. In FIGS. 12A-12D, the XNH groups
have a transposed arrangement (NHX) with respect to one
another. Referring to FIGS. 12A-12D, R 1 and R 2 , if present,
can be an aliphatic or aromatic group; X, if present =CO,
S0 2 , CONH, or alkyl; Z, if present, is alkyl; and phosphate
mimic=that shown in FIGS. 10 and 11, e.g., C0 2 H, S03 H,
P0 3 H, N0 2 , CH 2 C0 2 H, CF 2 C0 2 H, orCF(C0 2 H) 2 tetrazole.
Preferably, R 2 is a hydrophobic group or part of a hydrophobic group. In one embodiment, R 1 , if present, is H, alkyl,
alkenyl, cycloalkyl, heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, and aryl, any of which may be optionally
substituted; and R 2 , if present is H, alkyl, alkenyl, cycloalkyl,
heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, and
aryl, any of which may be optionally substituted. In a preferred embodiment, Rv if present, is aryl, substituted aryl,
heteroaryl or alkyl; and R 2 , if present is a hydrophobic group
such as aryl, substituted aryl, heteroaryl or alkyl.
FIG. 13 shows the chemical structure of the compound
HL2-006-l, an analog of S3I-201.
FIG. 14 shows the chemical structure of the compound
HL2-006-2, an analog of S3I-201.
FIG. lS shows the chemical structure of the compound
HL2-006-3, an analog of S3I-201.
FIG. 16 shows the chemical structure of the compound
HL2-006-4, an analog of S3I-201.
FIG. 17 shows the chemical structure of the compound
HL2-006-5, an analog of S3I-201.
FIG. 18 shows the chemical structure of the compound
HL2-011-1, an analog of S3I-201.
FIG. 19 shows the chemical structure of the compound
HL2-011-2, an analog of S3I-201.
FIG. 20 shows the chemical structure of the compound
HL2-011-3, an analog of S3I-201.
FIG. 21 shows the chemical structure of the compound
HL2-001-4, an analog of S3I-201.
FIG. 22 shows the chemical structure of the compound
HL2-011-5, an analog of S3I-201.
FIG. 23 shows the chemical structure of the compound
BG2069-l, an analog of S3I-201.
FIG. 24 shows the chemical structure of the compound
HL2-011-6, an analog of S3I-201.
FIG. 2S shows the chemical structure of the compound
HL2-011-7, an analog of S3I-201.
FIG. 26 shows the chemical structure of the compound
HL2-005, an analog of S3I-201.
FIG. 27 shows the chemical structure of the compound
HL2-003, an analog of S3I-201.
FIG. 28 shows the chemical structure of the compound
BG2066, an analog of S3I-201.
FIG. 29 shows the chemical structure of the compound
BG2074, an analog of S3I-201.
FIG. 30 shows the chemical structure of the compound
BG3004, an analog of S3I-201.
FIG. 31 shows the chemical structure of the compound
BG3006A, an analog of S3I-201.
FIG. 32 shows the chemical structure of the compound
BG3006B, an analog of S3I-201.
FIG. 33 shows the chemical structure of the compound
BG3006D, an analog of S3I-201.
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FIG. 34 shows the chemical structure of the compound
BG3009, an analog of S3I-201.
FIG. 35 shows the chemical structure of compounds
RPM381, RPM384, and RPM385, wherein X=H, C0 2 Et,
and C0 2 H, respectively.
FIG. 36 shows the chemical structure of compounds
RPM405 and RPM411, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 37 shows the chemical structure of compounds
RPM407 and RPM412, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 38 shows the chemical structure of compounds
RPM408 and RPM410, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 39 shows the chemical structure of compounds
RPM415 and RPM416, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 40 shows the chemical structure of compounds
RPM418 and RPM418-A, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 41 shows the chemical structure of compound
RPM427, wherein X=C0 2 H.
FIG. 42 shows the chemical structure of compound,
RPM431, whereinX=C0 2 Me.
FIG. 43 shows the chemical structure of compound
RPM432, wherein X=C0 2 H.
FIG. 44 shows the chemical structure of compounds
RPM444 and RPM448, wherein X=C0 2 Et and C0 2 H,
respectively.
FIG. 45 shows the chemical structure of compounds
RPM445 and RPM447, wherein X=C0 2 Et and X=C0 2 H,
respectively.
FIG. 46 shows the chemical structure of compound
RPM452, wherein X=C0 2 H.
FIG. 47 shows the chemical structure of compounds
RPM202.
FIG. 48 shows the chemical structure ofNSC-263435.
FIG. 49 shows the chemical structure ofNSC-11421.
FIG. 50 shows the chemical structure ofNSC-75912.
FIG. 51 shows the chemical structure ofNSC-91529.

phosphotyrosine peptide derived from the X-ray crystal structure of the Stat3~ homodimer. S3I-201 inhibits Stat3:Stat3
complex formation, and Stat3 DNA-binding and transcriptional activities. Furthermore, S3I-201 inhibits growth and
induces apoptosis preferentially in tumors cells that contain
persistently activated Stat3. Constitutively-dimerized and
active Stat3C and Stat3 SH2 domain rescue tumor cells from
S3I-201-induced apoptosis. Finally, S3I-201 inhibits the
expression of the Stat3-regulated genes Cyclin Dl, Bcl-xL
and Survivin, and inhibits the growth of human breast tumors
in vivo. These findings strongly suggest that the antitumor
activity of S3I-201 is mediated in part through inhibition of
aberrant Stat3 activation and provide the proof-of-concept for
the potential clinical use ofStat3 inhibitors, such as S3I-201,
in tumors harboring aberrant Stat3.
Aspects of the invention include, but are not limited to,
Stat3 inhibitors, compositions comprising these compounds,
and methods of using these compounds and compositions as
inhibitors ofStat3 and/or as inhibitors of aberrant cell growth,
e.g., as anti-cancer agents. In one embodiment, the compound
has a structure encompassed by Formula A, B, C, D, E, or Fin
FIGS.10-12A-D, respectively, or a pharmaceutically acceptable salt or analog thereof. In another embodiment, the compound is NSC 74859 (S3I-201; shown in FIG. 7), NSC 59263
(shown in FIG. 8), NSC42067 (shown in FIG. 9), NSC 75912
(shown in FIG. 50), NSC 11421 (shown in FIG. 49), NSC
91529 (shown in FIG. 51), NSC 263435 (shown in FIG. 48),
or a pharmaceutically acceptable salt or analog of any of the
foregoing. In another embodiment, the compound is an analog of S3I-201 shown in FIGS. 13-47, i.e., a compound
selected from the group consisting of HL2-006- l, HL2-0062, HL2-006-3, HL2-006-4, HL2-006-5, HL2-011-1, HL2011-2, HL2-011-3, HL2-011-4, HL2-011-5, BG2069-l,
HL2-011-6, HL2-011-7, HL2-005, HL2-003, BG2066,
BG2074, BG3004, BG3006A, BG3006B, BG3006D,
BG3009, RPM381, RPM384, RPM385, RPM405, RPM411,
RPM407, RPM412, RPM408, RPM410, RPM415, RPM416,
RPM418, RPM418-A, RPM427, RPM431, RPM432,
RPM444, RPM448, RPM445, RPM447, RPM452, and
RPM202, or a pharmaceutically acceptable salt or analog of
any of the foregoing. In another embodiment, the compound
is one listed in Table 4, or a pharmaceutically acceptable salt
or analog thereof.
One aspect of the subject invention provides methods for
using the compounds of the invention as Stat3 inhibitors
and/or as anti-proliferative agents. Thus, in one embodiment,
the method of the invention comprises administering a compound of the invention to cells in vitro or in vivo in an amount
sufficient to achieve the desired result, e.g., reduction ofStat3
activation. In another embodiment, the method comprises
administering a compound of the invention to a human or
non-human subject in an amount effective to achieve the
desired therapeutic result. In one embodiment, more than one
compound of the invention is administered to the cells in vitro
or in vivo. In a preferred embodiment, the compound is S3I201, or a pharmaceutically acceptable salt or analog thereof.
As used herein, the terms "treatment" and "treating", and
grammatical variations thereof, include therapy and prophylaxis. When used as a therapy, the compounds of the invention, by themselves or in conjunction with other agents, alleviate or reduce one or more symptoms associated with a
proliferation disorder (e.g., cancer). Thus, the treatment
methods may or may not be curative in nature. When used as
a prophylactic treatment, the compounds of the invention, by
themselves or in conjunction with other agents, delay the
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BRIEF DESCRIPTION OF THE SEQUENCES
SEQ ID NO: 1 is the native pTyr-peptide (APY*LKT;
*=phosphorylation).
SEQ ID N0:2 is the biotinylated conjugate pTyr-peptide
(EPQpYEEIEL (where pY represents pTyr)).
SEQ ID N0:3 is the sequence of the hSIE (high affinity
sis-inducible element from the c-fos gene, m67 variant) oligonucleotide probe.
SEQ ID N0:4 is the sequence of the MGFe (mannnary
gland factor element from the bovine ~-casein gene promoter) oligonucleotide probe.
DETAILED DESCRIPTION OF THE INVENTION
The present invention concerns isolated compounds, compositions comprising these compounds, and methods of using
these compounds and compositions as inhibitors of Stat3 and
inhibitors of aberrant cell growth, e.g., as anti-cancer agents.
Constitutively-active Stat3 is a prevalent molecular abnormality with a critical role inhuman malignant transformation,
and which represents a valid target for novel anticancer drug
design. S3I-201 (NSC 74859) is a novel inhibitor of Stat3
activity identified from the National Cancer Institute chemical libraries using structure-based virtual screening with a
computer model of the Stat3 SH2 domain bound to its Stat3
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onset of (and may prevent) one or more symptoms associated
with a proliferation disorder (e.g., cancer), or may prevent the
genesis of the condition.
In one aspect, the method of the invention is a method for
treating a proliferation disorder, such as cancer, comprising
administering an effective amount of a compound of the
invention to a subject in need thereof.
In another aspect, the method of the invention is a method
for inhibiting the growth of cancer cells in vitro or in vivo,
comprising administering an effective amount of a compound
of the invention to the cancer cells.
In another aspect, the subject invention provides compositions comprising at least one isolated compound of the invention, and a pharmaceutically acceptable carrier.
By inhibiting the growth of cells proliferating in an aberrant mamier, the methods, compounds, and compositions of
the present invention can be used to treat a number of cell
proliferation disorders, such as cancers, including, but not
limited to, leukemias and lymphomas, such as acute lymphocytic leukemia, acute non-lymphocytic leukemias, chronic
lymphocytic leukemia, chronic myelogenous leukemia,
Hodgkin's Disease, non-Hodgkin's lymphomas, and multiple myeloma, childhood solid tumors such as brain tumors,
neuroblastoma, retinoblastoma, Wilms' Tumor, bone tumors,
and soft-tissue sarcomas, common solid tumors of adults such
as lung cancer, colon and rectum cancer, breast cancer, prostate cancer, urinary cancers, uterine cancers, bladder cancers,
oral cancers, pancreatic cancer, melanoma and other skin
cancers, stomach cancer, ovarian cancer, brain tumors, liver
cancer, laryngeal cancer, thyroid cancer, esophageal cancer,
and testicular cancer. The methods of the subject invention
can be carried out in vivo or in vitro, to inhibit the growth of
cells (e.g., cancer cells) in humans and non-human manmials.
Treatment for a proliferation disorder can proceed by the
Stat3 inhibitor's anti-proliferative activity such as pro-apoptotic activity, or by other mechanisms. In one embodiment,
the proliferation disorder is one on which the Stat3
inhibitor(s) act by inhibition of Stat3 DNA-binding.
Compounds of the invention having the capability to
modulate (e.g., reduce or eliminate) signaling of the STAT3
and/or STATS signaling pathway in vitro and/or in vivo, or to
inhibit the growth of cancer cells in vitro and/or in vivo by
inhibition of STAT3 and/or STATS signaling or a different
mechanism, would be considered to have the desired biological activity in accordance with the subject invention. For
therapeutic applications, compounds of the subject invention
have the capability to inhibit activation of the STAT3 and/or
STATS signaling pathway, or to inhibit the growth of cancer
cells in vitro and/or in vivo by inhibition of STAT3 and/or
STATS signaling or a different mechanism. Inhibition of
STAT3 and/or STATS signaling can be assessed directly or
indirectly by various methods, including assays for inhibition
of STAT3 dimerization, inhibition of STAT3 DNA-binding,
and/or inhibition of STATS DNA-binding, for example. InhibitionofSTAT3 and/or STATS signaling by compounds of the
invention selectively promotes apoptosis in tumor cells that
harbor constitutively activated STAT3. Therefore, the desirable goals of promoting apoptosis ("programmed cell death")
of selective cancerous cells and suppression of malignant
transformation of normal cells within a patient are likewise
accomplished through administration of antagonists or
inhibitors of STAT 3 signaling of the present invention, which
can be administered as simple compounds or in a pharmaceutical formulation.
In one embodiment, the proliferation disorder to be treated
is a cancer producing a tumor characterized by over-activation of Stat!, Stat3, Stats, or a combination of two or all three

of the foregoing. Examples of such cancer types include, but
are not limited to, breast cancer, ovarian cancer, multiple
myeloma and blood malignancies, such as acute myelogenous leukemia.
In addition to cancer, the proliferation disorder to be treated
using the compounds, compositions, and methods of the
invention can be one characterized by aberrant Stat3 activation within cells associated with a non-malignant disease,
pathological state or disorder (collectively "disease"), and
likewise comprising administering or contacting the cells
with a an effective amount of one or more Stat3 inhibitors to
reduce or inhibit the proliferation. The proliferation, hypertrophy or overgrowth of cells that is common to these diseases
is mediated by overactivation of Stat3. This protein becomes
activated by a series of biochemical events. The activation of
Stat3 then leads to another series of inter-related biochemical
reactions or signal transduction cascades that ultimately produce cell growth and division.
In one embodiment, the proliferation disorder to be treated
is characterized by a proliferation ofT-cells such as autoimmune disease, e.g., type 1 diabetes, lupus and multiple sclerosis, and pathological states such as graft rejection induced
by the presentation of a foreign antigen such as a graft in
response to a disease condition (e.g., kidney failure). Other
non-malignant diseases characterized by proliferation of cells
include cirrhosis of the liver and restenosis.
The methods of the present invention can be advantageously combined with at least one additional treatment
method, including but not limited to, chemotherapy, radiation
therapy, or any other therapy known to those of skill in the art
for the treatment and management of proliferation disorders
such as cancer.
In one embodiment, the methods and compositions of the
invention include the incorporation of a ras antagonist. Ras
protein is the on/off switch between hormone/growth factor
receptors and the regulatory cascading that result in cell division. For Ras to be activated (i.e., turned on) to stimulate the
regulatory cascades, it must first be attached to the inside of
the cell membrane. Ras antagonist drug development aimed
at blocking the action of Ras on the regulatory cascades has
focused on interrupting the association of Ras with the cell
membrane, blocking activation of Ras or inhibiting activated
Ras. The details of the approaches to development of Ras
antagonists are reviewed in Kloog, et al., Exp. Opin. Invest.
Drugs, 1999, 8(12):2121-2140. Thus, by the term "ras
antagonist'', it is meant any compound or agent that targets
one or more of these phenomena so as to result in inhibition of
cell proliferation.
The Ras antagonists that may be used in conjunction with
the Stat3 inhibitors of the invention affect (e.g., inhibit) the
binding of Ras to the cell membrane, which in tum reduces or
inhibits the unwanted cell proliferation. Preferred Ras
antagonists include farnesyl thiosalicylic acid (FTS) and
structurally related compounds or analogs thereof, which are
believed to function by displacing or dislodging Ras from its
membrane anchor. These organic compounds may be administered parenterally or orally. In a particularly preferred
embodiment, the Ras antagonist is formulated for oral or
parenteral administration by complexation with cyclodextrin.
While compounds of the invention can be administered to
cells in vitro and in vivo as isolated compounds, it is preferred
to administer these compounds as part of a pharmaceutical
composition. The subject invention thus further provides
compositions comprising a compound of the invention, such
as those shown in FIGS. 7-9 (NSC 748S9 (S3I-201), NSC
S9263, NSC 42067), FIGS. 48-51(NSC42067, NSC 7S912,
NSC 11421NSC91S29, andNSC26343S), FIGS.10-12A-D
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(Formulas A, B, C, D, E, and F), FIGS. 13-47 (HL2-006-l,
HL2-006-2, HL2-006-3, HL2-006-4, HL2-006-5, HL2-0111, HL2-011-2, HL2-011-3, HL2-011-4, HL2-011-5,
BG2069-l, HL2-011-6, HL2-0ll-7, HL2-005, HL2-003,
BG2066, BG2074, BG3004, BG3006A, BG3006B,
BG3006D, BG3009, RPM381, RPM384, RPM385,
RPM405, RPM411, RPM407, RPM412, RPM408, RPM410,
RPM415, RPM416, RPM418, RPM418-A, RPM427,
RPM431, RPM432, RPM444, RPM448, RPM445, RPM447,
RPM452, and RPM202), and listed in Tables 4 and 5, or
physiologically acceptable salt(s) or analogs of any of the
foregoing; in association with at least one pharmaceutically
acceptable carrier. The pharmaceutical composition can be
adapted for various routes of administration, such as enteral,
parenteral, intravenous, intramuscular, topical, subcutaneous, and so forth. Administration can be continuous or at
distinct intervals, as can be determined by a person of ordinary skill in the art.
The compounds of the invention can be formulated according to known methods for preparing pharmaceutically useful
compositions. Formulations are described in a number of
sources which are well known and readily available to those
skilled in the art. For example, Remington's Pharmaceutical
Science (Martin, E.W., 1995, Easton Pa., Mack Publishing
Company, l 9'h ed.) describes formulations which can be used
in connection with the subject invention. Formulations suitable for administration include, for example, aqueous sterile
injection solutions, which may contain antioxidants, buffers,
bacteriostats, and solutes that render the formulation isotonic
with the blood of the intended recipient; and aqueous and
nonaqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be
presented in unit-dose or multi-dose containers, for example
sealed ampoules and vials, and may be stored in a freeze dried
(lyophilized) condition requiring only the condition of the
sterile liquid carrier, for example, water for injections, prior to
use. Extemporaneous injection solutions and suspensions
may be prepared from sterile powder, granules, tablets, etc. It
should be understood that in addition to the ingredients particularly mentioned above, the compositions of the subject
invention can include other agents conventional in the art
having regard to the type of formulation in question.
The compounds of the present invention include all
hydrates and salts of the compounds shown in FIGS. 7-9
(NSC 74859 (S3I-201), NSC 59263, NSC 42067), FIGS.
10-12A-D (Formulas A, B, C, D, E, and F), FIGS. 48-51
(NSC 42067, NSC 75912, NSC 11421NSC91529, and NSC
263435), or FIGS.13-47 (e.g., HL2-006-l, HL2-006-2, HL2006-3, HL2-006-4, HL2-006-5, HL2-0l 1-1, HL2-011-2,
HL2-0ll-3, HL2-011-4, HL2-011-5, BG2069-l, HL2-0116, HL2-011-7, HL2-005, HL2-003, BG2066, BG2074,
BG3004, BG3006A, BG3006B, BG3006D, BG3009,
RPM381, RPM384, RPM385, RPM405, RPM411, RPM407,
RPM412, RPM408, RPM410, RPM415, RPM416, RPM418,
RPM418-A, RPM427, RPM431, RPM432, RPM444,
RPM448, RPM445, RPM447, RPM452, and RPM202), and
listed in Tables 4 and 5, or of their analogs, that can be
prepared by those of skill in the art. Under conditions where
the compounds of the present invention are sufficiently basic
or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate.
Examples of pharmaceutically acceptable salts are organic
acid addition salts formed with acids that form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate,
ascorbate,
alpha-ketoglutarate,
and alpha-

glycerophosphate. Suitable inorganic salts may also be
formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts of compounds (e.g.,
Stat3 inhibitors) may be obtained using standard procedures
well known in the art, for example, by reacting a sufficiently
basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for
example, sodium, potassium or lithium) or alkaline earth
metal (for example calcium) salts of carboxylic acids can also
be made.
As used herein, the term "analogs" refers to compounds
which are substantially the same as another compound but
which may have been modified by, for example, adding side
groups, oxidation or reduction of the parent structure. Analogs of the Stat3 inhibitors shown in FIGS. 7-9 (e.g., NSC
74859 (S3I-201), NSC 59263, and NSC 42067) FIGS. 49-52
(NSC 42067, NSC 75912, NSC 11421NSC91529, andNSC
263435), and other compounds disclosed herein can be
readily prepared using commonly known standard reactions.
These standard reactions include, but are not limited to,
hydrogenation, alkylation, acetylation, and acidification
reactions. Chemical modifications can be accomplished by
those skilled in the art by protecting all functional groups
present in the molecule and deprotecting them after carrying
out the desired reactions using standard procedures known in
the scientific literature (Greene, T. W. and Wuts, P. G. M.
"Protective Groups in Organic Synthesis" John Wiley &
Sons, Inc. New York. 3rd Ed. pg. 819, 1999; Honda, T. et al.
Bioorg. Med. Chem. Lett., 1997, 7:1623-1628; Honda, T. et
al.Bioorg. Med. Chem. Lett., 1998, 8:2711-2714; Konoike, T.
etal.JOrg. Chem., 1997, 62:960-966; Honda, T. etal.J. Med.
Chem., 2000, 43:4233-4246; each of which are hereby incorporated herein by reference in their entirety). Analogs exhibiting the desired biological activity (such as induction of
apoptosis, cytotoxicity, cytostaticity, induction of cell cycle
arrest, etc.) can be identified or confirmed using cellular
assays or other in vitro or in vivo assays. For example, assays
that detect inhibition of Stat3 activation, G 2 /M cell cycle
arrest, and/or reduction of tumor growth may be utilized.
It will be appreciated that the compounds of the invention
can contain one or more asymmetrically substituted carbon
atoms (i.e., carbon centers). The presence of one or more of
the asymmetric centers in an analog of the invention, can give
rise to stereoisomers, and in each case, the invention is to be
understood to extend to all such stereoisomers, including
enantiomers and diastereomers, and mixtures including racemic mixtures thereof.
FIGS. 12A-12D show formulas C-F, respectively, describing compounds of the invention. InFIGS.12A-12D, theXNH
groups have a transposed arrangement (NHX) with respect to
one another.
Referring to FIGS. 12A-12D, R 1 and R 2 , if present, can be
an aliphatic or aromatic group; X, if present =CO, S0 2 ,
CONH, or alkyl; Z, if present, is alkyl; and phosphate
mimic=that shown in FIGS. 10 and 11, e.g., C0 2 H, S03 H,
P0 3 H, N0 2 , CH 2 C0 2 H, CF 2 C0 2 H, orCF(C0 2 H) 2 tetrazole.
Preferably, R 2 is a hydrophobic group or part of a hydrophobic group. In one embodiment, R 1 , if present, is H, alkyl,
alkenyl, cycloalkyl, heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, and aryl, any of which may be optionally
substituted; and R 2 , if present is H, alkyl, alkenyl, cycloalkyl,
heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, and
aryl, any of which may be optionally substituted. In a preferred embodiment, Ru if present, is aryl, substituted aryl,
heteroaryl or alkyl; and R 2 , if present is a hydrophobic group
such as aryl, substituted aryl, heteroaryl or alkyl.
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The term "alkyl group" is intended to mean a group of
atoms derived from an alkane by the removal of one hydrogen
atom. Thus, the term includes straight or branched chain alkyl
moieties including, for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, and the like. Preferred
alkyl groups contain from 1 to about 14 carbon atoms (C 1 _14
alkyl).
The term "aryl group" is intended to mean a group derived
from an aromatic hydrocarbon by removal of a hydrogen
from the aromatic system. Preferred aryl groups contain phenyl or substituted phenyl groups. Thus, the term "aryl"
includes an aromatic carbocyclic radical having a single ring
or two condensed rings. This term includes, for example,
phenyl or naphthyl.
The term "heteroaryl" refers to aromatic ring systems of
five or more atoms (e.g., five to ten atoms) of which at least
one atom is selected from 0, N and S, and includes for
example furanyl, thiophenyl, pyridyl, indolyl, quinolyl and
the like.
The term "acyl group" is intended to mean a group having
the formula RCO-, wherein R is an alkyl group or an aryl
group.
The term "alkenyl" refers to a straight or branched chain
alkyl moiety having two or more carbon atoms (e.g., two to
six carbon atoms, C 2 _6 alkenyl) and having in addition one
double bond, of either E or Z stereochemistry where applicable. This term would include, for example, vinyl, 1-propenyl, 1- and 2-butenyl, 2-methyl-2-propenyl, etc.
The term "cycloalkyl" refers to a saturated alicyclic moiety
having three or more carbon atoms (e.g., from three to six
carbon atoms) and which may be optionally benzofused at
any available position. This term includes, for example,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, indanyl
and tetrahydronaphthyl.
The term "heterocycloalkyl" refers to a saturated heterocyclic moiety having three or more carbon atoms (e.g., from
three to six carbon atoms) and one or more heteroatom from
the group N, 0, S (or oxidized versions thereof) and which
may be optionally benzofused at any available position. This
term includes, for example, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, indolinyl and tetrahydroquinolinyl.
The term "cycloalkenyl" refers to an alicyclic moiety having three or more carbon atoms (e.g., from three to six carbon
atoms) and having in addition one double bond. This term
includes, for example, cyclopentenyl or cyclohexenyl.
The term "heterocycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and one or more
heteroatoms from the group N, 0, S (or oxides thereof) and
having in addition one double bond. This term includes, for
example, dihydropyranyl.
The term "halogen" means a halogen of the periodic table,
such as fluorine, chlorine, bromine, or iodine.
The term "optionally substituted" means optionally substituted with one or more of the aforementioned groups (e.g.,
alkyl, aryl, heteroaryl, acyl, alkenyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, or halogen), at
any available position or positions.
Specifically, "alkyl" can include, for example, methyl,
ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl,
3-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl,
tridecyl, tetradecyl or pentadecyl; "alkenyl" can include
vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl,
1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl,
6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl,

3-decenyl,4-decenyl,5-decenyl,decenyl, 7-decenyl,8-decenyl, 9-decenyl; 1-undecenyl, 2-undecenyl, 3-undecenyl,
4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl,
7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl,
11-dodecenyl, 1-tridecenyl, 2-tridecenyl, 3-tridecenyl,
4-tridecenyl, 5-tridecenyl, 6-tridecenyl, 7-tridecenyl, 8-tridecenyl, 9-tridecenyl, 10-tridecenyl, 11-tridecenyl, 12-tridecenyl, 1-tetradecenyl, 2-tetradecenyl, 3-tetradecenyl, 4-tetradecenyl, 5-tetradecenyl, 6-tetradecenyl, 7-tetradecenyl,
8-tetradecenyl, 9-tetradecenyl, 10-tetradecenyl, 11-tetradecenyl, 12-tetradecenyl, 13-tetradeceny, 1-pentadecenyl,
2-pentadecenyl, 3-pentadecenyl, 4-pentadecenyl, 5-pentadecenyl, 6-pentadecenyl, 7-pentadecenyl, 8-pentadecenyl,
9-pentadecenyl, 10-pentadecenyl, 11-pentadecenyl, 12-pentadecenyl, 13-pentadecenyl, or 14-pentadecenyl; "alkoxy"
can include methoxy, ethoxy, propoxy, isopropoxy, butoxy,
iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, hexoxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy,
tridecyloxy, tetradecyloxy, or pentadecyloxy; "alkanoyl" can
include acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl,
heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, or pentadecanoyl;
"cycloalkyl" can include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, for example;
"aryl" can include phenyl, indenyl, 5,6,7,8-tetrahydronaphthyl, or naphthyl, for example; and "heteroaryl" can include
fury!, imidazolyl, tetrazolyl, pyridyl, (or its N-oxide ), thienyl,
pyrimidinyl (or its N-oxide), indolyl, or quinolyl (or its N-oxide ), for example.
The compounds of the invention are useful for various
non-therapeutic and therapeutic purposes. The compounds
(e.g., Stat3 inhibitors) may be used for reducing aberrant cell
growth in animals and humans. Because of such anti-proliferative properties of the compounds, they are useful in reducing unwanted cell growth in a wide variety of settings including in vitro and in vivo. In addition to their use in treatment
methods, the Stat3 inhibitors of the invention are useful as
agents for investigating the role of Stat3 in cellular metabolism, and controlling Stat3-mediated malignant or non-malignant cell growth in vitro or in vivo. They are also useful as
standards and for teaching demonstrations.
Therapeutic application of the compounds and compositions comprising them can be accomplished by any suitable
therapeutic method and technique presently or prospectively
known to those skilled in the art. Further, the compounds of
the invention can be used as starting materials or intermediates for the preparation of other useful compounds and compositions.
Compounds of the invention (e.g., Stat3 inhibitors) may be
locally administered at one or more anatomical sites, such as
sites of unwanted cell growth (such as a tumor site, e.g.,
injected or topically applied to the tumor), optionally in combination with a pharmaceutically acceptable carrier such as
an inert diluent. Compounds of the invention may be systemically administered, such as intravenously or orally, optionally
in combination with a pharmaceutically acceptable carrier
such as an inert diluent, or an assimilable edible carrier for
oral delivery. They may be enclosed in hard or soft shell
gelatin capsules, may be compressed into tablets, or may be
incorporated directly with the food of the patient's diet. For
oral therapeutic administration, the active compound may be
combined with one or more excipients and used in the form of
ingestible tablets, buccal tablets, troches, capsules, elixirs,
suspensions, syrups, wafers, aerosol sprays, and the like.
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The tablets, troches, pills, capsules, and the like may also
contain the following: binders such as gum tragacanth, acacia, com starch or gelatin; excipients such as di calcium phosphate; a disintegrating agent such as com starch, potato
starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
When the unit dosage form is a capsule, it may contain, in
addition to materials of the above type, a liquid carrier, such
as a vegetable oil or a polyethylene glycol. Various other
materials may be present as coatings or to otherwise modify
the physical form of the solid unit dosage form. For instance,
tablets, pills, or capsules may be coated with gelatin, wax,
shellac, or sugar and the like. A syrup or elixir may contain the
active compound, sucrose or fructose as a sweetening agent,
methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material
used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the
amounts employed. In addition, the Stat3 inhibitor may be
incorporated into sustained-release preparations and devices.
The active agent (compounds of the invention) may also be
administered intravenously or intraperitoneally by infusion
or injection. Solutions of the active agent can be prepared in
water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene
glycols, triacetin, and mixtures thereof and in oils. Under
ordinary conditions of storage and use, these preparations can
contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or
infusion can include sterile aqueous solutions or dispersions
or sterile powders comprising the compounds of the invention
which are adapted for the extemporaneous preparation of
sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. The ultimate dosage form
should be sterile, fluid and stable under the conditions of
manufacture and storage. The liquid carrier or vehicle can be
a solvent or liquid dispersion medium comprising, for
example, water, ethanol, a polyol (for example, glycerol,
propylene glycol, liquid polyethylene glycols, and the like),
vegetable oils, nontoxic glyceryl esters, and suitable mixtures
thereof. The proper fluidity can be maintained, for example,
by the formation of liposomes, by the maintenance of the
required particle size in the case of dispersions or by the use
of surfactants. Optionally, the prevention of the action of
microorganisms can be brought about by various antibacterial
and antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thimerosal, and the like. In many cases, it
will be preferable to include isotonic agents, for example,
sugars, buffers or sodium chloride. Prolonged absorption of
the injectable compositions can be brought about by the
inclusion of agents that delay absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating
the compounds of the invention in the required amount in the
appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. In the
case of sterile powders for the preparation of sterile injectable
solutions, the preferred methods of preparation are vacuum
drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the compounds may be applied
in pure-form, i.e., when they are liquids. However, it will
generally be desirable to administer them topically to the skin

as compos1t10ns, in combination with a dermatologically
acceptable carrier, which may be a solid or a liquid.
The compounds of the subject invention can be applied
topically to a subject's skin to reduce the size (and may
include complete removal) of malignant or benign growths.
The compounds of the invention can be applied directly to the
growth. Preferably, the compound is applied to the growth in
a formulation such as an ointment, cream, lotion, solution,
tincture, or the like. Drug delivery systems for delivery of
pharmacological substances to dermal lesions can also be
used, such as that described in U.S. Pat. No. 5,167,649
(Zook).
Useful solid carriers include finely divided solids such as
talc, clay, microcrystalline cellulose, silica, alumina and the
like. Useful liquid carriers include water, alcohols or glycols
or water-alcohol/glycol blends, in which the Stat3 inhibitor
can be dissolved or dispersed at effective levels, optionally
with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to
optimize the properties for a given use. The resultant liquid
compositions can be applied from absorbent pads, used to
impregnate bandages and other dressings, or sprayed onto the
affected area using pump-type or aerosol sprayers, for
example.
Thickeners such as synthetic polymers, fatty acids, fatty
acid salts and esters, fatty alcohols, modified celluloses or
modified mineral materials can also be employed with liquid
carriers to form spreadable pastes, gels, ointments, soaps, and
the like, for application directly to the skin of the user.
Examples of useful dermatological compositions which can
be used to deliver the Stat3 inhibitors to the skin are disclosed
in Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat.
No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and
Woltzman (U.S. Pat. No. 4,820,508).
Useful dosages of the pharmaceutical compositions of the
present invention can be determined by comparing their in
vitro activity, and in vivo activity in animal models. Methods
for the extrapolation of effective dosages in mice, and other
animals, to humans are known to the art; for example, see U.S.
Pat. No. 4,938,949.
Accordingly, the present invention includes a pharmaceutical composition comprising a compound of the invention in
combination with a pharmaceutically acceptable carrier.
Pharmaceutical compositions adapted for oral, topical or
parenteral administration, comprising an amount of a compound of the invention constitute a preferred embodiment of
the invention. The dose administered to a patient, particularly
a human, in the context of the present invention should be
sufficient to achieve a therapeutic response in the patient over
a reasonable time frame, without lethal toxicity, and preferably causing no more than an acceptable level of side effects
or morbidity. One skilled in the art will recognize that dosage
will depend upon a variety of factors including the condition
(health) of the subject, the body weight of the subject, kind of
concurrent treatment, if any, frequency of treatment, therapeutic ratio, as well as the severity and stage of the pathological condition.
Depending upon the disorder or disease condition to be
treated, a suitable dose(s) may be that amount that will reduce
proliferation or growth of the target cell(s). In the context of
cancer, a suitable dose(s) is that which will result in a concentration of the active agent (the compound of the invention)
in cancer tissue, such as a malignant tumor, which is known to
achieve the desired response. The preferred dosage is the
amount which results in maximum inhibition of cancer cell
growth, without unmanageable side effects. Administration
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of a compound of the invention can be continuous or at
distinct intervals, as can be determined by a person of ordinary skill in the art.
To provide for the administration of such dosages for the
desired therapeutic treatment, in some embodiments, pharmaceutical compositions of the invention can comprise
between about 0.1%and45%, and especially, 1and15%, by
weight of the total of one or more of the compounds of the
invention based on the weight of the total composition including carrier or diluents. Illustratively, dosage levels of the
administered active ingredients can be: intravenous, 0.01 to
about 20 mg/kg; intraperitoneal, 0.01 to about 100 mg/kg;
subcutaneous, 0.01 to about 100 mg/kg; intramuscular, 0.01
to about 100 mg/kg; orally 0.01 to about 200 mg/kg, and
preferably about 1 to 100 mg/kg; intranasal instillation, 0.01
to about 20 mg/kg; and aerosol, 0.01 to about 20 mg/kg of
animal (body) weight.
Mammalian species which benefit from the disclosed
methods include, but are not limited to, primates, such as
apes, chimpanzees, orangutans, humans, monkeys; domesticated animals (e.g., pets) such as dogs, cats, guinea pigs,
hamsters, Vietnamese pot-bellied pigs, rabbits, and ferrets;
domesticated farm animals such as cows, buffalo, bison,
horses, donkey, swine, sheep, and goats; exotic animals typically found in zoos, such as bear, lions, tigers, panthers,
elephants, hippopotamus, rhinoceros, giraffes, antelopes,
sloth, gazelles, zebras, wildebeests, prairie dogs, koala bears,
kangaroo, opossums, raccoons, pandas, hyena, seals, sea
lions, elephant seals, otters, porpoises, dolphins, and whales.
Other species that may benefit from the disclosed methods
include fish, amphibians, avians, and reptiles. As used herein,
the terms "patient" and "subject" are used interchangeably
and are intended to include such human and non-human spe-

cies. Likewise, in vitro methods of the present invention can
be carried out on cells of such human and non-human species.
Patients in need of treatment using the methods of the
present invention can be identified using standard techniques
known to those in the medical or veterinary professions, as
appropriate.
As used herein, the terms "cancer" and "cancerous" refer to
or describe the physiological condition in mammals that is
typically characterized by unregulated cell growth. The cancer may be multi-drug resistant (MDR) or drug-sensitive.
Examples of cancer include but are not limited to, carcinoma,
lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers include breast cancer, prostate
cancer, colon cancer, squamous cell cancer, small-cell lung
cancer, non-small cell lung cancer, gastrointestinal cancer,
pancreatic cancer, cervical cancer, ovarian cancer, peritoneal
cancer, liver cancer, e.g., hepatic carcinoma, bladder cancer,
colorectal cancer, endometrial carcinoma, kidney cancer, and
thyroid cancer.
Other non-limiting examples of cancers are basal cell carcinoma, biliary tract cancer; bone cancer; brain and CNS
cancer; choriocarcinoma; connective tissue cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric
cancer; intra-epithelial neoplasm; larynx cancer; lymphoma
including Hodgkin's and Non-Hodgkin's lymphoma; melanoma; myeloma; neuroblastoma; oral cavity cancer (e.g., lip,
tongue, mouth, and pharynx); retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; uterine
cancer; cancer of the urinary system, as well as other carcinomas and sarcomas. Examples of cancer types that may
potentially be treated using the Stat3 inhibitors of the present
invention are also listed in Table 1.
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TABLE 1
Examples of Cancer Types
Acute Lymphoblastic Leukemia, Adult
Acute Lymphoblastic Leukemia,
Childhood
Acute Myeloid Leukemia, Adult
Acute Myeloid Leukemia, Childhood
Adrenocortical Carcinoma
Adrenocortical Carcinoma, Childhood
AIDS-Related Cancers
AIDS-Related Lymphoma
Anal Cancer
Astrocytoma, Childhood Cerebellar
Astrocytoma, Childhood Cerebral
Basal Cell Carcinoma
Bile Duct Cancer, Extrahepatic
Bladder Cancer
Bladder Cancer, Childhood
Bone Cancer, Osteosarcoma/Malignant
Fibrous Histiocytoma
Brain Stem Glioma, Childhood
Brain Tumor, Adult
Brain Tumor, Brain Stem Glioma,
Childhood
Brain Tumor, Cerebellar Astrocytoma,
Childhood
Brain Tumor, Cerebral
Astrocytoma!Malignant Glioma,
Childhood
Brain Tumor, Ependymoma, Childhood
Brain Tumor, Medulloblastoma,
Childhood
Brain Tumor, Supratentorial Primitive
Neuroectodermal Tumors, Childhood
Brain Tumor, Visual Pathway and
Hypothalamic Glioma, Childhood
Brain Tumor, Childhood
Breast Cancer

Hairy Cell Leukemia
Head and Neck Cancer
Hepatocellular (Liver) Cancer, Adult
(Primary)
Hepatocellular (Liver) Cancer, Childhood
(Primary)
Hodgkin's Lymphoma, Adult
Hodgkin's Lymphoma, Childhood
Hodgkin's Lymphoma During Pregnancy
Hypopharyngeal Cancer
Hypothalamic and Visual Pathway Glioma,
Childhood
Intraocular Melanoma
Islet Cell Carcinoma (Endocrine Pancreas)
Kaposi's Sarcoma
Kidney (Renal Cell) Cancer
Kidney Cancer, Childhood
Laryngeal Cancer
Laryngeal Cancer, Childhood
Leukemia, Acute Lymphoblastic, Adult
Leukemia, Acute Lymphoblastic, Childhood
Leukemia, Acute Myeloid, Adult
Leukemia, Acute Myeloid, Childhood
Leukemia, Chronic Lymphocytic
Leukemia, Chronic Myelogenous
Leukemia, Hairy Cell
Lip and Oral Cavity Cancer
Liver Cancer, Adult (Primary)
Liver Cancer, Childhood (Primary)
Lung Cancer, Non-Small Cell
Lung Cancer, Small Cell
Lymphoma, AIDS-Related
Lymphoma, Burkitt's
Lymphoma, Cutaneous T-Cell, see Mycosis
Fungoides and Sezary Syndrome
Lymphoma, Hodgkin's, Adult
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TABLE I-continued
Examples of Cancer Types
Breast Cancer, Childhood
Breast Cancer, Male
Bronchial Adenomas/Carcinoids,
Childhood
Burkitt's Lymphoma
Carcinoid Tumor, Childhood
Carcinoid Tumor, Gastrointestinal
Carcinoma of Unknown Primary
Central Nervous System Lymphoma,
Primary
Cerebellar Astrocytoma, Childhood
Cerebral Astrocytoma!Malignant
Glioma, Childhood
Cervical Cancer
Childhood Cancers
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Myeloproliferative Disorders
Colon Cancer
Colorectal Cancer, Childhood
Cutaneous T-Cell Lymphoma, see
Mycosis Fungoides and Sezary
Syndrome
Endometrial Cancer
Ependymoma, Childhood
Esophageal Cancer
Esophageal Cancer, Childhood
Ewing's Family of Tumors
Extracranial Germ Cell Twnor,
Childhood
Extragonadal Germ Cell Tumor
Extrahepatic Bile Duct Cancer
Eye Cancer, Intraocular Melanoma
Eye Cancer, Retinoblastoma
Gallbladder Cancer
Gastric (Stomach) Cancer
Gastric (Stomach) Cancer, Childhood
Gastrointestinal Carcinoid Twnor
Germ Cell Tumor, Extracranial,
Childhood
Germ Cell Tumor, Extragonadal
Germ Cell Tumor, Ovarian
Gestational Trophoblastic Tumor
Glioma, Adult
Glioma, Childhood Brain Stem
Glioma, Childhood Cerebral
Astrocytoma
Glioma, Childhood Visual Pathway and
Hypothalamic
Skin Cancer (Melanoma)
Skin Carcinoma, Merkel Cell
Small Cell Lung Cancer
Small Intestine Cancer
Soft Tissue Sarcoma, Adult
Soft Tissue Sarcoma, Childhood
Squamous Cell Carcinoma, see Skin
Cancer (non-Melanoma)
Squamous Neck Cancer with Occult
Primary, Metastatic
Stomach (Gastric) Cancer
Stomach (Gastric) Cancer, Childhood
Supratentorial Primitive
Neuroectodermal Tumors, Childhood
T-Cell Lymphoma, Cutaneous, see
Mycosis Fungoides and Sezary
Syndrome
Testicular Cancer
Thymoma, Childhood
Thymoma and Thymic Carcinoma
Thyroid Cancer
Thyroid Cancer, Childhood
Transitional Cell Cancer of the Renal
Pelvis and Ureter
Trophoblastic Tumor, Gestational
Unknown Primary Site, Carcinoma of,
Adult
Unknown Primary Site, Cancer of,
Childhood

Lymphoma, Hodgkin's, Childhood
Lymphoma, Hodgkin's During Pregnancy
Lymphoma, Non-Hodgkin's, Adult
Lymphoma, Non-Hodgkin's, Childhood
Lymphoma, Non-Hodgkin's During
Pregnancy
Lymphoma, Primary Central Nervous System
Macroglobulinemia, WaldenstrOm 's
Malignant Fibrous Histiocytoma of
Bone/Osteosarcoma
Medulloblastoma, Childhood
Melanoma
Melanoma, Intraocular (Eye)
Merkel Cell Carcinoma
Mesothelioma, Adult Malignant
Mesothelioma, Childhood
Metastatic Squamous Neck Cancer with
Occult Primary
Multiple Endocrine Neoplasia Syndrome,
Childhood
Multiple Myeloma!Plasma Cell Neoplasm
Mycosis Fungoides
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Myelogenous Leukemia, Chronic
Myeloid Leukemia, Adult Acute
Myeloid Leukemia, Childhood Acute
Myeloma, Multiple
Myeloproliferative Disorders, Chronic
Nasal Cavity and Paranasal Sinus Cancer
Nasopharyngeal Cancer
Nasopharyngeal Cancer, Childhood
Neuroblastoma
Non-Hodgkin's Lymphoma, Adult
Non-Hodgkin's Lymphoma, Childhood
Non-Hodgkin's Lymphoma During Pregnancy
Non-Small Cell Lung Cancer
Oral Cancer, Childhood
Oral Cavity Cancer, Lip and
Oropharyngeal Cancer
Osteosarcoma!Malignant Fibrous
Histiocytoma of Bone
Ovarian Cancer, Childhood
Ovarian Epithelial Cancer
Ovarian Germ Cell Tumor
Ovarian Low Malignant Potential Tumor
Pancreatic Cancer
Pancreatic Cancer, Childhood
Pancreatic Cancer, Islet Cell
Paranasal Sinus and Nasal Cavity Cancer
Parathyroid Cancer
Penile Cancer
Pheochromocytoma
Pineoblastoma and Supratentorial Primitive
Neuroectodermal Tumors, Childhood
Pituitary Tumor
Plasma Cell Neoplasm/Multiple Myeloma
Pleuropulmonary Blastoma
Pregnancy and Breast Cancer
Pregnancy and Hodgkin's Lymphoma
Pregnancy and Non-Hodgkin's Lymphoma
Primary Central Nervous System Lymphoma
Prostate Cancer
Rectal Cancer
Renal Cell (Kidney) Cancer
Renal Cell (Kidney) Cancer, Childhood
Renal Pelvis and Ureter, Transitional Cell
Cancer
Retinoblastoma
Rhabdomyosarcoma, Childhood
Salivary Gland Cancer
Salivary Gland Cancer, Childhood
Sarcoma, Ewing's Family ofTwnors
Sarcoma, Kaposi's
Sarcoma, Soft Tissue, Adult
Sarcoma, Soft Tissue, Childhood
Sarcoma, Uterine
Sezary Syndrome
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TABLE I-continued
Examples of Cancer Types
Unusual Cancers of Childhood
Ureter and Renal Pelvis, Transitional
Cell Cancer
Urethral Cancer
Uterine Cancer, Endometrial
Uterine Sarcoma
Vaginal Cancer
Visual Pathway and Hypothalamic
Glioma, Childhood
Vulvar Cancer
Waldenstriim's Macroglobulinemia
Wilms'Tumor

Skin Cancer (non-Melanoma)
Skin Cancer, Childhood

15

As used herein, the term "tumor" refers to all neoplastic
cell growth and proliferation, whether malignant or benign,
and all pre-cancerous and cancerous cells and tissues. For
example, a particular cancer may be characterized by a solid
mass tumor. The solid tumor mass, if present, may be a
primary tumor mass. A primary tumor mass refers to a growth
of cancer cells in a tissue resulting from the transformation of
a normal cell of that tissue. In most cases, the primary tumor
mass is identified by the presence of a cyst, which can be
found through visual or palpation methods, or by irregularity
in shape, texture or weight of the tissue. However, some
primary tumors are not palpable and can be detected only
through medical imaging techniques such as X-rays (e.g.,
mammography) or magnetic resonance imaging (MRI), or by
needle aspirations. The use of these latter techniques is more
common in early detection. Molecular and phenotypic analysis of cancer cells within a tissue can usually be used to
confirm if the cancer is endogenous to the tissue or if the
lesion is due to metastasis from another site. The treatment
methods of the invention can be utilized for early, middle, or
late stage disease, and acute or chronic disease. In some
embodiments, the tumor is characterized as one exhibiting
aberrant activation of Stat3.
According to the method of the subject invention, a compound of the invention can be administered to a patient by
itself, or co-administered with one or more other agents such
as another compound of the invention, or a different agent or
agents. Co-administration can be carried out simultaneously
(in the same or separate formulations) or consecutively. Furthermore, according to the method of the subject invention,
compounds of the invention can be administered to a patient
as adjuvant therapy. For example, compounds can be administered to a patient in conjunction with chemotherapy.
Thus, the compounds of the invention, whether administered separately, or as a pharmaceutical composition, can
include various other components as additives. Examples of
acceptable components or adjuncts which can be employed in
relevant circumstances include antioxidants, free radical
scavenging agents, peptides, growth factors, antibiotics, bacteriostatic agents, immunosuppressives, anticoagulants, buffering agents, anti-inflammatory agents, anti-angiogenics,
anti-pyretics, time-release binders, anesthetics, steroids, and
corticosteroids. Such components can provide additional
therapeutic benefit, act to affect the therapeutic action of the
compounds of the invention, or act towards preventing any
potential side effects which may be posed as a result of
administration of the compounds. The Stat3 inhibitors of the
subject invention can be conjugated to a therapeutic agent, as
well.
Additional agents that can be co-administered to target
cells in vitro or in vivo, such as in a patient, in the same or as
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a separate formulation, include those that modify a given
biological response, such as immunomodulators. For
example, proteins such as tumor necrosis factor (TNF), interferon (such as alpha-interferon and beta-interferon), nerve
growth factor (NGF), platelet derived growth factor (PDGF),
and tissue plasminogen activator can be administered. Biological response modifiers, such as lymphokines, interleukins
(such as interleukin-I (IL-I), interleukin-2 (IL-2), and interleukin-6 (IL-6)), granulocyte macrophage colony stimulating
factor (GM-CSF), granulocyte colony stimulating factor
(G-CSF), or other growth factors can be administered. In one
embodiment, the methods and compositions of the invention
incorporate one or more agents selected from the group consisting of anti-cancer agents, cytotoxic agents, chemotherapeutic agents, anti-signaling agents, and anti-angiogenic
agents.
EXEMPLIFIED EMBODIMENTS
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I. An isolated compound having the structure of S3I-201
(shown in FIG. 7), NSC-59263 (shown in FIG. 8), NSC42067 (shown in FIG. 9), Formula A (shown in FIG. 10),
Formula B (shown in FIG. 11), Formula C (shown in FIG.
12A), Formula D (shown in FIG. 12B), Formula E, shown in
FIG. 12C, Formula F (shown in FIG. 12D), NSC 759I2
(shown in FIG. 50), NSC I I42I (shown in FIG. 49), NSC
9I529 (shown in FIG. 51), NSC 263435 (shown in FIG. 48),
HL2-006-I (shown in FIG. 13), HL2-006-2 (shown in FIG.
14), HL2-006-3 (shown in FIG. 15), HL2-006-4 (shown in
FIG. 16), HL2-006-5 (shown in FIG.17), HL2-01 I-I (shown
in FIG. 18), HL2-011-2 (shown in FIG. 19), HL2-01I-3
(shown in FIG. 20), HL2-011-4 (shown in FIG. 21), HL2011-5 (shown in FIG. 22), BG2069-I (shown in FIG. 23),
HL2-011-6 (shown in FIG. 24), HL2-0I I-7 (shown in FIG.
25), HL2-005 (shown in FIG. 26), HL2-003 (shown in FIG.
27), BG2066 (shown in FIG. 28), BG2074 (shown in FIG.
29), BG3004 (shown in FIG. 30), BG3006A (shown in FIG.
31), BG3006B (shown in FIG. 32), BG3006D (shown in FIG.
33), BG3009 (shown in FIG. 34), RPM38I (shown in FIG.
35), RPM384 (shown in FIG. 35), RPM385 (shown in FIG.
35), RPM405 (shown in FIG. 36), RPM411 (shown in FIG.
36), RPM407 (shown in FIG. 37), RPM4I2 (shown in FIG.
37), RPM408 (shown in FIG. 38), RPM4IO (shown in FIG.
38), RPM4I5 (shown in FIG. 39), RPM4I6 (shown in FIG.
39), RPM4I8 (shown in FIG. 40), RPM4I8-A (shown in FIG.
40), RPM427 (shown in FIG. 41), RPM43I (shown in FIG.
42), RPM432 (shown in FIG. 43), RPM444 (shown in FIG.
44) RPM448 (shown in FIG. 44), RPM445 (shown in FIG.
45), RPM447 (shown in FIG. 45), RPM452 (shown in FIG.
46), RPM202 (shown in FIG. 47), a compound listed in Table
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4, a compound listed in Table 5, or a pharmaceutically acceptable salt or analog of any of the foregoing.
2. A pharmaceutical composition comprising at least one
isolated compound selected from selected from embodiment
1; and a pharmaceutically acceptable carrier.
3. The composition of embodiment 2, wherein the compound is S3I-201.
4. The composition of embodiment 2 or 3, further comprising an additional anti-cancer agent.
5. The composition of any of embodiments 2-4, further
comprising an agent selected from the group consisting of an
antioxidant, free radical scavenging agent, peptide, growth
factor, antibiotic, bacteriostatic agent, immunosuppressive,
anticoagulant, buffering agent, anti-inflanmiatory agent, antiangiogenic agent, anti-pyretic, time-release binder, anesthetic, steroid, and corticosteroid.
6. The composition of any of embodiments 2-5, comprising
more than one of said compounds.
7. A method of treating a proliferation disorder in a subject,
comprising administering an effective amount of at least one
compound of embodiment 1 to the subject.
8. The method of embodiment 7, wherein said administering comprising administering an effective amount ofS3I-201
to the subject.
9. The method of embodiment 7 or 8, wherein the proliferation disorder is cancer.
10. The method of any of embodiments 7-9, wherein the
compound is administered locally at the site of a tumor.
11. The method of any of embodiments 7-10, wherein the
proliferation disorder is cancer, and wherein the subject is
suffering from a tumor and the compound inhibits growth of
the tumor.
12. The method of embodiment 7 or 8, wherein the proliferation disorder is a non-malignant disease characterized by
aberrant Stat3 activation of cells.
13. The method of any of embodiments 7-12, wherein the
compound is administered locally at the site of the proliferation disorder.
14. The method of any of embodiments 7-9, wherein the
subject is not suffering from the proliferation disorder, and
wherein the compound is administered to delay onset of the
proliferation disorder.
15. The method of any of embodiments 7-14, wherein the
route of administration is selected from the group consisting
of intravenous, intramuscular, oral, and intra-nasal.
16. The method of any of embodiments 7-15, wherein the
subject is human.
17. The method of any of embodiments 7-15, wherein the
subject is a non-human manmial.
18. The method of any of embodiments 7-13 or 15-17,
further comprising identifying the subject as one suffering
from the proliferation disorder.
19. The method of embodiment 8, wherein the subject is
suffering from a tumor and wherein said administering comprises administering S3I-201 at the site of the tumor.
20. A method of suppressing the growth of, or inducing
apoptosis in, malignant cells, the method comprising contacting the cells with an effective amount of at least one compound of embodiment 1.
21. The method of embodiment 20, wherein said administering is carried out in vitro.
22. The method of embodiment 20, wherein said administering is carried out in vivo.
23. The method of any of embodiments 20-22, wherein the
cells are mammalian cancer cells.
24. The method of any of embodiments 20-23, wherein the
cells consist essentially of human breast cancer cells.

25. The method of any of embodiments 20-24, wherein
said contacting comprises contacting the cells with an effective amount of S3I-201.
26. A method of inhibiting constitutive activation of Stat3
in cells, comprising contacting the cells with an effective
amount of at least one compound of embodiment 1.
27. The method of embodiment 26, wherein said administering is carried out in vitro.
28. The method of embodiment 26, wherein said administering is carried out in vivo.
29. The method of embodiment 27 or 28, wherein said
contacting comprises contacting the cells with an effective
amount of S3I-201.
30. The method of any of embodiments 26-29, wherein the
cells are cancer cells.
31. The method of any of embodiments 26-30, wherein the
cells consist essentially of human breast cancer cells.
32. A method of preventing Stat3 dimerization in a mammalian cell, the method comprising contacting the cell with
an effective amount of at least compound of embodiment 1.
33. The method of embodiment 32, wherein said contacting comprises contacting the cell with an effective amount of
S3I-201.
34. A method of disrupting Stat3-DNA binding or Stat5DNA binding, the method comprising contacting the Stat3 or
Stat5 with an effective amount of at least one compound of
embodiment 1.
35. The method of embodiment 34, wherein said contacting comprises contacting the Stat3 or Stat5 with an effective
amount ofS3I-201.
36. An in-vitro screening test for presence of malignant
cells in a mammalian tissue, the test comprising:
obtaining a sample containing viable cells of said tissue;
culturing said sample under conditions promoting growth
of the viable cells contained therein;
treating the cultured sample with a compound; and
analyzing the treated sample by a method effective to determine percent apoptosis of cells as an indicator of presence of
malignant cells in the sample, wherein the compound is at
least one compound of embodiment 1.
37. The screening test of embodiment 36, wherein said
treating comprising contacting the cells with S3I-201.
38. A method of identifying inhibitors of constitutive Stat3
activation, Stat3-DNA binding, Stat5-DNA binding, and/or
Stat3 dimerization, the method comprising selecting a compound having a structure of Formula A, B, C, D, E, or F
(shown in FIGS. 10-12A-D); and determining whether the
compound inhibits constitutive Stat3 activation, disrupts
Stat3-DNA binding, disrupts Stat5-DNA binding, prevents
Stat3 dimerization, or determining two or more of the foregoing.
39. The method of embodiment 38, wherein the compound
is not one selected from embodiment 1.
40. A method ofidentifying anti-cancer agents, the method
comprising selecting a compound having a structure of Formulas A, B, C, D, E, or F (shown in FIGS. 10-12A-D); and
determining whether the compound inhibits the growth of
cancer cells in vitro or in vivo.
41. The method of embodiment 41, wherein the compound
is not one selected from embodiment 1.
Assays known in the art and/or disclosed herein may be
used to evaluate cell apoptosis and/or inhibition of Stat signaling in carrying out the in vitro screening test and methods
set forth in the above embodiments, such as assays for inhibition of dimerization (see, for example, Schust, J., Berg, T.,
Analytical Biochemistry, 2004, 330(1):114-118, which is
incorporated by reference herein in its entirety); and assays
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for inhibition of DNA binding (see, for example, Turkson J. et
al., J. Biol. Chem., 2001, 276(48):45443-45455, which is
incorporated by reference herein in its entirety). Likewise,
such assays may be used to confirm the desired biological
activity possessed by analogs of the invention.

cells, inhibits their formation, and/or causes their destruction
in vitro or in vivo. Examples include, but are not limited to,
cytotoxic agents (e.g., 5-fluorouracil, TAXOL), chemotherapeutic agents, and anti-signaling agents (e.g., the PI3K inhibitor LY). In some embodiments, the anti-cancer agent is a ras
antagonist.
As used herein, the term "cytotoxic agent" refers to a
substance that inhibits or prevents the function of cells and/or
causes destruction of cells in vitro and/or in vivo. The term is
intended to include radioactive isotopes (e.g.,At211 , I 131 , I 125 ,
y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , and radioactive isotopes
of Lu), chemotherapeutic agents, toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, and antibodies, including fragments and/or variants thereof.
As used herein, the term "chemotherapeutic agent" is a
chemical compound useful in the treatment of cancer, such as,
for example, taxanes, e.g., paclitaxel (TAXOL, BRISTOLMYERS SQUIBB Oncology, Princeton, N.J.) and doxetaxel
(TAXOTERE, Rhone-Poulenc Rorer, Antony, France),
chlorambucil, vincristine, vinblastine, anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting
4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene,
LYl 17018, onapristone, and toremifene (FARESTON, GTx,
Memphis, Tenn.), and anti-androgens such as flutamide,
nilutamide, bicalutamide, leuprolide, and goserelin, etc.
Examples of chemotherapeutic agents that may be used in
conjunction with the compounds of the invention are listed in
Table 2. In a preferred embodiment, the chemotherapeutic
agent is one or more anthracyclines. Anthracyclines are a
family of chemotherapy drugs that are also antibiotics. The
anthracyclines act to prevent cell division by disrupting the
structure of the DNA and terminate its function by: (1) intercalating into the base pairs in the DNA minor grooves; and (2)
causing free radical damage of the ribose in the DNA. The
anthracyclines are frequently used in leukemia therapy.
Examples of anthracyclines include daunorubicin (CERUBIDINE), doxorubicin (ADRIAMYCIN, RUBEX), epirubicin
(ELLENCE, PHARMORUBICIN), andidarubicin (IDAMYCIN).

DEFINITIONS
As used herein, the terms "treat" or "treatment" refer to
both therapeutic treatment and prophylactic or preventative
measures, wherein the object is to prevent or slow down
(lessen) an undesired physiological change or disorder, such
as the development or spread of cancer or other proliferation
disorder. For purposes ofthis invention, beneficial or desired
clinical results include, but are not limited to, alleviation of
symptoms, diminishment of extent of disease, stabilized (i.e.,
not worsening) state of disease, delay or slowing of disease
progression, amelioration or palliation of the disease state,
and remission (whether partial or total), whether detectable or
undetectable. For example, treatment with a compound of the
invention may include reduction of undesirable cell proliferation, and/or induction of apoptosis and cytotoxicity. "Treatment" can also mean prolonging survival as compared to
expected survival if not receiving treatment. Those in need of
treatment include those already with the condition or disorder
as well as those prone to have the condition or disorder or
those in which the condition or disorder is to be prevented or
onset delayed. Optionally, the patient may be identified (e.g.,
diagnosed) as one suffering from the disease or condition
(e.g., proliferation disorder) prior to administration of the
Stat3 inhibitor of the invention.
As used herein, the term "(therapeutically) effective
amount" refers to an amount of the compound of the invention
or other agent (e.g., a drug) effective to treat a disease or
disorder in a mammal. In the case of cancer or other proliferation disorder, the therapeutically effective amount of the
agent may reduce (i.e., slow to some extent and preferably
stop) unwanted cellular proliferation; reduce the number of
cancer cells; reduce the tumor size; inhibit (i.e., slow to some
extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably
stop) tumor metastasis; inhibit, to some extent, tumor growth;
reduce Stat3 signaling in the target cells (such as by inhibiting
the binding of DNA and Stat3), and/or relieve, to some extent,
one or more of the symptoms associated with the cancer. To
the extent the administered compound prevents growth of
and/or kills existing cancer cells, it may be cytostatic and/or
cytotoxic. For cancer therapy, efficacy can, for example, be
measured by assessing the time to disease progression (TTP)
and/or determining the response rate (RR).
As used herein, the term "growth inhibitory amount" of the
compound of the invention refers to an amount which inhibits
growth or proliferation of a target cell, such as a tumor cell,
either in vitro or in vivo, irrespective of the mechanism by
which cell growth is inhibited (e.g., by cytostatic properties,
cytotoxic properties, etc.). In a preferred embodiment, the
growth inhibitory amount inhibits (i.e., slows to some extent
and preferably stops) proliferation or growth of the target cell
in vivo or in cell culture by greaterthan about 20%, preferably
greater than about 50%, most preferably greater than about
75% (e.g., from about 75% to about 100%).
The terms "cell" and "cells" are used interchangeably
herein and are intended to include either a single cell or a
plurality of cells, in vitro or in vivo, unless otherwise specified.
As used herein, the term "anti-cancer agent" refers to a
substance or treatment that inhibits the function of cancer
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Examples of Chemotherapeutic Agents
45

13-cis-Retinoic Acid
2-Amino-6Mercaptopurine

2-CdA
2-Chlorodeoxyadenosine
5-fluorouracil

50 5-FU
6-TG
6-Thioguanine
6-Mercaptopurine

6-MP
Accutane
55 Actinomycin-D
Adriamycin
Adrucil
Agrylin
Ala-Cort
Aldesleukin
60

~:~:~~~:ab

Mylocel
Letrozole
Neosar
Neulasta
Neumega
Neupogen
Nilandron
Nilutamide
Nitrogen Mustard
Novaldex
Novantrone

Octreotide
Octreotide acetate
Oncospar

Oncovin
Ontak
Onxal
Oprevelkin
Orapred
Orasone

Alkaban-AQ
Alkeran

Oxaliplatin
Paclitaxel

All-transretinoic acid

Parnidronate
Panretin

Alpha interferon
Altretamine
65 Amethopterin
Arnifostine

Paraplatin
Pediapred
PEG Interferon
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TABLE 2-continued

TABLE 2-continued

Examples of Chemotherapeutic Agents
Aminoglutethimide
Anagrelide
Anandron
Anastrozole
Arabinosylcytosine
Ara-C
Aranesp
Are di a
Arimidex
Aromasin
Arsenic trioxide
Asparaginase
ATRA
Avastin

BCG
BCNU
Bevacizumab
Bexarotene
Bicalutamide
BiCNU
Blenoxane
Bleomycin
Bortezomib
Busulfan
Busulfex
C225
Calciwn Leucovorin
Campath
Camptosar
Camptothecin-11
Capecitabine
Carac

Carboplatin
Carmustine
Carmustine wafer

Casodex
CCNU
CDDP
CeeNU
Cerubidine
cetuximab
Chlorambucil
Cisplatin
Citrovorurn Factor

Cladribine
Cortisone
Cosme gen
CPT-11
Cyclophosphamide
Cytadren
Cytarabine
Cytarabine liposomal
Cytosar-U
Cytoxan
Dacarbazine
Dactinomycin
Darbepoetin alfa
Daunomycin
Daunorubicin
Daunorubicin
hydrochloride
Daunorubicin liposomal
DaunoXome
Decadron
Delta-Cortef
Deltasone
Denileukin diftitox
DepoCyt
Dexarnethasone
Dexarnethasone acetate
dexarnethasone sodiwn
phosphate
Dexasone
Dexrazoxane
DHAD
DIC
Diodex
Docetaxel

P egaspargase
Pegfilgrastim
PEG-INTRON
PEG-L-asparaginase
Phenylalanine Mustard
Platinol
Platinol-AQ
Prednisolone
Prednisone
Prelone
Procarbazine
PROCRIT
Proleukin
Prolifeprospan 20 with Carmustine implant
Purinethol
Raloxifene

Examples of Chemotherapeutic Agents
Doxil
Doxorubicin
Doxorubicin liposomal
Droxia
DTIC
DTIC-Dome
Dural one
10 Efudex
Eligard
Ellence
Eloxatin
Elspar
Emcyt
Epirubicin
15
Epoetin alfa
Erbitux

Rheumatrex

Rituxan
Rituximab
Roveron-A (interferon alfa-2a)
Rub ex
Rubidomycin hydrochloride
Sandostatin
Sandostatin LAR
Sargrarnostim
Solu-Cortef
Solu-Medrol
STI-571
Streptozocin
Tarnoxifen
Targretin
Taxol
Taxotere
Temodar
Temozolomide
Teniposide
TESPA
Thalidomide
Thalomid
TheraCys
Thioguanine
Thioguanine Tabloid
Thiophosphoamide
Thioplex
Thiotepa
TICE
Toposar
Topotecan
Toremifene

Erwinia L-asparaginase
Estrarnustine

Ethyol
Etopophos
20 Etoposide
Etoposide phosphate
Eulexin
Evista
Exemestane
Fareston

25 Faslodex
Femara

30

35

40

Trastuzwnab
Tretinoin

Trexall
Trisenox
TSPA
VCR
Velban
Velcade
VePesid
Vesanoid
Viadur
Vinblastine
Vinblastine Sulfate
Vincasar Pfs
Vincristine
Vinorelbine
Vinorelbine tartrate
VLB
VP-16
Vumon
Xeloda
Zanosar
Zevalin

45

50

55

60

Zinecard
Zoladex
Zoledronic acid
Zometa
Gliadel wafer
Glivec

65

Filgrastim
Floxuridine
Fludara
Fludarabine
Fluoroplex
Fluorouracil
Fluorouracil (cream)
Fluoxymesterone
Flutamide
FolinicAcid
FUDR
Fulvestrant
G-CSF
Gefitinib
Gemcitabine
Gemtuzumab ozogarnicin
Gemzar
Gleevec
Lupron
Lupron Depot
Matulane
Maxidex
Mechlorethamine
Mechlorethamine
Hydrochlorine
Medralone
Medrol
Megace
Megestrol
Megestrol Acetate
Melphalan
Mercaptopurine
Mesna
Mesnex
Methotrexate
Methotrexate Sodium
Methylprednisolone

GM-CSF
Goserelin
granulocyte-colony stimulating factor
Granulocyte macrophage colony stimulating
factor
Halotestin
Herceptin
Hexadrol
Hexalen
Hexamethylmelamine
HMM
Hycamtin
Hydrea
HydrocortAcetate
Hydrocortisone
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
Hydrocortone phosphate
Hydroxyurea
Ibritumomab
Ibritumomab Tiuxetan
Idamycin
Idarubicin
Ifex
IFN-alpha
Ifosfamide
IL-2
IL-11
Imatinib mesylate
Imidazole Carboxamide
Interferon alfa
InterferonAlfa-2b (PEG conjugate)
Interleukin-2
Interleukin-11
IntronA (interferon alfa-2b)
Leucovorin
Leukeran
Leukine
Leuprolide
Leurocristine
Leustatin
Liposomal Ara-C
Liquid Pred
Lomustine
L-PAM
L-Sarcolysin
Meticorten
Mitomycin
Mitomycin-C
Mitoxantrone
M -Predniso 1
MTC
MTX
Mustargen
Mustine
Mutamycin
Myleran
Iressa
Irinotecan
Isotretinoin
Kidrolase
Lanacort
L-asparaginase
LCR

As used herein, the term "Stat" refers to signal transducers
and activators of transcription, which represent a family of
proteins that, when activated by protein tyrosine kinases in
the cytoplasm of the cell, migrate to the nucleus and activate
gene transcription. Examples of mammalian STATs include
STATl, STAT2, STAT3, STAT4, STAT5a, STAT5b, and
STAT6.
As used herein, the term "signaling" and "signaling transduction" represents the biochemical process involving transmission of extracellular stimuli, via cell surface receptors
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through a specific and sequential series of molecules, to genes
in the nucleus resulting in specific cellular responses to the
stimuli.
As used herein, the term "constitutive activation," as in the
constitutive activation of the STAT pathway, refers to a condition where there is an abnormally elevated level of tyrosine
phosphorylated STAT3 within a given cell(s), e.g., cancer
cells, as compared to a corresponding normal (e.g., noncancer or non-transformed) cell. Constitutive activation of
STAT3 has been exhibited in a large variety of malignancies,
including, for example, breast carcinoma cell lines; primary
breast tumor specimens; ovarian cancer cell lines and tumors;
multiple myeloma tumor specimens; and blood malignancies, such as acute myelogenous leukemia, as described in
published PCT international application WO 00/44 77 4 (Jove,
R. et al.), the disclosure of which is incorporated herein by
reference in its entirety.
Methods for determining whether a human or non-human
mammalian subject has abnormally high levels of constitutively-activated Stat3 are known in the art and are described,
for example, in U.S. patent publication 2004-0138189-Al
and PCT publication 02/078617 A, each of which are incorporated herein by reference in their entirety. Optionally, the
methods of the invention further comprise identifying a
patient suffering from a condition (e.g., cancer) associated
with an abnormally elevated level of tyrosine phosphorylated
STAT3, or determining whether the cancer cells can be characterized as having abnormally elevated levels of tyrosine
phosphorylated Stat3.
As used herein, the term "pharmaceutically acceptable salt
or prodrug" is intended to describe any pharmaceutically
acceptable form (such as an ester, phosphate ester, salt of an
ester or a related group) of a compound of the invention,
which, upon administration to a subject, provides the mature
or base compound (e.g., a Stat3-inhibitory compound). Pharmaceutically acceptable salts include those derived from
pharmaceutically acceptable inorganic or organic bases and
acids. Suitable salts include those derived from alkali metals
such as potassium and sodium, alkaline earth metals such as
calcium and magnesium, among numerous other acids well
known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for
example hydrolyzed or oxidized, in the host to form the
compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
Prodrugs include compounds that can be oxidized, reduced,
aminated, deaminated, hydroxylated, dehydroxylated,
hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated,
deacylated, phosphorylated, dephosphorylated to produce
the active compound.
The term "pharmaceutically acceptable esters" as used
herein, unless otherwise specified, includes those esters of
one or more compounds, which are, within the scope of sound
medical judgment, suitable for use in contact with the tissues
of hosts without undue toxicity, irritation, allergic response
and the like, are commensurate with a reasonable benefit/risk
ratio, and are effective for their intended use.
The terms "comprising", "consisting of' and "consisting
essentially of' are defined according to their standard meaning. The terms may be substituted for one another throughout
the instant application in order to attach the specific meaning
associated with each term.
The terms "isolated" or "biologically pure" refer to material that is substantially or essentially free from components
which normally accompany the material as it is found in its
native state.

As used in this specification, the singular forms "a", "an",
and "the" include plural reference unless the context clearly
dictates otherwise. Thus, for example, a reference to "a compound" includes more than one such compound. A reference
to "a Stat3 inhibitor" includes more than one such inhibitor,
and so forth.
The practice of the present invention can employ, unless
otherwise indicated, conventional techniques of molecular
biology, microbiology, recombinant DNA technology, electrophysiology, and pharmacology that are within the skill of
the art. Such techniques are explained fully in the literature
(see, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning:
A Laboratory Manual, Second Edition (1989); DNA Cloning,
Vols. I and II (D. N. Glover Ed. 1985); Perbal, B., A Practical
Guide to Molecular Cloning (1984); the series, Methods In
Enzymology (S. Colowick and N. Kaplan Eds., Academic
Press, Inc.); Transcription and Translation (Hames et al. Eds.
1984); Gene Transfer Vectors For Manmialian Cells (J. H.
Miller et al. Eds. (1987) Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y.); Scopes, Protein Purification: Principles
and Practice (2nd ed., Springer-Verlag); and PCR: A Practical
Approach (McPherson et al. Eds. (1991) IRL Press)), each of
which are incorporated herein by reference in their entirety.
Following are examples that illustrate materials, methods,
and procedures for practicing the invention. The examples are
illustrative and should not be construed as limiting.
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Cells and reagents. Normal mouse fibroblasts (NIH3T3)
and their counterparts transformed by v-Src (NIH3T3/v-Src ),
v-Ras (NIH3T3/v-Ras) or overexpressing the human EGF
receptor (NIH3T3/hEGFR), and the human breast cancer
(MDA-MB-231, MDA-MB-435, MDA-MB-453, andMDAMB-468) cells have all been previously reported (Turkson, J.
et al. J. Biol. Chem., 2001, 276:45443-45455; Yu, C. L. et al.
Science, 1995, 269:81-83; Garcia, R. et al. Oncogene, 2001,
20:2499-2513; Johnson, P. J. et al. Mal. Cell. Biol., 1985,
5:1073-1083). Cells were grown in Dulbecco's modified
Eagle's medium (DMEM) containing 10% heat-inactivated
fetal bovine serum. Antibodies C-136 and E23X for Stat!,
C20 and C20X for Stat3 and L-20 and L-20X for Stat5A were
obtained from Santa Cruz Biotechnology, Santa Cruz, Calif.,
and polyclonal anti-Src and anti-phosphoSrc antibodies from
Cell Signaling Technology, Danvers, Mass.
Transient transfection of cells and treatment with compound. Twelve to twenty-four hours following seeding, normal mouse fibroblasts (NIH3T3) were transiently co-transfected with 4 µg each of pLucTKS3, pLucSRE, or ~-Casein
Luc and 4 µg pMvSrc and 100 ng ~-galactosidase (for normalizing), or the human breast carcinoma MDA-MB-231
cells were transiently transfected with pRc/CMV-Stat3C
(kindly provided by J. Bromberg and J. Darnell (Bromberg, J.
F. et al. Cell, 1999, 98:295-303)), or with FLAG-tagged
N-terminus of Stat3 (Stat3-NT) or FLAG-tagged Stat3 SH2
domain (ST3-SH2) (Zhang, T. et al. J. Biol. Chem., 2002,
277:17556-175563), or mock transfected for 4 hours using
Lipofectamine plus (Invitrogen, Carlsbad, Calif.) and following the manufacturer's protocol. Twenty-four hours after
transfection, cells were untreated (0.05% DMSO) or treated
with S3I-201 (100 µM) for an additional 24 hours, harvested
and cytosolic extracts prepared for luciferase assay, as previously done (Turkson, J. et al. J. Biol. Chem., 2001, 276:
45443-45455; Turkson, J. et al. Mal. Cell. Biol., 1998,
18:2545-2552) or cells were analyzed by Annexin V binding
and Flow Cytometry.
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Cytosolic extracts and cell lysates preparation, luciferase
and ~-galactosidase assay. Cytosolic extract preparation from
mammalian cells for luciferase and ~-gal assays, and from
recombinant baculovirus-infected Sf9 cells to obtain Statl,
Stat3, and Stat5 monomers, and Src proteins are as described
previously (Turkson, J. et al. J. Biol. Chem., 2001, 276:
45443-45455; Turkson, J. et al. Mal. Cell. Biol., 1998,
18:2545-2552; Zhang, Y. et al. J. Biol. Chem., 2000, 275:
24935-24944). Luciferase assays were done according to the
supplier's (Promega, Madison, Wis.) manual and measured
with a luminometer. ~-gal assays were performed on lysates
from transfected cells, as previously reported (Turkson, J. et
al. J. Biol. Chem., 2001, 276:45443-45455; Turkson, J. et al.
Mal. Cell. Biol., 1998, 18:2545-2552).
Nuclear extract preparation, gel shift assays and densitometric analysis. Nuclear extract preparations and electrophoretic mobility shift assay (EMSA) were carried out as
previously described (Yu, C. L. et al. Science, 1995, 269:8183; Garcia, R. eta!. Oncogene, 2001, 20:2499-2513; Turkson,
J. et al. Mal. Cell. Biol., 1998, 18:2545-2552). The 32 P-labeled oligonucleotide probes used were hSIE (high affinity
sis-inducible element from the c-fos gene, m67 variant,
5'-AGCTTCATTTCCCGTAAATCCCTA) (SEQ ID N0:3)
that binds Statl and Stat3 (Garcia, R. et al. Oncogene, 2001,
20:2499-2513; Wagner, M. et al. Pancreas, 1999, 19:370376) and MGFe (mammary gland factor element from the
bovine ~-casein gene promoter, 5'-AGATTTCTAGGAATTCAA) (SEQ ID N0:4) for Statl and Stat5 binding (Gouilleux, F. et al. Endocrinology, 1995, 136:5700-5708; Seidel,
H. M. eta!. Proc. Natl.Acad. Sci. USA, 1995, 92:3041-3045).
Except where indicated, nuclear extracts were pre-incubated
with compound for 30 minutes at room temperature prior to
incubation with the radio labeled probe. Bands corresponding
to DNA-binding activities were scanned and quantified for
each concentration of compound and plotted as percent of
control (vehicle) against concentration of compound, from
which the IC 50 values were derived, as previously reported
(Turkson, J. et al. J. Biol. Chem., 2001, 276:45443-45455;
Turkson, J. et al. J Biol. Chem., 2005, 280:32979-32988).
Immunoprecipitation (IP) and Western blotting. Wholecell lysates and tumor tissue lysates from pulverized tumor
tissue were prepared in boiling SDS sample loading buffer to
extract total proteins, as previously described (Turkson, J. et
al. Mal Cancer Ther, 2004, 3:261-269; Turkson, J. et al. Mal.
Cancer. Ther., 2004, 3:1533-1542; Turkson, J. et al. J Biol.
Chem., 2005, 280:32979-32988; Garcia, R. et al. Oncogene,
2001, 20:2499-2513). For IP, lysates were prepared from
NIH3T3/v-Src mouse fibroblasts overexpressing the FLAGtagged Stat3 (FLAG-ST3) and Stat3-YFP in the IP buffer (25
mM Tris-HCl, pH 7.2, 150 mM NaCl, 25 mM NaF, 0.5 mM
Na orthovanadate, 20 mM PNPP, 1 mM benzamidine, 1 mM
DTT, 1% Triton X-100, 2 µg/ml aprotinin, 2 µg/ml leupeptin,
1 µg/ml pepstatin, 100 µg/ml PMSF). FLAG-ST3 and Stat3YFP were then immunoprecipitated by adding monoclonal
anti-FLAG M2 (Sigma-Aldrich, St. Louis, Mo.) or anti-YFP
(Santa Cruz) antibody and incubating at 4 ° C. overnight with
gentle rocking. ProteinA/G PLUS-Agarose (Santa Cruz) was
added at 1: 10 and incubated with rocking for 3 hours at 4 ° C.
and centrifuged at 14,000 rpm at 4° C. for 30 seconds. Bead
pellets were washed 5x in the IP buffer, equivalent volume of
3xSDS sample loading buffer added, vortexed, and boiled for
5 minutes. Equivalent amounts of total protein were electrophoresed on an SDS-7.5-15% polyacrylamide gel and transferred onto nitrocellulose membranes. Probing of nitrocellulose membranes with primary antibodies and detection of
horseradish peroxidase-conjugated secondary antibodies by
enhanced chemiluminescence (Amersham, Piscataway, N.J.)

were performed, as described previously (Turkson, J. et al.
Mal Cancer Ther, 2004, 3:261-269; Turkson, J. et al. J Biol.
Chem., 2005, 280:32979-32988; Garcia, R. et al. Oncogene,
2001, 20:2499-2513). The probes used were anti-cyclin Dl,
anti-Bcl-xL, anti-phosphoTyr-Stat3, anti-phospho-Shc, antiSurvivin, anti-Erkl/2, anti-phosphoTyr, 4G10 clone, and
anti-~-actin (Cell Signaling Technology, Beverly, Mass.),
anti-Stat3, anti-Stat5A, and anti-pErkl/2 (Santa Cruz), antiSrc (Cell Signaling Technology), anti-FLAG M2 (Sigma),
and anti-YFP (Santa Cruz).
Lck-SH2 domain-phosphopeptide binding assay. In vitro
ELISA study involving the Lck-SH2-GST protein and the
conjugate pTyr peptide, biotinyl-E-Ac-EPQpYEEIEL-OH
(SEQ ID N0:2) (Bachem Bioscience, Pa.) was performed as
previously described (Lee, T. R. and Lawrence, D. S. J Med.
Chem., 2000, 43:1173-1179). Briefly, 100 µl ofbiotinyl-EAc-EPQpYEEIEL-OH (Bachem) (in 50 mM Tris, 150 mM
NaCl, pH 7 .5) was added to each well of a streptavidin-coated
96-well microtiter plates (Pierce, Rockford, Ill.) and incubated with shaking at 4 ° C. overnight. Then plates were rinsed
with PBS-Tween 20 and then two times with 200 µl ofBSAT-PBS (0.2% BSA, 0.1% Tween 20, PBS). Then 50 µl of
Lck-SH2-GST (Santa Cruz Biotechnology) fusion protein
(6.4 ng/ml in BSA-T-PBS) was added to each well of the
96-well plate in the presence and absence of 50 µl ofS3I-201
(for 30 and 100 µM final concentrations) and the plate was
shaken at room temperature for 4 hours. After solutions were
removed, each well was rinsed four times with BSA-T-PBS
(200 µl) and 100 µl polyclonal rabbit anti-GST antibody
(CHEMICON, Temecula, Calif.) (100 ng/ml in BSA-T-PBS)
was added to each well, incubated at 4 ° C. overnight. Following washing with BSA-T-PBS, 100 µl of 200 ng/ml BSA-TPBS horseradish peroxidase conjugated mouse anti-rabbit
antibody (Amersham Biosciences) was added to each well
and incubated for 45 minutes at room temperature. After 4
washing steps each with BSA-T-PBS and 3 washing steps
each with PBS-T, 100 µl of peroxidase substrate (I-Step
Turbo TMB-ELISA, Pierce) was added to each well and
incubated for 5-15 minutes. Peroxidase reaction was stopped
by adding 100 µl IM sulfuric acid solution and absorbance
was read at 450 nm with an ELISA plate reader.
Soft-agar colony formation assay. Colony formation
assays were carried out in 6-well dishes, as described previously (Turkson, J. et al. J. Biol. Chem., 2001, 276:4544345455). Brie fly, each well contained 1.5 ml of 1% agarose in
Dulbeco's modified Eagle's medium as the bottom layer and
1.5 ml of 0.5% agarose in Dulbeco's modified Eagle's
medium containing 4000 or 6000 NIH3T3/v-Src or NIH3T3/
v-Ras fibroblasts, respectively, as the top layer. Treatment
with S3I-201 was initiated 1 day after seeding cells by adding
100 µl of medium with or without S3I-201, and repeating
every 3 days, until large colonies were evident. Colonies were
quantified by staining with 20 µl of 1 mg/ml iodonitrotetrazolium violet, incubating at 37° C. overnight, and counting
the next day.
Measurement of apoptosis by Flow Cytometry. Proliferating cells were treated with or without S3I-201 for up to 48
hours. In some cases, cells were first transfected with Stat3C,
ST3-NT, or ST3-SH2 domain or mock-transfected for 24
hours prior to treatment with compound for an additional
24-48 hours. Cells were then detached and analyzed by
Annexin V binding (BD Biosciences, San Diego) according
to the manufacturer's protocol and Flow Cytometry to quantify the percent apoptosis.
Mice and in vivo tumor studies. Six-week-old female athymic nude mice were purchased from Harlan (Indianapolis,
Ind.) and maintained in the institutional animal facilities
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approved by the American Association for Accreditation of
Laboratory Animal Care. Athymic nude mice were injected in
the left flank area s.c. with 5xl06 human breast cancer MDAMB-231 cells in 100 µL of PBS. After 5 to 10 days, tumors
with a diameter of 3 mm were established. Animals were
given S3I-201 i.v. at 5 mg/kg every 2 or 3 days for two weeks
and monitored every 2 or 3 days. Animals were stratified so
that the mean tumor sizes in all treatment were nearly identical. Tumor volume was calculated according to the formula
V=0.52xa 2 xb, where a, smallest superficial diameter, b, largest superficial diameter.
It should be understood that the examples and embodiments described herein are for illustrative purposes only and
that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included
within the spirit and purview of this application.

Arg609, whereas the phenolic hydroxyl group interacts with
Lys591 of the phosphotyrosine binding site of the Stat3 SH2
domain.

Identification of a Novel Chemical Probe as an
Inhibitor of Stat3 DNA-Binding Activity
10

15

Example 1
20

Computational Modeling and Virtual Screening
The computational modeling and virtual screening study
used the GLIDE (Grid-based Ligand Docking from Energetics) software (Friesner, R. et al. J. Med. Chem., 2004,
47:1739-1749; Halgren, T. et al. J. Med. Chem., 2004,
47:1750-1759) (available from Schriidinger, L.L.C.) for the
docking simulations, and relied on the X-ray crystal structure
of the Stat3~ homodimer bound to DNA (Becker, S. et al.
Nature, 1998, 394: 145-151) determined at 2.25 A resolution
(IBG 1 in the Protein Databank). The modeling approach was
used as a platform for structure-based virtual high throughput
screening of the chemical libraries of the NCI Diversity Set
(""2,400 3D structures) and the NCI Plated Set (""151,000 3D
structures). For the virtual screening, DNA was removed and
only one of the two monomers was employed (see FIGS. IA
and lB). To validate the docking approach, the native pTyr
peptide, APY*LKT (SEQ ID NO: 1), was extracted from the
crystal structure of one of the monomers and docked to the
other monomer, whereby GLIDE produced a docking mode
that closely resembled the X-ray crystal structure (data not
shown). Three-dimensional structures of compounds from
the NCI's chemical libraries were downloaded from the NCI
DTP website and processed with LigPrep (available from
Schriidinger, L.L.C.) to produce 2,392 3D structures for the
Diversity Set and 150,829 3D structures for the Plated Set.
Then GLIDE 2.7 SP (Standard Precision mode) docked each
chemical structure (for small-molecule) into the p Tyr peptide
binding site within the SH2 domain of the monomer in order
to obtain the best docking mode and docking score.
For stronger interactions of small-molecules within the
Stat3 SH2 domain relative to the native pTyrpeptide, emphasis is placed on maintaining the critical atomic contacts that
make the greatest contribution to the overall binding free
energy. Strong hydrogen bonding and hydrophobic interactions within the SH2 domain are observed for compounds
identified with good docking scores, which will be predicted
to be strong binders to Stat3 and potent Stat3 inhibitors. The
best score observed from the docking studies was -11. 7 kcal/
mo!, relative to the native phosphopeptide sequence
APY*LKT (SEQ IDNO:l) (scored as -l 1.9kcal/mol). Typically, compounds receiving highly favorable scores (more
negative values) have structural features that include sulfony I,
carboxyl and hydroxyl functional groups. For example, the
current hit, S3I-201(NSC74859), contains all 3 groups (FIG.
7), and from the modeling data the carboxylate moiety of
S3I-201 is predicted to interact with Ser613, Ser611, and
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The best scoring compounds from the virtual screening
studies were selected for experimental analysis using an in
vitro Stat3 DNA-binding assay. Nuclear extracts containing
activated STATs were incubated for 30 minutes with or without increasing concentrations of compounds prior to incubation with the radiolabeled hSIE probe that binds to Stat! and
to Stat3 ortheMGFeprobethatbinds to Stat! and to Stat5 and
subjected to EMSA analysis, as described under "Materials
and Methods". Results for the confirmed hit, S3I-201 (FIG.
7), show differential inhibition of DNA-binding activities of
STATs. FIG. 2A, left panel shows potent inhibition of Stat3
DNA-binding activity by S3I-201 with an average IC 50 value
of 86±33 µM (Table 3). For selectivity against STAT family
members, nuclear extract preparations from EGF-stimulated
mouse fibroblasts over-expressing the human epidermal
growth factor receptor (NIH3T3/hEGFR) containing activated Stat!, Stat3, and Stat5 were pre-incubated with or without S3I-201 prior to incubation with the radio labeled probes,
as described in "Materials and Methods". EMSA analysis of
the DNA-binding activities shows Stat3:Stat3 (upper), Stat!:
Stat3 (intermediate) and Statl:Statl (lower) bands of complexes with the hSIE probe (FIG. 2A-2) and Stat5:Stat5 (upper) and Statl:Statl (lower) bands of complexes with the
MGFe probe (FIG. 2A-2). S3I-201 preferentially inhibits
Stat3 DNA-binding activity over that of Stat!, and inhibits
that ofStat5 with a 2-fold less potency (FIG. 2A-2 and Table
3 ). The appearance of different degrees of activity of S3I-201
at 300 µM is due to the fact that different nuclear extract
preparations were used, one from the v-Src transformed
mouse fibroblasts (NIH3T3/v-Src) containing only activated
Stat3 (FIG. 2A-1) and the other from the EGF-stimulated
NIHT3T3/hEGFR that contains activated Stat!, Stat3, and
Stat5 (FIG. 2A-2). Supershift analysis with anti-Stat3 antibody shows protein:hSIE complex (FIG. 2A-1) contains
Stat3, while use of anti-Stat! antibody or anti-Stat5 antibody
confirms protein:MGFe complexes contain Stat! or Stat5,
respectively (FIG. 2A-2). These studies have identified S3I201 from the NCI chemical libraries as a potential binder
within the Stat3 SH2 domain and an inhibitor of Stat3 activation. S3I-201 shows 2-fold preference for Stat3 over Stat5
and greater than 3-fold preference over Stat! (FI GS. 2A-1 and
2A-2, and Table 3).
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TABLE3
IC 50 (mM) values for the inhibition of STATs
DNA-binding activity in vitro
55

NSC#

Stat3:3

Stall :3

Stall :1

Stat5:5

74859
(S31-201)

86 ± 33

160 ± 43

>300

166 ± 17
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Example 3
S3I-201 Disrupts Stat3:Stat3 Complex Formation In
Vitro and in Intact Cells
65

Based on the computational modeling, S3I-201 is predicted to interact with the SH2 domain of Stat3, thereby
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inhibiting active Stat3 DNA-binding activity (see FIGS. lA
and lB). To provide experimental data in support of S3I201 's binding to Stat3, the present inventors investigated
whether unphosphorylated, inactive Stat3 monomer could
interfere with the inhibitory effect ofS3I-201 on active Stat3
DNA-binding (inactive Stat3 monomer will interfere with the
inhibitory activity of S3I-201 if it interacts with the compound). To make this determination, cell lysates of unphosphorylated, inactive Stat3 monomer protein prepared from
Sf-9 insect cells infected with only baculovirus containing
Stat3, as previously described (Turkson, J. et al. J. Biol.
Chem., 2001, 276:45443-45455; Turkson, J. et al. Mal Cancer Ther, 2004, 3:261-269; Turkson, J. et al. Mal. Cancer.
Ther., 2004, 3:1533-1542; Turkson, J. et al. J Biol. Chem.,
2005, 280:32979-32988), and cell lysates of activated Stat3
dimer protein were mixed together and the mixture was preincubated with S3I-201 for 30 minutes prior to incubation
with the radiolabeled hSIE probe and EMSA analysis, as was
previously done in FIGS. 2A-1and2A-2. The unphosphorylated, inactive Stat3 monomer by itself had no significant
effect on DNA-binding activity of activated Stat3 (FIG. 2B-1,
compare lane 2 to lane 1), as inactive Stat3 monomer is
incapable of binding DNA (Turkson, J. et al. J Biol. Chem.,
2005, 280:32979-32988). Consistent with results in FIGS.
2A-1and2A-2, pre-incubation of activated Stat3 lysates with
100 µM S3I-201 completely inhibited Stat3 DNA-binding
activity (FIG. 2B-1, lanes 3 and 4). By contrast, the presence
of inactive Stat3 monomer diminished the inhibitory effect of
S3I-201 on the activated Stat3 in a dose-dependent manner,
resulting in the recovery of the active Stat3 DNA-binding
activity (FIG. 2B-1, lanes 5-7). The Stat3 DNA-binding activity that was otherwise inhibited (FIG. 2B-1, lanes 3 and 4)
was partially or completely restored in the presence of 4 or 5
µl of inactive Stat3 lysates, respectively (FIG. 2B-1, lanes 6
and 7). Therefore, while the inactive Stat3 monomer protein
is unable to bind DNA, it is capable of interacting with S3I201 by virtue of its SH2 domain. In turn, this interaction
reduces the concentration of S3I-201 that is available to
inhibit the activated Stat3. These findings support the S3I201: Stat3 interaction, which is consistent with the predictions
from the computational modeling, and suggest the interaction
is independent of the activation status ofStat3. To determine
whether unphosphorylated, inactive Stat! or Stat5 monomer
or the unrelated Src protein (with a SH2 domain) would have
effect on S3I-201, similar studies were performed using independently prepared cell lysates from Sf-9 insect cells infected
with only the baculovirus containing either Stat!, Stat5 or
Src, as the present inventors have previously reported (Turkson, J. et al. J. Biol. Chem., 2001, 276:45443-45455; Turkson,
J. et al. Mal Cancer Ther, 2004, 3:261-269; Turkson, J. et al.
Mal. Cancer. Ther., 2004, 3:1533-1542; Turkson, J. et al. J
Biol. Chem., 2005, 280:32979-32988), and containing either
of these proteins. In contrast to the effect observed with the
inactive Stat3 monomer (FIG. 2B-1, lanes 5 to 7), EMSA
analysis shows the presence of inactive Stat!, Stat5, or Src
lysate induces no significant recovery ofStat3 DNA-binding
activity (FIG. 2B-1, lanes 8 to 10, 11to13, and 14 to 16). In
the case of the Stat! monomer lysate, minimal recovery of
Stat3 DNA-binding activity is observed (FIG. 2B-1, lane 10),
which is evidence of a weak interaction of the Stat! protein
with S3I-201, as revealed in the initial evaluation (FIG.
2A-2). Compared to the effect of inactive Stat3 monomer
lysates, the minimal to no effect of inactive Stat! or Stat5
monomer, or the unrelated Src lysate suggests selective interaction of Stat3 with S3I-201, presumably through its SH2
domain. The amounts of proteins for each of Stat!, Stat3, or
Stat5 monomer, or the Src lysate used in these studies was

determined by SDS-PAGE and Western blot analysis to be
nearly similar (FIG. 2B-2, lanes 17 to 20).
To further confirm the interaction of S3I-201 with Stat3
and to demonstrate that it blocks Stat3:Stat3 dimerization in
intact cells, Stat3 pull-down assays involving two differentlytagged Stat3 proteins, FLAG-tagged Stat3 (FLAG-ST3) and
Stat3-YFP, expressed in cells were performed. Viral Src
transformed (NIH3T3/v-Src) mouse fibroblasts stably
expressing Stat3-YFP were transiently-transfected with
FLAG-ST3, and treated either with 0.05% DMSO (control)
or with S3I-201for24 hours and then subjected to pull-down
assay using anti-FLAG or anti-YFP antibody and SDSPAGE. Analysis by Western blot for FLAG of whole-cell
lysates shows equal expression of the FLAG-ST3 protein in
the lysates in the transiently-transfected cells in both the
control (DMSO-treated) and S3I-201-treated cells (FIG.
2C-2). Western blot analysis probing with anti-FLAG antibody of the Stat3-YFP immunoprecipitates shows the presence of FLAG-ST3 protein in the pulled-down lysate from
control cells (FIG. 2C-l, left panel, upper lane 1), suggesting
Stat3-YFP and FLAG-ST3 proteins were pulled down
together as a complex. By contrast, Western blot analysis
probing with anti-FLAG antibody shows no detectable level
ofFLAG-ST3 protein in the Stat3-YFP immunoprecipitates
from S3I-201-treated cells (FIG. 2C-l, left panel, upper lane
2 vs. lane 1), suggesting the disruption by S3I-201 of the
complex formation between Stat3-YFP and FLAG-ST3 proteins. The amounts of Stat3-YFP in the immunoprecipitates
are shown (FIG. 2C-l, lower left panel). Similarly, Western
blot analysis probing with anti-YFP antibody of the FLAGST3 immunoprecipitates shows Stat3-YFP present in the
pulled-down lysate from the 0.05% DMSO-treated (control)
cells (FIG. 2C-l, right panel, lower lane 3), but significantly
reduced in the FLAG-ST3 immunoprecipitates from the S3I201-treated cells (FIG. 2C-l, right panel, lower lane 4 vs. lane
3). These findings suggest FLAG-ST3:Stat3-YFP complex is
strongly formed in the control cells, but is significantly diminished in the S3I-201-treated cells. The FLAG-ST3 protein
amounts in the immunoprecipitates are shown (FIG. 2C-l,
upper right panel). Together the findings indicate that S3I-201
disrupts Stat3:Stat3 dimers, suggesting that the compound
interacts with the Stat3 SH2 domain in intact cells.
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S3I-201 does not Interfere with Lck-SH2
Domain-Phosphotyrosine Interaction
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The computational modeling predicts that S3I-201 interacts with the Stat3 SH2 domain, thereby inhibiting Stat3
DNA-binding activity (FIGS. lA and lB). To further investigate the selectivity ofS3I-201 and to rule out the possibility
that it interacts with other SH2 domain-containing proteins,
the present inventors evaluated its effect on the binding
between the unrelated Src family protein, Lek, and the cognate phosphopeptide, EPQp YEEIEL (SEQ ID N0:2) (where
p Y represents pTyr of SEQ ID NO: 1). The present inventors
used the in vitro ELISA study involving the Lck-SH2-GST
protein and the conjugate pTyr peptide, biotinyl-E-AcEPQpYEEIEL-OH (SEQ ID N0:2) (Lee, T. R. and
Lawrence, D. S. J Med. Chem., 2000, 43: 1173-1179), as
described in "Materials and Methods". Results from the
ELISA show that the co-presence of the Lck-SH2-GST protein and its cognate pTyr peptide results in signal induction
(FIG. 2D, bar 4), suggesting an interaction between the two
(Lee, T. R. and Lawrence, D. S.JMed. Chem., 2000, 43:11731179). The addition of30 µMand 100 µM S3I-201 has no
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effect on the signal induction (FIG. 2D, compare bars 5 and 6
to the bar 4), indicating that S3I-201 does not interfere with
the binding of the Lek SH2 domain to its cognate pTyr peptide, EPQpYEEIEL (SEQ ID N0:2).

(Turkson, J. et al. Mal. Cell. Biol., 1998, 18:2545-2552),
v-Src protein mediated induction of the Stat3-dependent
luciferase reporter, pLucTKS3 activity by about 7-fold (FIG.
3A). This Stat3-dependent pLucTKS3 induction was significantly inhibited by the treatment of cells with S3I-201 in a
dose-dependent manner (FIG. 3A). To examine specificity of
effects, normal mouse fibroblasts were co-transfected with
the Stat3-independent luciferase reporters, pLucSRE (Turkson, J. et al. Mal. Cell. Biol., 1998, 18:2545-2552) or
~-Casein promoter-driven Luc (Galbaugh, T. et al. BMC Cell
Biol., 2006, 7:34) together with v-Src plasmid and treated
with S3I-201 or without (0.05% DMSO). In contrast to the
effect on the induction of pLucTKS3 luciferase reporter,
v-Src-mediated induction of Stat3-independent pLucSRE
(Turkson, J. et al. Mal. Cell. Biol., 1998, 18:2545-2552) or the
~-Casein promoter Luc (Galbaugh, T. et al. BMC Cell Biol.,
2006, 7:34) was not affected by treatment with S3I-201
(FIGS. 3B and 3C). These results demonstrate that S3I-201
selectively inhibits Stat3-dependent transcriptional activity,
with no effect on Stat3-independent transcriptional events.

5

Example 5
S3I-201 Inhibits Stat3 Activation in Intact Cells
It has previously been shown that Stat3 is constitutivelyactivated in a variety of malignant cells (Yu, C. L. et al.
Science, 1995, 269:81-83; Garcia, R. et al. Oncogene, 2001,
20:2499-2513; Turkson, J. et al. Mal. Cell. Biol., 1998,
18:2545-2552). To determine the effect of S3I-201 on intracellular Stat3 activation, NIH3T3/v-Src mouse fibroblasts
and human breast cancer MDA-MB-231, MDA-MB-435 and
MDA-MB-468 cells that harbor constitutively-active Stat3
were treated with the compound and nuclear extracts prepared for Stat3 DNA-binding activity in vitro and EMSA
analysis. Compared to control (0.05% DMSO-treated cells,
lane 1), treatment with S3I-201 induced a time-dependent
inhibition of constitutive Stat3 activation in NIH3T3/v-Src
fibroblasts (FIG. 2E, lanes 4-6). By 24 hours, constitutive
Stat3 activation was significantly inhibited in the v-Src-transformed mouse fibroblasts and in the human breast cancer
MDA-MB-231, MDA-MB-435 and MDA-MB-468 cells
(FIG. 2E, lanes 4-6 and 8, 10, and 12). Furthermore, SDSPAGE and Western blot analysis of whole-cell lysates from
NIH3T3/v-Src fibroblasts show pTyr705 Stat3 levels were
significantly diminished following 24-hour treatment with
S3I-201 (FIG. 2F), while total Stat3 protein level remained
unchanged. This inhibition of tyrosine phosphorylation may
be explained by the fact that by binding to the Stat3 SH2
domain, S3I-201 prevents Stat3 from binding to the pTyr
motifs of the receptor tyrosine kinases (RTKs) and subsequently blocks de nova phosphorylation by tyrosine kinases.
To investigate non-specific effects, SDS-PAGE and Western
blot analysis was performed on whole-cell lysates from
mouse fibroblasts transformed by v-Src (NIH3T3/v-Src) or
overexpressing the human EGFR (NIH3T3/hEGFR) and
stimulated by EGF to determine the ability to inhibit other
signaling proteins. Treatment with S3I-201 for 24 hours had
no significant effect on the phosphorylation of She (pShc),
Erkl/2 (pErkl/2), or Src (pSrc) in cells (FIGS. 2G-l and
2G-2). Total Erkl/2 protein levels were unchanged. Moreover, SDS-PAGE and Western blot analysis with the anti-pTyr
antibody 4G 10 clone shows no significant changes in the pTyr
profile ofNIH3T3/v-Src fibroblasts following 24-hour treatment with S3I-201 (FIG. 2G-4), while same treatment condition significantly diminishes pTyr705 Stat3 levels (FIG.
2F). These results together indicate that at the concentrations
that inhibit Stat3 activity, S3I-201 does not significantly interfere with other signal transduction mechanisms.
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Selective Inhibition of Stat3 Transcriptional Activity
by S3I-201
The ability of S3I-201 to inhibit Stat3:Stat3 complex formation and Stat3 DNA-binding activity prompted us to investigate its effect on Stat3-dependent transcriptional activity.
Normal mouse fibroblasts (NIH3T3) were transiently cotransfected with the Stat3-dependent luciferase reporter,
pLucTKS3 and a plasmid encoding the v-Src oncoprotein
that activates Stat3 and cells were untreated (0.05% DMSO,
control) or treated with S3I-201. As previously reported

60

65

The above results of FIGS. 2 and 3 demonstrate that S3I201 disrupts Stat3 activation. The present inventors next
determined whether this Stat3 activity inhibitor is able to
inhibit the anchorage-dependent and -independent (transformation) growth of human and mouse cancer cell lines and
whether this inhibition is dependent on the presence of persistently-active Stat3. The human breast carcinoma (MDAMB-231, MDA-MB-435 and MDA-MB-468) cell lines and
the v-Src-transformed mouse fibroblasts (NIH3T3/v-Src)
that harbor constitutively-active Stat3, and the human breast
carcinoma MDA-MB-453 cell line and normal mouse fibroblasts (NIH3T3) that do not harbor aberrant Stat3 activity
were treated with S3I-201 and analyzed for viable cell number by trypan blue exclusion and microscopy (FIG. 4A-4F) or
MTT assay (data not shown). Treatment with S3I-201 significantly reduced viable cell numbers and inhibited growth of
transformed mouse fibroblasts NIH3T3/v-Src and breast carcinoma cell lines (MDA-MB-231, MDA-MB-435 and MDAMB-468) (FIGS. 4E, 4D, and 4F, respectively). By contrast,
growth and viability of normal mouse fibroblasts (NIH3T3)
and breast carcinoma cell line (MDA-MB-453) without aberrant Stat3 activity were not significantly altered (FIGS. 4A
and 4B). Thus, S3I-201 affected only those cell lines harboring aberrant Stat3, consistent with inhibition of Stat3 DNAbinding activity (Table 3 and FIG. 2).
To further examine the effects of S3I-201 on Stat3 biological functions, the compound was tested for its ability to
inhibit the growth of v-Src transformed mouse fibroblasts
(NIH3T3/v-Src) in soft-agar suspension in colony formation
assays. Results show that growth ofv-Src transformed mouse
fibroblasts in soft-agar suspension is significantly inhibited
by S3I-201 (FIG. 4G). By contrast, soft-agar growth ofv-Ras
transformed counterpart (NIH3T3/v-Ras) that is independent
of constitutively-active Stat3 is unaffected by treatment with
S3I-201 (FIG. 4G), indicating that S3I-201 selectively inhibits Stat3-mediated malignant transformation.
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without S3I-201. Annexin V binding and Flow Cytometry
showed that while mock-transfected cells were strongly
induced by S3I-201 to undergo apoptosis (FIG. SB, left
panel), similar to the Stat3C-transfectedcells, the overexpression of the Stat3-SH2 domain diminished the apoptotic
effects of S3I-201 (FIG. SB, left panel). In contrast, cells
overexpressing the ST3-NT region showed strong induction
of apoptosis (FIG. SB, left panel), suggesting ST3-NT has no
effect on the ability ofS3I-201 to induce apoptosis of malignant cells. The present inventors infer that the exogenous
ST3-SH2 domain binds to S3I-201, thereby preventing the
compound from binding to and inhibiting endogenous constitutively-active Stat3 protein and its biological functions.

S3I-201 Preferentially Induces Apoptosis of
Malignant Cells Harboring Constitutively-Active
Stat3
The present inventors next determined if the S3I-201
induced loss of tumor cell viability is due to apoptosis. To this
end, the human breast carcinoma cell lines, MDA-MB-453
and MDA-MB-435, and the normal mouse fibroblasts
(NIH3 T3) and their v-Src transformed counterpart (NIH3 T3/
v-Src) were untreated (0.05% DMSO, control) or treated with
S3I-201 for48hours and analyzed by Annexin Vbindingand
Flow Cytometry. At 30-100 µM, S3I-201 induced significant
apoptosis in the representative human breast carcinoma cell
line, MDA-MB-435 and the NIH3T3/v-Src, all of which harbor constitutively-active Stat3 (FIG. SA). The breast carcinoma MDA-MB-435 cell line is more sensitive to 30 µM
S3I-201 (FIG. SA). By contrast, the human breast cancer
MDA-MB-453 cells and the normal mouse fibroblasts
(NIH3T3) that do not contain abnormal Stat3 activity are less
sensitive to S3I-201 at 100 µM or less (FIG. SA). These
findings indicate that at concentrations that inhibit Stat3
activity, S3I-201 selectively induces apoptosis of transformed cells harboring aberrant Stat3 signaling, suggesting
the inhibition of constitutively-active Stat3 is part of the
underlying mechanism of apoptosis by S3I-210. At 300 µMor
higher, S3I-201 induced general, non-specific cytotoxicity
independent of Stat3 activation status.
The present inventors reasoned that ifthe ability ofS3I-201
to induce tumor cell apoptosis is due to its ability to inhibit
Stat3 activation, then the constitutively-dimerized and persistently-activated Stat3C (Bromberg, J. F. et al. Cell, 1999,
98:295-303) should rescue from S3I-201-induced apoptosis.
To this end, the breast carcinoma MDA-MB-231 cells that
harbor activated Stat3 were transiently transfected with
Stat3C and evaluated for apoptosis. Twenty-four hours after
transfection, cells were treated or untreated with S3I-201 for
an additional 24-48 hours, harvested and analyzed by
Annexin V binding and Flow Cytometry. Consistent with
results in FIG. SA, S3I-201 induced 50-80% apoptosis in
untransfected or mock-transfected human breast carcinoma
MDA-MB-231 cells (FIG. SB, left panel). By contrast, cells
transfected with Stat3C and treated with S3I-201 showed
greatly diminished apoptosis (FIG. SB, left panel)-less than
2-fold compared with 9- or 5-fold apoptosis in non-transfected or mock-transfected cells, respectively. There is
increased in the background level of cell death, which could
be due to the effects of transfection. The rescue from the
apoptotic effects ofS3I-201 can be explained on the basis that
the artificially-designed activated Stat3C is not inhibited by
S3I-201 and is sufficient to promote the biological effects of
the endogenous Stat3. Thus the activated Stat3C rescues cells
from the apoptotic effects ofS3I-201 by compensating forthe
loss of endogenous Stat3 activity due to inhibition by S3I201.
To establish that the effect of S3I-201 is due to its interaction with the Stat3 SH2 domain, similar studies were performed in cells which were transiently-transfected with either
an expression vector for the N-terminal region of Stat3 (ST3NT) or the Stat3 SH2 domain (ST3-SH2) and treated with or
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S3I-201 Represses the Expression of the Stat3
Regulated Genes Cyclin Dl, Bcl-xL, and Survivin
To investigate the molecular mechanisms for the cell
growth inhibition and apoptosis by S3I-201, the present
inventors examined the expression of the known Stat3 target
genes in the v-Src-transformed mouse fibroblasts (NIH3T3/
v-Src) and the human breast carcinoma MDA-MB-231 cell
line that harbor constitutively-active Stat3. Immunoblot
analysis ofwhole-cell lysates shows significant reduction in
expression of the Cyclin D 1, Bcl-xL and Survivin proteins in
response to S3I-201 treatment (FIG. SC), indicating that S3I201 represses induction of the cell cycle and anti-apoptotic
regulatory genes in malignant cells. These findings are consistent with the biological effects induced by S3I-201 (FIGS.
3-S), and correlate with the inhibition of aberrant Stat3 activity.
Example 10
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S3I-201 Induces Regression of Human Breast Tumor
Xenografts
The aforementioned findings demonstrate that S3I-201
possesses a strong inhibitory activity against aberrant Stat3,
potently inhibits anchorage-dependent and -independent
tumor cell growth, and induces apoptosis of malignant cells in
a Stat3-dependent manner. The present inventors extended
these studies to evaluate the antitumor efficacy of S3I-201
using mouse models of human breast tumor xenografts that
harbor constitutively-active Stat3. Human breast (MDA-MB231) tumor-bearing mice were given i.v. injection ofS3I-201
or vehicle every 2 or every 3 days for two weeks, and tumor
measurements were taken every 2 to 3 days. Compared to
control (vehicle-treated) tumors, which continued to grow,
strong growth inhibition of human breast tumors were
observed in mice that received S3I-201 (FIG. 6A). Continued
evaluation of treated mice upon termination of treatment
showed no resumption of tumor growth (data not shown),
suggesting potentially a long-lasting effect of S3I-201 on
tumor growth. To determine that target was inhibited by S3I201, lysates were prepared from tumor tissue from one control animal and from the residual tumor tissue in two treatedmice for Stat3 DNA-binding activity in vitro, as the present
inventors have previously done (Turkson, J. et al. Mal. Cancer. Ther., 2004, 3:1533-1542). EMSA analysis showed
strong inhibition of Stat3 DNA binding activity in residual
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tumor tissue from mice treated with S3I-201 (Tl and T2)
compared to control tumor (FIG. 6B, lanes 1 to 3). SDSPAGE and Western blot analysis of the lysates revealed minimal to no detection of pTyr Stat3 (pYStat3) in residual tumor
tissue from treated mice (Tl and T2) compared to control
(FIG. 6C, upper panel). Total Stat3 protein remained
unchanged (FIG. 6C, lower panel). Moreover, EMSA analysis of in vitro Stat3 DNA-binding activity also shows that
pre-incubation of lysates of equal total protein from control
tumor tissue with 10, 30, and 100 µM S3I-201 prior to incubation with radiolabeled hSIE probe resulted in a dose-dependent abrogation ofStat3 activity (FIG. 6B, lanes 4 to 6), as
observed originally in FIG. 2A-1. Together, these studies
establish the proof-of-concept for the antitumor effect of
S3I-201 in tumors that harbor constitutively-active Stat3.
The data in the Examples demonstrate the feasibility of
using X-ray crystallographic data and computational modeling as a basis for a structure-based virtual screening to identify chemical probes and small-molecule binders of the Stat3
SH2 domain. The docking approach with GLIDE 2.7
(Friesner, R. et al. J. Med. Chem., 2004, 47:1739-1749; Halgren, T. et al. J. Med. Chem., 2004, 47:1750-1759) was first
validated using the native pTyr peptide, APY*LKT, which
produced a docking mode that closely resembled the X-ray
crystal structure (Becker, S. et al. Nature, 1998, 394:145151). By this approach, the present inventors have docked and
scored small-molecules from the NCI Chemical libraries into
the Stat3 SH2 domain, and identified potent binders that
ranked within the top -0.1 % of the docked and scored Plated
Set 3D structures. S3I-201 (NSC 74859) emerged as a potent
inhibitorofStat3 DNA-binding activity in vitro. Similar computational analysis has been applied in the development of
inhibitors of Stat3 and other proteins (Shao, H. et al. J Biol.
Chem., 2004, 279:18967-18973; Song, H. et al. Proc Natl
Acad Sci USA, 2005, 102:4700-4705). The docking pose of
S3I-201 suggests that its aminosalicylic moiety mimics the
phenylphosphate group of the PY*LKT motif. Furthermore,
its carboxyl group is hydrogen bonded totheArg 609, Ser611
and Ser 613 of Stat3, while the phenolic hydroxyl group is
hydrogen-bonded to Lys 591. Moreover, the proximity of the
Lys 591 to the benzene ring that contains the phenolic
hydroxyl group suggests the possibility of a stabilizing pication interaction. Also, the tolyl group is buried within a
partially hydrophobic pocket, which contains the tetramethylene portion of the side chain ofLys 592 and the trimethylene portion of the side chain of Arg 595, along with residues
Ile 597 and Ile 634. The present inventors believe that these
features (the phosphate mimic and hydrophobic side chain)
combine and explain how S3I-201 binds to the SH2 domain
of Stat3.
The native pTyr peptide inhibitor of Stat3, APY*LKT
(SEQ ID NO: 1), was previously shown to disrupt Stat3:Stat3
dimerization, thereby inducing antitumor cell effects (Turkson, J. et al. Mal Cancer Ther, 2004, 3:261-269). The computational analysis predicts that S3I-201 is a reasonably
strong binder within the Stat3 SH2 domain, raising the possibility that it might disrupt Stat3:Stat3 dimerization as a
mode of inhibition of Stat3. Using differently-tagged Stat3
monomer proteins in pull-down assays, the present inventors
demonstrate that S3I-201 disrupts the complex formation
between two Stat3 monomers. S3I-201 preferentially interacts with Stat3 monomer protein over Statl or the Src family
protein, and has a 2-fold lower potency for Stat5. In cells, the
interactions with Stat3 will prevent binding of the Stat3 SH2
to RTKs and Src and/or Jaks and inhibit de nova phosphorylati on and activation of Stat3 monomer. Thus, S3 I-201 mediates selective inhibition of Stat3 transcriptional activity,

induces cell growth inhibition, loss of viability, and apoptosis
of human breast cancer and v-Src-transformed mouse cells
that harbor constitutively-active Stat3, as well as blocks v-Src
transformation, events which are all consistent with the abrogation of Stat3 activation (Turkson, J. et al. J. Biol. Chem.,
2001, 276:45443-45455; Turkson, J. et al. Mal Cancer Ther,
2004, 3:261-269; Garcia, R. et al. Oncogene, 2001, 20:24992513; Catlett-Falcone, R. et al. Immunity, 1999, 10:105-115;
Mora, L. B. et al. Cancer Res, 2002, 62:6659-6666). The
observation that overexpressed exogenous Stat3 SH2
domain, but not Stat3 N-terminus in malignant cells protects
against S3I-201-induced apoptosis strongly supports the
Stat3 SH2 domain as thetargetofS3I-201, and for that reason
will bind to S3I-201 in cells, thereby preventing the S3I-201
from inhibiting endogenous Stat3 activity. Moreover, the rescue from the apoptotic effects of S3I-201 by the ectopic
expression of the constitutively-active Stat3C in malignant
cells demonstrates that Stat3C compensates for the absence
of aberrant Stat3 signaling. Thus, these findings further
strongly suggest the anti-tumor cell effects of S3I-201 are
mediated by suppressing aberrant Stat3-induced dysregulation of the cell cycle control and the anti-apoptotic genes.
Furthermore, in vivo antitumor effects of S3I-201 in human
breast tumor xenografts establish the proof-of-concept forthe
therapeutic potential of S3I-201 as a Stat3 inhibitor in human
tumors that harbor constitutively-active Stat3.
Described herein is the first report of a Stat3 SH2 domain
binder and an inhibitor of Stat3 signaling, which is structurally different from previously identified dimerization disruptors, peptides and peptidomimetics (Turkson, J. et al. J. Biol.
Chem., 2001, 276:45443-45455; Turkson, J. et al. Mal Cancer Ther, 2004, 3:261-269), or other Stat3 inhibitors, such as
the g-quartet oligonucleotides (Jing, N. et al. DNA Cell Biol,
2003, 22:685-696), peptide aptamers (Nagel-Wolfrum, K. et
al. Mal Cancer Res, 2004, 2:170-182), platinum (IV) complexes (Turkson, J. et al. Mal. Cancer. Ther., 2004, 3: 15331542; Turkson, J. et al. J Biol. Chem., 2005, 280:3297932988), cucurbitacin (Blaskovich, M. A. et al. Cancer Res,
2003, 63:1270-1279), and STA-21 (NSC 628869) (Song, H.
et al. Proc NatlAcad Sci USA, 2005, 102:4700-4705). While
SH2 domains have been noted to have a high sequence similarity in their 100 amino acids (Sheinerman, F. B. et al. J Mal.
Biol., 2003, 334:823-841; Kuriyan, J. andCowburn, D.Annu
Rev Biophys Biomol Struct., 1997, 26:259-288), S3I-201 has
preference for Stat3 in that at concentrations that inhibit
Stat3, S3I-201 has low effect on Statl and Stat5, no interaction with the Src family proteins, weak inhibition ofErks 1/2
and She activation, and low toxicity to cells with no aberrant
Stat3.
The study described herein supports computational modeling application in structure-based virtual screening for
identifying Stat3 inhibitors from chemical libraries, and
together with another report (Song, H. et al. Proc Natl Acad
Sci USA, 2005, 102:4700-4705) is among the first to identify
Stat3 inhibitors by this approach. S3I-201 represents a new
lead for developing combinatorial libraries with increased
diversity, thereby setting a new course in the Stat3 inhibitor
design.
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The following compounds were prepared according to
Scheme 1.
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Ethyl 2-(tosyloxy)acetate (2). A solution of ethyl glycolate
(500 mg, 4.8 mmol) and tosyl chloride (915 mg, 4.8 mmol) in
anhydrous diethyl ether (2 ml) at 0° C. was treated dropwise
with triethylamine (1.34 ml, 9.6 mmol). The temperature was
maintained at 0° C. with stirring for a further 2 h. After this
time, water was added and the phases separated. The aqueous
phase was extracted with fresh diethyl ether. The combined
organic extracts were dried (MgSO4 ), filtered and the solvent
removed in vacuo. The crude product was purified by column
chromatography over silica gel (Rf=0.29, 25% ethyl acetate in
hexane) affording the tosylate 2 as a colorless oil which
solidified on standing as a white solid (868 mg, 70% ). [This
procedure was repeated on 2x scale (1.8 g, 73%)]. OH (400
MHz, CDC1 3 ) 1.22-1.27 (3H, m, CH 3 ), 2.46 (3H, s,ArCH 3 ),
4.16-4.22 (2H, m, CH 2 CH 3 ), 4.58-4.59 (2H, m, OCH 2 ), 7.36
(2H, d, J=8.2Hz,ArHf,7.84 (2H, d, J=8.2 Hz,ArH); oc(I00.6
MHz, CDC1 3 ) 14.2, 21.9, 62.1, 64.9, 128.3, 130.1, 132.9,
145.5, 166.2; MS (ES+) 276.0 (100%, [M+H 2 0t) (ion not
detected in ES-).
2-(Tosyloxy)acetic acid (3). A solution of ethyl 2-(tosyloxy)acetate (2, 860 mg, 3.33 mmol) in ethanol (4 ml) was
treated at room temperature with 5% NaOH aqueous solution
(2 ml). The resulting mixture was stirred at room temperature
for 3 h. The ethanol was removed in vacuo and aqueous 5%
HCl solution (2.7 ml) was added. The aqueous mixture was
extracted with chloroform and the organic extracts dried
(Na2 S04 ), filtered and the solvent removed under reduced
pressure. The remaining white solid was recrystallized from
hexane/ethyl acetate as a white powder (476 mg, 62%). [This
reaction was repeated on 2x scale (1.449 g, 94%)]. OH (400
MHz, MeOD) 2.45 (3H, s, Me), 4.58 (2H, s, CH 2 ), 7.44 (2H,
d, J=8.2 Hz, ArH), 7.82 (2H, d, J=8.2 Hz, ArH); oc (100.6
MHz, MeOD) 20.4, 64.7, 128.0, 129.9, 133.0, 145.6, 168.2;
MS (ES+) 247.8 (100%, [M+H 2 0t); MS (ES-) 170.1 (100%,
Tso-).
2-Chloro-2-oxoethyl-4-methylbenzenesulfonate (4). A
mixture of 2-(tosyloxy)acetic acid (3, 400 mg, 1.74 mmol)
and thionyl chloride (I ml) was heated at reflux for 1.5 h. The
excess thionyl chloride was removed in vacuo and the resulting white solid dried under high vacuum at 50° C. for 1.5 h.
The product acid chloride was used without further purification.
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2-Hydroxy-4-(2-(tosyloxy )acetamido )benzoic acid
(NSC-59263). A mixture of p-amino salicylic acid (I 02 mg,
0.67 mmol) and NaOH (27 mg, 0.67 mmol) in water (6 ml)
was stirred at room temperature for I 0 min until all of the
solid material had dissolved. Na2 C0 3 (59 mg, 0.5561 mmol)
was then added and the mixture cooled to 0° C. A solution of
2-chloro-2-oxoethyl-4-methylbenzenesulfonate (4, 200 mg,
0.8044 mmol) in THF (2 ml) was injected rapidly and the
resulting solution allowed to warm to room temperature and
stirred for 2 h. Then reaction mixture was poured into a
separating funnel containing diethyl ether. The phases were
separated and the aqueous phase washed with a further portion of diethyl ether. The aqueous phase was acidified to pH I
by addition of IN HCl solution and the product extracted into
ethyl acetate. The ethyl acetate was washed twice with IN
HCl solution and the organic phase was dried (Na2 S04 ),
filtered and the solvent removed in vacuo. The resulting pale
yellow solid was triturated with chloroform leaving I as a
white powder (155 mg, 63%). OH (400 MHz, DMSO) 2.37
(3H, s, Me), 4.68 (2H, s, CH 2 ), 6.93 (lH, d, J=7.4 Hz, ArH),
7.17 (lH, s, ArH), 7.46 (2H, d, J=6.8 Hz, ArH), 7.69 (lH, d,
1=7.4 Hz, ArH), 7.81 (2H, d, J=6.8 Hz, ArH), 10.32 (lH, s,
NH); oc(I00.6 MHz, DMSO) 21.8, 68.0, 107.0, 110.7, 128.5,
130.9, 131.7, 132.7, 144.5, 146.0, 162.8, 164.5, 172.2; MS
(ES+) 366.0 (100%, [M+Ht), 388.0 (50%, [M+Nat); (ion
not detected in ES-).
4-(2-(Tosyloxy)acetamido)benzoic acid (5). A mixture of
p-aminobenzoic acid (92 mg, 0.67 mmol) and NaOH (27 mg,
0.67 mmol) in water (6 ml) was stirred at room temperature
for I 0 min until all of the solid material had dissolved.
Na 2 C0 3 (59 mg, 0.5561 mmol) was then added and the mixture cooled to 0° C. A solution of 2-chloro-2-oxoethyl-4methylbenzenesulfonate (4, 200 mg, 0.8044 mmol) in THF (2
ml) was injected rapidly and the resulting solution allowed to
warm to room temperature and stirred for 2 h. Then reaction
mixture was poured into a separating funnel containing
diethyl ether. The phases were separated and the aqueous
phase washed with a further portion of diethyl ether. The
aqueous phase was acidified to pH I by addition of IN HCl
solution and the product extracted into ethyl acetate. The
ethyl acetate was washed twice with IN HCl solution and the
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organic phase was dried (Na 2S04 ), filtered and the solvent
removed in vacuo. The resulting pale orange solid was recrystallized from chloroform/MeOH (20: 1) affording 5 as a white
powder (146 mg, 62%). OH (400 MHz, DMSO) 2.37 (3H, s,
Me), 4.70 (2H, s, CH 2), 7.46 (2H, d, 1=8 Hz,ArH), 7.59 (2H,
d, 1=8.6 Hz, ArH), 7.82 (2H, d, 1=8 Hz, ArH), 7.87 (2H, d,
1=8.6 Hz, ArH), 10.39 (lH, s, NH), 12.72 (lH, C0 2H); oc
(100.6 MHz, DMSO) 21.8, 68.0, 119.4, 126.4, 128.5, 130.9,
131.1, 132.7, 142.7, 146.0, 164.4, 167.5; MS (ES+) 349.7
(100%, [M+Ht), 371.7 (40%, [M+Nat); MS (ES-) 347.9
(100%, [M-Hn; HRMS [M-H]- requires 348.05473, found
348.05334.
Compounds 6, 7, and 8

The following compounds were prepared according to
Scheme 2.
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General Procedure: A suspension of the aniline derivative
(0.455 mmol) in water (6 ml) was stirred at room temperature
for 10 min. Na 2C0 3 ( 40 mg, 0.455 mmol) was then added and
the mixture cooled to 0° C. A solution of 2-chloro-2-oxoethyl-4-methylbenzenesulfonate (4, 125 mg, 0.5 mmol) in THF
(2 ml) was injected rapidly and the resulting solution allowed
to warm to room temperature and stirred for 2 h.
2-0xo-2-(pheny!amino )ethy I 4-methy lbenzenesulfonate
(6): A white precipitate formed in the reaction mixture. This
precipitate was collected by filtration, washed with water and
dried under high vacuum. This afforded 6 as an off white
powder (103 mg, 7 4% ). An analytical sample was obtained by
recrystallization from hexane/ethyl acetate (white needles).
oH(400 MHz, MeOD) 2.40 (3H, s, CH 3 ), 4.63 (2H, s, CH 2),
7.10 (lH, t, 1=7.6 Hz, ArH), 7.28 (2H, t, 1=7.6 Hz, ArH),
7.41-7.50 (4H,m,ArH), 7.85 (2H, d, 1=8Hz); oc(l00.6 MHz,
MeOD) 20.4, 67.2, 120.5, 124.7, 128.1, 128.6, 130.0, 132.6,
137.5, 145.9, 164.6; MS (ES+) 306.0 (100%, [M+Ht);
HRMS [M+Ht requires 306.07946, found 306.07944.
2-(4-Cyanophenylamino )-2-oxoethyl 4-methylbenzenesulfonate (7): A orange precipitate formed in the reaction
mixture. This precipitate was collected by filtration, washed
with water and dried under high vacuum. The solid was
shown by NMR analysis to comprise of the desired product
and starting material. The solid was purified by colunm chromatography (Rf=0.39, 50% ethyl acetate in hexane) affording
7 as anoffwhitepowder(58mg, 39%). oH(400MHz, MeOD/
DMSO spike) 2.41 (3H, s, CH 3 ), 4.68 (2H, s, CH 2), 7.44 (2H,
d, 1=8 Hz,ArH), 7.66-7.71 (4H, m,ArH), 7.86 (2H, d, 1=8 Hz,
ArH); oc (1000.6 MHz, MeOD/DMSO spike) 20.5, 67.3,
107.1, 118.6, 120.1, 128.2, 130.1, 133.1, 142.2, 146.0, 165.0;
MS (ES+) 330.7 (55%, [M+Ht), 347.7 (100%, [M+H2on.
2-0xo-2-(4-sulfamoylphenylamino )ethyl 4-methylbenzenesulfonate (8): A white precipitate formed in the reaction
mixture. This precipitate was collected by filtration, washed
with water and dried under high vacuum. This afforded 8 as an
off white powder (109 mg, 62%). An analytical sample was
obtained by recrystallization from acetone/ethyl acetate (colourless/white crystals). OH (400 MHz, MeOD/DMSO spike)
2.42 (3H, s, CH 3 ), 4.68 (2H, s, CH 2), 7.44 (2H, d, 1=8 Hz,
ArH), 7.67 (2H, d, 1=8.4 Hz, ArH), 7.83 (2H, d, 1=8.4 Hz,
ArH), 7.87 (2H, d, 1=8 Hz, ArH); oc (100.6 MHz, MeOD/
DMSO spike) 20.5, 67.3, 119.8, 127.0, 128.2, 130.1, 132.7,
139.3, 141.2, 146.0, 164.9; MS (ES+) 348.0 (100%), 385.0
(20%, [M+Ht), 402.0 (50%, [M+H2on.
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2-(4-Methylphenylsulfonamido)acetic acid (9). Glycine (1
g, 13.32 mmol) was dissolved in IN NaOH (aq.) and a solutionoftosyl chloride (2.62 g, 13.72 mmol) in diethyl ether(15
ml) was added portion wise with stirring over 10 min. The
resulting mixture was allowed to stir at room temperature for
3 h. The ethereal layer was separated and the aqueous layer
treated with 2N HCI solution until acidified to pH 5. After
cooling the resulting solution to 0° C., the product began to
precipitate from the solution. The solid was collected by
filtration and the mother liquor placed in a fridge overnight
causing more of the desired product to precipitate. The solid
was again collected by filtration and the combined collected
solid was dried under high vacuum affording 9 as a white
powder (613 mg, 21%). oH(400 MHz, MeOD) 2.41 (3H, s,
CH 3 ), 3.66 (2H, s, CH 2), 7.35 (2H, d, 1=8 Hz,ArH), 7.73 (2H,
d, 1=8 Hz, ArH); oc (100.6 MHz, MeOD) 20.3, 43.6, 127.0,
129.5, 137.6, 143.6, 171.0; MS (ES+) 246.8 (100%,
[M+H 20t); MS (ES-) 227.9 (100%, [M-Hn; HRMS
[M-H]- requires 228.03360, found 228.03364.
2-(4-Methylphenylsulfonamido)acetyl chloride (10). A
mixture of 2-( 4-methylphenylsulfonamido )acetic acid (9,
200 mg, 0.873 mmol) and thionyl chloride (1 ml) was heated
at reflux for 1.5 h. The excess thionyl chloride was removed in
vacuo and the resulting white solid dried under high vacuum
at 50° C. for 1.5 h. The product acid chloride 10 was used
without further purification.
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Hydroxy-4-[ 4-methylphenylsulfonamido )acetamido ]benzoic acid (11 ). A mixture of p-aminosalicylic acid (111 mg,
0.728 mmol) and NaOH (29 mg, 0.728 mmol) in water (6 ml)
was stirred at room temperature for I 0 min until all of the
solid material had dissolved. Na 2C0 3 (64 mg, 0.604 mmol)
was then added and the mixture cooled to 0° C. A solution of
2-( 4-methylphenylsulfonamido )acetyl chloride (I 0, 216 mg,
0.873 mmol) in THF (2 ml) was injected rapidly and the
resulting solution allowed to warm to room temperature and
stirred for 2 h. Then reaction mixture was poured into a
separating funnel containing diethyl ether. The phases were
separated and the aqueous phase washed with a further portion of diethyl ether. The aqueous phase was acidified to pH I
by addition of IN HCl solution and the product extracted into
ethyl acetate. The ethyl acetate was washed twice with IN
HCl solution and the organic phase was dried (Na 2S04 ),
filtered and the solvent removed in vacuo. The resulting pale
yellow solid was triturated with chloroform leaving 11 as an
offwhitepowder(187 mg, 71 %). oH(400MHz, MeOD) 2.36
(3H, s, CH 3 ), 3.72 (2H, s, CH 3 ), 6.90 (lH, dd, 1=8.6 Hz and
1.8 Hz, ArH), 7.17 (lH, d, l=l.6, ArH), 7.33 (2H, d, 1=8 Hz,
ArH), 7.73-7.76 (3H, m,ArH); oc (100.6 MHz, MeOD) 21.6,
46.6, 106.7, 110.9, 127.3, 130.2, 131.7, 138.1, 143.4, 145.5,
162.7, 167.7, 172.2; MS (ES+) 364.7 (100%, [M+Ht), (ion
not detected in ES-).
Ethyl 2-( 4'-chlorobiphenyl-4-ylsulfonyloxy)acetate (12).
A suspension of ethyl glycolate (73 mg, 0.6964 mmol) and
4-chloro[l ,1 '-biphenyl]-4-sulfonyl chloride (200 mg, 0.6964
mmol) in anhydrous diethyl ether (I ml) at 0° C. was treated
dropwise with triethylamine (0.194 ml, 1.393 mmol). The
temperature was maintained at 0° C. with stirring for a further
2 h. After this time, water was added and the phases separated.
The aqueous phase was extracted with fresh diethy1ether. The
combined organic extracts were dried (MgS04 ), filtered and
the solvent removed in vacuo. The crude product was purified
by colunm chromatography over silica gel (Rf=0.45, 25%
ethyl acetate in hexane) affording 12 as a colorless oil which
solidified on standing as an off white solid (213 mg, 86%). OH
(400 MHz, CDC1 3 ) 1.25 (3H, t, 1=7.2 Hz, CH 3 ), 4.21 (2H, q,
1=7.2 Hz, CH 2), 4.65 (2H, s, CH 2), 7.46-7.55 (4H, m, ArH),
7 .73 (2H, d, 1=8.8 Hz, ArH), 8.03 (2H, d, 1=8.4 Hz, ArH); oc
(100.6 MHz, CDC1 3 ) 14.2, 62.2, 65.0, 127.9, 128.8, 129.0,
129.6, 134.8, 135.4, 137.6, 146.1, 166.2; MS (ES+) 372.0
(100%, [M+H20t); MS (Es-) 266.9 (100%, [M-Hn.
2-(4'-Chlorobiphenyl-4-ylsulfonyloxy)acetic acid (13). A
solution of ester 12 (200 mg, 0.5633 mmol) in ethanol (0.7
ml) was treated at room temperature with 5% NaOH aqueous
solution (0.45 ml). The resulting mixture was stirred at room
temperature for 3 h. The ethanol was removed in vacuo and
aqueous 5% HCl solution (0.46 ml) was added. The aqueous
mixture was extracted with chloroform and the organic
extracts dried (Na 2S04 ), filtered and the solvent removed
under reduced pressure. The remaining white solid was
recrystallized from chloroform as a white powder (133 mg,
72% ). (Material that did not crystallize was collected by
colunm chromatography using a gradient ethyl acetate to
50% MeOH in ethyl acetate). OH (400 MHz, MeOD) 4.65
(2H, s, CH 2), 7.50 (2H, d, 1=8.4 Hz,ArH), 7.70 (2H, d, 1=8.4
Hz,ArH), 7.88 (2H, d, 1=8.4 Hz,ArH), 8.02 (2H, d, 1=8.4 Hz,
ArH); oc (100.6 MHz, MeOD) 65.2, 127.7, 128.6, 128.8,
129.1, 134.9, 135.0, 137.7, 145.7, 168.3; MS (ES+) 343.7
(100%, [M+H 20t), 323.7 (5%, [M+Ht), (ion not detected
in ES-).
2-Chloro-2-oxoethy1 4'-chloro bipheny1-4-sulfonate (14 ).
A mixture of acid 13 (100 mg, 0.306 mmol) and thionyl
chloride (I ml) was heated at reflux for 1.5 h. The excess
thionyl chloride was removed in vacuo and the resulting pale

yellow/white solid dried under high vacuum at 50° C. for 1.5
h. The product acid chloride 14 was used without further
purification.
4-(2-( 4'-Chlorobiphenyl-4-ylsulfonyloxy)acetamido )-2hydroxybenzoic acid (15).Amixture of p-aminosalicylic acid
(43 mg, 0.278 mmol) and NaOH (II mg, 0.278 mmol) in
water (6 ml) was stirred at room temperature for I 0 min until
all of the solid material had dissolved. Na2C0 3 (25 mg, 0.231
mmol) was then added and the mixture cooled to 0° C. A
suspension of 14 (105 mg, 0.306 mmol) in THF (2 ml) was
injected rapidly and the resulting solution allowed to warm to
room temperature and stirred for 2 h. Then reaction mixture
was poured into a separating funnel containing diethyl ether.
The phases were separated and the aqueous phase washed
with a further portion of diethyl ether. The aqueous phase was
acidified to pH I by addition of IN HCl solution and the
product extracted into ethyl acetate. The ethyl acetate was
washed twice with IN HCl solution and the organic phase
was dried (Na2SO4 ) and filtered. The product was found to be
in both the diethyl ether and ethyl acetate fractions so these
organic phases were combined and the solvent removed in
vacuo. The product was purified by colunm chromatography
over silica gel (R1=0.27, 10% MeOH in ethyl acetate) affording 15 as a yellow powder (45 mg, 35%). An analytical
sample was obtained by further purification by recrystallization from EtOAc/MeOH. OH (400 MHz, MeOD) 4.72 (2H, s,
CH 2), 6.89 (lH, dd, 1=8.6 Hz and 1.8 Hz, ArH), 7.13 (lH, d,
1=1.8 Hz, ArH), 7.46 (2H, d, 1=8.4 Hz, ArH), 7.58 (2H, d,
1=8.4 Hz, ArH), 7.70 (lH, d, 1=8.6 Hz, ArH), 7.82 (2H, d,
1=8.4 Hz, ArH), 8.03 (2H, d, 1=8.4 Hz, ArH); MS (ES-) 401.9
(100%), 459.8 (75%, [M-Hn.
Ethy12-(bipheny1-4-ylsulfony loxy )acetate ( 16). A suspension of ethyl glycolate (374 µl, 3.957 mmol) and biphenyl-4sulfonyl chloride (I g, 3.957 mmol) in anhydrous diethyl
ether (2 ml) at 0° C. was treated dropwise with triethylamine
(I.I ml, 7.914 mmol). The temperature was maintained at 0°
C. with stirring for a further 2 h. After this time, water was
added and the phases separated. The aqueous phase was
extracted with fresh diethyl ether. The combined organic
extracts were dried (MgS04 ), filtered and the solvent
removed in vacuo. The crude product was purified by column
chromatography over silica gel (Rf=0.26, 25% ethyl acetate in
hexane) affording 16 as a colourless oil (1.055 g, 83%). OH
(400 MHz, CDC1 3 ) 1.25 (3H, t, 1=6.8 Hz, CH 3 ), 4.20 (2H, q,
1=6.8 Hz, CH 2), 4.65 (2H, s, CH 2), 7.44-7.51 (3H, m, ArH),
7.61 (2H, d, 1=7.6 Hz,ArH), 7.76 (2H, d, 1=8 Hz,ArH), 8.01
(2H, d, 1=8 Hz, ArH); oc (100.6 MHz, CDC1 3 ) 14.2, 62.2,
65.0, 127.6, 128.1, 128.9, 129.0, 129.4, 134.4, 139.2, 147.4,
166.2; MS (ES+) 338.1 (100%, [M+H2on.
2-(Biphenyl-4-ylsulfonyloxy)acetic acid (17). A solution
of ester 16 (1.05 g, 3.281 mmol) in ethanol (4 ml) was treated
at room temperature with 5% NaOH aqueous solution (2.6
ml). The resulting mixture was stirred at room temperature
for 3 h. The ethanol was removed in vacuo and aqueous 5%
HCl solution (2.6 ml) was added. The aqueous mixture was
extracted with chloroform and the organic extracts dried
(Na 2S04 ), filtered and the solvent removed under reduced
pressure. The remaining white solid was recrystallized from
hexane/ethyl acetate as a white powder (806 mg, 84%). OH
(400 MHz, MeOD) 4.66 (2H, s, CH 2), 7.41-7.51 (3H, m,
ArH), 7.69 (2H, d, 1=7.2 Hz, ArH), 7.87 (2H, d, 1=8.4 Hz,
ArH), 8.01 (2H, d, 1=8.4 Hz, ArH); oc (100.6 MHz, MeOD)
64.9, 127.2, 127.7, 128.6, 128.7, 129.0, 134.5, 139.1, 147.2,
168.2.
2-Chloro-2-oxoethyl biphenyl-4-sulfonate (18). A mixture
of acid 17 (200 mg, 0.685 mmol) and thionyl chloride (I ml)
was heated at reflux for 1.5 h. The excess thionyl chloride was
removed in vacuo and the residue dried under high vacuum at
50° C. for 1.5 h. The product acid chloride 18 was used
without further purification.
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4-(2-(bipheny1-4-ylsulfonamido )acetamido )-2-hydroxybenzoic acid (19).A mixture of p-aminosalicylic acid (95 mg,
0.623 mmol) and NaOH (25 mg, 0.623 mmol) in water (6 ml)
was stirred at room temperature for I 0 min until all of the
solid material had dissolved. Na 2 C0 3 (55 mg, 0.517 mmol)
was then added and the mixture cooled to 0° C. A suspension
of 18 (213 mg, 0.685 mmol) in THF (2 ml) was injected
rapidly and the resulting solution allowed to warm to room
temperature and stirred for 2 h. Then reaction mixture was
poured into a separating funnel containing diethyl ether. The
phases were separated and the aqueous phase washed with a
further portion of diethyl ether. The aqueous phase was acidified to pH I by addition of IN HCl solution and the product
extracted into ethyl acetate. The ethyl acetate was washed
twice with IN HCl solution and the organic phase was dried
(Na2 S04 ), filtered and the solvent removed in vacuo. The
product was found to be in both the diethyl ether and ethyl
acetate fractions so these organic phases were combined and
the solvent removed in vacuo. The product was purified by
colunm chromatography over silica gel (Rf=0.22, 10%
MeOH in ethyl acetate) affording 19 as a yellow powder (I 09
mg, 41 %). An analytical sample was obtained by further
purification by recrystallization from EtOAc/hexane. OH (400
MHz, DMSO) 4.76 (2H, s, CH 2 ), 6.96 (lH, d, J=8.4 Hz,ArH),
7.22 (lH, s,ArH), 7.42-7.74 (6H, m,ArH), 7.93-8.01 (4H, m,
ArH), 10.37 (lH, s, NH); MS (ES+) 428.0 (100%, [M+Ht).

4-(2-(Bipheny1-4-ylsulfony loxy)acetamido) benzoic acid
(20). A mixture of p-aminobenzoic acid (43 mg, 0.31 mmol)
and NaOH (12.5 mg, 0.31 mmol) in water (3 ml) was stirred
at room temperature for I 0 min until all of the solid material
had dissolved. Na 2 C0 3 (27 mg, 0.258 mmol) was then added
and the mixture cooled to 0° C. A suspension of sulfonyl
chloride 18 (106mg, 0.341 mmol) in THF (I ml) was injected
rapidly and the resulting solution allowed to warm to room
temperature and stirred for 2 h. Then reaction mixture was
poured into a separating funnel containing diethyl ether. The
phases were separated and the aqueous phase washed with a
further portion of diethyl ether. The aqueous phase was acidified to pH I by addition of IN HCl solution and the product
extracted into ethyl acetate. The ethyl acetate was washed
twice with IN HCl solution and the organic phase was dried
(Na 2 S04 ), filtered and the solvent removed in vacuo. The
resulting solid was recrystallized from hexane/ethyl acetate
affording acid 20 as an off white powder (81 mg, 64%). OH
(400 MHz, DMSO) 4.79 (2H, s, CH 2 ), 7.45-7.70 (9H, m,
ArH), 7.86-8.03 (4H, m, ArH), 10.43 (lH, NH); oc (100.6
MHz, DMSO) 68.2, 119.4, 126.5, 127.9, 128.6, 129.2, 129.6,
129.8, 131.1, 134.3, 138.7, 142.7, 146.7, 164.4, 167.5; MS
(ES+) 411.7 (100%, [M+Ht).
The following compounds were prepared according to similar method as shown in Scheme 3
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32 and 31 were synthesized as outlined in the Scheme 3
Synthesis of the intermediate la: The sulfonyl chloride
(0.99S g, 3.94 mmol) was suspended in pyridine:DCM (10
ml: S ml) and ethyl glycinate (O.SOO g, 3.S8 mmol) was added
at room temperature under argon atmosphere, and stirred at
room temperature for 4 h. The reaction mixture was diluted
with EtOAc and washed with 4M HCl followed by brine. The
organic phase was dried (MgS04 ) and concentrated to obtain
the intermediate la (0.941 g). This intermediate was carried
to the next stage without purification.
The intermediate 1b was synthesized using the same procedure.
Synthesis of the intermediate 2a: The intermediate la (900
mg, 2.82 mmol) was suspended in EtOH:H 2 0 (9 ml: 1 ml)
andNaOH (S%wt, SO mg) was added to the reaction mixture
and refluxed for 3 h. The reaction mixture was cooled to room
temperature, acidified (pH=2-3) and extracted with EtOAc.
The combined organic phase was dried (MgS04 ) and concentrated to obtain the required acid (770 mg) as a white powder.
The carboxylic acid obtained was refluxed with thionyl chloride:DCM (3:1) for 2-3 h. The excess thionyl chloride was
removed under vacuum to give the intermediate 2a (820 mg).
This product was carried to the next stage.
The intermediate 2b was synthesized using the same procedure.
4-[2-{ 4-(Phenyl)phenylsulfonamido) }acetamido]benzoic
acid (32). para-Aminosalicylic acid (S4 mg, 0.3S mmol) was
suspended in water (4 ml) and 3 drops of THF was added to
dissolve the compound. Na 2 C0 3 was added to the reaction
mixture and cooled to 0° C. A solution ofintermediate 2a (100
mg, 0 .3 22 mmol) in THF ( 1. S ml) was added over l S min. The
reaction mixture was stirred at room temperature for 3 h. A
solution of 4M HCl was added portionwise to obtain a precipitate. The white precipitate was filtered and washed with
water and dried under vacuum to obtain 32 (4S mg) as a pure
compound: 1 H NMR (DMSO-d6 , 400 MHz) o 12.7 (broads,
lH), 8.17 (t, 1=12.0 Hz, lH), 7.88-7.81 (m, SH), 7.64 (d,
1=7.2 Hz, 2H), 7.S7(d,1=8.4 Hz, 2H), 7.47(t,1=7.2 Hz, 2H),
7.42 (d, 1=4.0 Hz, lH), 3.72 (d, 1=4.0 Hz, lH).
4-[2-{ 4-( 4'-chlorophenyl)phenylsulfonamido) }acetamido ]benzoic acid (31 ). The synthesis of 31 achieved in a
similarmannerto32. 1 HNMR(CD 3 0D, 400MHz) o7.9S (d,
1=8.4 Hz, 2H), 7.88(d,1=9.2 Hz, 2H), 7.72(d,1=8.0Hz, 2H),
7.S3-7.SO (m, 4H), 7.43 (d, 1=8.0 Hz, 2H), 3.80 (s, 2H).
Compounds 21, 22, 23, 24, 2S, 26, 27, 28, 29 and 30 were
synthesized using the procedure outlined for compound 32
from appropriate acyl chlorides and amines.
2-Hydroxy-4-(2-(4-bipheny lsulfony loxy)acetamido) benzoic acid (21). 1 H NMR (CD 3 0D, 400 MHz) o 7.93 (d, 1=8
Hz, 2H), 7.73(d,1=8.4 Hz, 2H), 7.18(d,1=8.4 Hz, lH), 7.SS
(d, 1=7.6 Hz, 2H), 7.44-7.3S (3H, m), 7.16 (appd, lH), 6.88
(dd, 1=8.4, 1.2 Hz, lH), 3.77 (s, 2H).
4-(2-(Benzyloxy)acetamido)benzoic acid (22). 1 H NMR
(CD 3 0D, 400MHz) o 7.97(d,1=6.4 Hz, 2H), 7.71(2H,1=6.8
Hz, 2H), 7.44-7.31 (m, SH), 4.68 (s, 2H), 4.11 (s, 2H).
4-(2-(Benzyloxy)acetamido )-2-hydroxybenzoic acid (23).
1
H NMR (CD 3 0D, 400 MHz) o 7.78 (d, 1=8.0 Hz, lH),
7.42-7.30 (m, 6H), 7.07-7.0S (d, 1=8.0 Hz, lH), 4.66 (s, 2H),
4.08 (s, 2H).
4-(3-(Phenylsulfonyl)propanamido )-2-hydroxybenzoic
acid(24). 1 HNMR (CD 3 0D, 400 MHz) o 7.9S-7.91(m,4H),
7.70-7.S6 (m, SH), 3.60 (t, 1=8.0 Hz, 2H), 2.81(t,1=8.0 Hz).
4-(3-(Phenylsulfonyl)propanamido )benzoic acid (2S). 1 H
NMR (CD 3 0D, 400 MHz) o 7.94 (d, 1=8.0 Hz, 4H), 7.73 (d,
1=8.8 Hz, 4H), 7.69 (d, 1=7.6 Hz, 2H), 7.63-7.S9 (m, 2H),
7.20 (d, 1=2.0 Hz, lH), 6.93 (dd, 1=8.4, 1.6 Hz, lH), 3.60 (t,
1=7.2 Hz, 2H), 2.79 (t, 1=6.8 Hz, 2H).
4-(4-Phenylbutanamido )-2-hydroxybenzoic acid (26). 1 H
NMR (CD 3 0D, 400 MHz) o 7.31 (appd, l=l.6 Hz, lH),

7.27-7.13 (m, SH), 7.01 (dd, 1=8.4, 1.6 Hz, lH), 2.67(t,1=7.2
Hz, 2H), 2.38 (t, 1=6.8 Hz, 2H), 2.02-l.9S (m, 2H).
4-(4-Phenylbutanamido)benzoic acid (27). 1 H NMR
(CD 3 0D, 400 MHz) o 7.9S (d, 1=8.8 Hz, 2H), 7.66 (d, 1=8.8
Hz, 2H), 7.27-7.lS (m, SH), 2.68 (t, 1=8 Hz, 2H), 2.40 (t,
1=8.0 Hz, 2H), 2.00 (m, 2H).
2-(Biphenyl-4-ylsulfonamido)-N-(4-cyanophenyl)acetamide (28). 1 H NMR (CD 3 0D, 400 MHz) o 8.09 (broad t, lH),
8.02(d,1=8.0 Hz, lH), 7.87(d,1=8.8 Hz, 2H), 7.7S-7.64 (m,
SH), 7.47-7.43 (m, 4H), 4.S3 (s, lH), 3.96 (appd, lH).
4-(2-(Biphenyl-4-ylsulfonamido )acetamido )benzenesulfonic acid (29). 1 H NMR (CD 3 0D, 400 MHz) o 7.94 (d,
1=8.4 Hz, 2H), 7.7S (d, 1=8.0Hz, 2H), 7.71(d,1=8.0Hz, 2H),
7.S8(d,1=8.0 Hz, 2H), 7.S0-7.38 (m, 6H), 3.78 (s, 2H).
2-(Biphenyl-4-ylsulfonamido)-N-(4-sulfamoylphenyl)acetamide (30). 1 H NMR (CD 3 0D, 400 MHz) o 10.27 (s, lH),
8.16 (broad t, lH), 7.84 (m, 4H), 7.69-7.63 (m, 6H), 7.48
(broad t, 2H), 7.43 (d, 1=6 Hz, lH), 7.23 (s, 2H), 3.72 (appd,
1=6 Hz, 2H).
The following compounds were prepared according to
Scheme 4
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61.04 (s) (C(CH 3 ) 3 ), 80.56 (s) (CH 2 CH 3 ), 119.07 (s) (2xCH,
Ar), 125.90 (s) (C, Ar), 129.0S(s) (2xCH, Ar), 129.17 (s)
(2xCH, Ar), 130.90 (s) (2xCH, Ar), 133.17 (s) (C, Ar),
140.35 (s) (C, Ar), 142.65 (s) (C, Ar), 157.54 (s) (C=O),
166.47 (s) (C=O), 170.32 (s) (C=O). vmax (pure sample)/
(cm- 1 )), 3353 (md), 1685 (st) (C=O), 1685 (st) (C=O),
1661 (st) (C=O), 1524 (st), 1273 (st), 1249 (st), 1188 (st),
769 (md).
4-Phenoxybenzenesulfonyl chloride. A solution of 4-phenoxybenzenesulfonic acid (3.14 g, 12.64 mmol) in thionyl
chloride (9 ml) was refluxed for 4 h in presence of DMF (2
drops). After cooling to room temperature, diethyl ether (20
ml) was added and the resulting white solid was separated by
filtration. The filtered solution was evaporated in vacuo to
give 4-phenoxybenzenesulfonyl chloride as a brown oil
which was used in the next step without further purification.
3-(4-Chlorophenyl)-4-( 4-methylphenylsulfonamido)-Nphenylbutanamide (36). To a solution of34 (0.106 g, 0.271
mmol) in DCM (2 ml) TFA (2 ml) was added. After stirring
for 2 h at room temperature, the solvent was distilled under
reduced pressure to give a brown solid. The crude residue was
dissolved as obtained in 1,4-dioxane:H2 0 1:1 (5 ml) and
K 2 C0 3 (0.225 g, 1.63 mmol, 6 eq) was added followed by
tosyl chloride (0.056 g, 0.298 mmol, 1.1 eq) at room temperature. After stirring for 2 h at room temperature, the resulting
mixture was evaporated in vacuo to dryness. Water (10 ml)
was added and the resulting white solid was separated by
filtration and dried. Pure 36 was obtained without further
purification (0.079 g, 0.179 mmol, 66%), mp 200-202° C. 1 H
NMR (400 MHz, CD 3 0D) ll 2.39 (3H, s, Ar-CH 3 ), 2.56
(lH, dd, J 9.2, 14.4 Hz, H--CHCO), 2.77 (lH, dd, Jo.8, 14.4
Hz, H-CHCO), 3.06 (Ill, dd, J 8.2, 13.0 Hz, H--CHNH),
3.15"(1H, dd, J 6.8, 13.2 Hz, H--CHNH) 7.03-T.07 (lH, m,
CH,Ar), 7.15 (2H, d, J 8.4 HZ,-2xCH,Ar), 7.21-7.26 (4H, s,
4xCH, Ar), 7.29 (2H, d, J 8.0 Hz, 2xCH, Ar), 7.36-7.38 (2H,
m, 2xCH, Ar), 7.62 (2H, d, J 8.8 Hz, 2xCH, Ar). 13 C NMR
(400 MHz, DMSO-d 6 ) ll21.63 (s) (Ar--CH 3 ), 40.73 (s)
(CH 2 CO), 41.87 (s) (CH 2 CHCH 2 ), 48.ff (s) (CH 2 NH),
1T9.79 (s) (2xCH, Ar), 113.80 (s) (CH, Ar), lTI.14 (s)
(2xCH, Ar), 128.80 (s) (2xCH, Ar), 129.29 (s) (2xCH, Ar),
130.23 (s) (2xCH,Ar), 130.36 (s) (2xCH,Ar), 131.80 (s) (C,
Ar), 138.14 (s) (C, Ar), 139.64 (s) (C, Ar), 141.53 (s) (C, Ar),
143.20 (s) (C, Ar), 169.81 (s) (C=O). vmax (pure sample)/
(cm- 1 ) 3340 (md) (N-H), 3141 (md) (N-H), 1665 (st)
(C=O), 1598 (st), 1547 (st), 1493 (md), 1444 (st), 1154 (st),
1087 (md). MS (API-ES): m/z 443 [M+Hr (100%), HRMS
(API-ES) m/z found 443.1201 [M+Hr.
Ethyl 4-(4-(4-benzylphenylsulfonamido)-3-(4-chlorophenyl)butanamido )benzoate (37). The compound was obtained
as a white solid in 65% from 35 and 4-phenoxybenzenesulfonyl chloride in a similar manner as described for preparation
of36, mp. 1 H NMR (400 MHz, CD 3 0D) ll 1.36 (3H, t, J 6.8
Hz, CH 2 CH 3 ), 2.60 (lH, dd, J 8.0, 14.8 Hz, H--CHCO), 2.82
(lH, dd, Jo.D, 14.8 Hz, H--CHCO), 3.09 (lH, dd, J 7.8, 13.4
Hz, H-CHNH), 3.16 (Ill, dd, J 6.4, 13.2 Hz, H--CHNH),
4.3T"{2H, q, J 7.2 Hz, CH 2 CH 3 ), 6.99 (2H, cl, J 7.2 Hz),
7.06-7.08 (2H, m), 7.18 (111, d, J 8.4 Hz), 7.18 (2H, d, J 8.4
Hz), 7.19-7.24 (3H, m), 7.40-744 (2H, m), 7.56 (2H, d, J 8.8
Hz), 7.72 (2H, d, J 8.8 Hz), 7.91 (2H, d, J 8.8 Hz). MS
(API-ES): m/z 593[M+Hr (100%), HRMS (API-ES) m/z
found 593.15134 [M+Ht.
Ethy I 4-(3-( 4-chlorophenyl )-4-(4-methy lpheny lsulfonamido )butanamido) benzoate (38). The compound was
obtained as a white solid in 96% from 35 and tosyl chloride in
a similar manner as described for preparation of 28, mp
187-189° C. 1 HNMR (400MHz, CD 3 0D) lll.36 (3H, t, 17.2
Hz, CH 2 CH 3 ), 2.39 (3H, s, Ar--CH 3 ), 2.60 (lH, dd, J 8.8,
14.8 Hz, ""H-CHCO), 2.82 (H-r,-dd, J 6.0, 14.8 Hz,
H--CHC0),3.06 (lH, dd, J 8.0, 13.2 Hz, H-CHNH), 3.14
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4-(tert-Butoxycarbony!amino )-3-(4-chloropheny I) butanoic acid (33). Ref J. of Peptide Research, 2003, 61, 331.
BOC 2 0 (5.32 g, 24.41 mmol, 1 eq) was added to a stirred
solution of Bacio fen (5.20 g, 24.41 mmol) and Na OH IM (73
ml) in water (73 ml) and 1,4-dioxane (73 ml) at 0° C. After
stirring for 4 hat room temperature, a 10% aqueous solution
o citric acid was added until pH 3. The formed white solid was
filtered, washed with water (50 ml) and dried. The pure acid
33 was obtained without further purification (6.43 g, 20.56
mmol, 84%), mp 139-141° C. 1 H NMR (400 MHz, CD 3 0D)
ll 1.37 (9H, s), 2.50 (lH, dd, J 8.8, 15.2 Hz), 2.66 (lH, dd, J
5.0, 15.4 Hz), 3.12-3.27 (3H, m), 7.22 (2H, d, J 8.4 Hz), 7.27
(2H, d, J 8.4 Hz).
tert-Butyl 2-( 4-chlorophenyl)-4-oxo-4-(phenylamino )butylcarbamate (34). To a solution of33 (0.206 g, 0.657 mmol,
1.2 eq) and aniline (0.051 g, 0.548 mmol) in dry DMF (5 ml)
HATU (0.315 g, 0.9087 mmol, 1.5 eq) and DIPEA (0.340 g,
2.63 mmol, 4 eq) was added at room temperature under Ar.
After stirring overnight at room temperature, the reaction
mixture was quenched with water ( 10 mL) and extracted with
ethyl acetate (2x15 ml). The organic extracts were collected,
dried over Na 2 S04 and the solvent was distilled off under
reduced pressure. The crude compound was purified by chromatography on silica gel (3:7 ethyl acetate/hexane, v/v, Rf
0.30) to give 34 as a white solid (0.120 g, 0.307 mo!, 47%),
mp 165-167° C. 1 H NMR (400 MHz, CDCl 3 ) ll 1.43 (9H, s),
2.55 (lH, dd, J 5.0, 13.8 Hz), 2.75 (lH, dd, J 8.4, 13.6 Hz),
3.16-3.39 (2H, m), 3.52-3.57 (lH, m), 4.60 (lH, bs), 7.077.13 (3H, m), 7.29-7.32 (4H, m), 7.54 (2H, d, J 8.4 Hz), 8.61
(lH, bs).
Ethyl 4-( 4-(tert-butoxycarbonylamino )-3-(4-chlorophenyl)butanamido )benzoate (35). The compound was prepared
from 33 and ethyl 4-aminobenzoate in a similar manner as
described for preparation of34. Chromatography on silica gel
(7:3 hexanes/ethyl (Rf0.20) afforded 35 as a brown solid in
72% yield. 1 H NMR (400 MHz, CD 3 0D) ll 1.35 (9H, s, C(
CH 3 ), 1.35 (3H, t, J 6.8 Hz, CH 2 CH 3 ), 2.63 (lH, dd, J 8.6,
T4:""0 Hz, H--CHCO), 2.77 (Hr,-dd, J 6.2, 14.6 Hz,
H-CHC0),3.35-3.40 (lH, m, CH 2 CHCH 2 ), 4.31 (2H, q, J
T.2 Hz, CH 2 CH 3 ), 7.24 (2H, d, J 8.8 Hz-;LxAr-H), 7.28 (2H,
d, J 8.8 Hz,2xAr-H), 7.57 (2H, d, J 8.4 Hz, 2xAr-H), 7.91
(2H, d, J 9.2 Hz, 2xAr-H). 13 C NMR (400 MHz, CDCl 3 ) ll
14.56 (s) (CH 2 CH 3 ), 28.56 (s) (C(CH 3 ) 3 ), 40.92 (s)
(CH 2 CO), 42.7r(s) (CH 2 CHCH 2 ), 4s:-97 (s) (CH 2 NH),
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(lH, dd, J 6.8, I3.2 Hz, H---CHNH) 4.32 (2H, q, J 7.2 Hz, C
H 2 CH 3 ), 7.I5 (2H, d, J lr.8 Hz), 7.22 (2H, d, J 8.4 Hz), 7.29
{LR, d, J 8.4 Hz), 7.54 (2H, d, J 8.8 Hz), 7.62 (2H, d, J 8.4 Hz),
7.9I (2H, d, J 9.2 Hz). 13 C NMR (400 MHz, DMSO-d 6 ) ll
I4.88 (s) (CH 2 CH 3 ), 21.62 (s) (Ar---CH 3 ), 40.74 (s)
(CH 2 CO), 41.7o(s) (CH 2 CHCH 2 ), 48.23 (s) (CH 2 NH),
6T.08 (s) (CH 2 CH 3 ), II9.0o(s) (2xCH, Ar), I24.78 (s) (C,
Ar), I27.34{s) (2xCH,Ar), I28.83 (s) (2xCH,Ar), I30.23 (s)
(2xCH, Ar), I30.36 (s) (2xCH, Ar), I30.84 (s) (2xCH, Ar),
I31.83 (s) (C, Ar), I38.I5 (s) (C, Ar), I41.42 (s) (C, Ar),
I43.20 (s) (C, Ar), I43.95 (s) (C, Ar), I65.98 (s) (C=O),
I 70.47 (s) (C=O). v max (pure sample)/( cm- 1 ) 3320 (md),
3292 (md), I 7I2 (st) (C=O), I677 (st) (C=O), I598 (md),
I540 (st), 13I5 (st), I272 (st), 1149 (st), II04 (st). MS (APIES): m/z 5I5 [M+Ht (100%), HRMS (API-ES) m/z found
5I5.I4II [M+Ht.
4-(3-( 4-Chlorophenyl)-4-( 4-methylphenylsulfonamido)
butanamido )benzoic acid (39). A solution of 36 (0.023 g,
0.044 mmol) in methanol (I ml) and THF (I ml) was stirred

in presence ofNaOH IM (I ml) overnight at rt. The solution
remaining was concentrated in vacuo. HCl IM (I ml) was
added and the formed white solid was filtered, washed with
water (5 ml) and dried. Pure 39 was obtained without further
need for purification (O.OI5 g, 0.030 mmol, 68%), mp 2502520 C. 1 H NMR (400 MHz, CD 3 0D) ll 2.39 (3H, s, Ar---C
H3 ), 2.60 (lH, dd, J 8.8, I4.8 Hz, H---CHCO), 2.82 (lH, dd,
J6.4, I4.8 Hz, H---CHCO), 3.06(1H, dd, J 8.0, I3.2 Hz,
H---CHNH), 3.I4(1H, dd, J 6.8, I3.2 Hz, H-CHNH), 7.I6
PH, d, J 8.8 Hz), 7.23 (2H, d, J 8.4 Hz), 7.29{:2H, d, J 8.0Hz),
7.54 (2H, d, J 9.2 Hz), 7.62 (2H, d, J 8.4 Hz), 7.92 (2H, d, J 8.8
Hz). 13 C NMR (100 MHz, DMSO-d 6 ) ll. vmax (pure sample)/
(cm- 1 ) I864 (st), I665 (st), I653 (st), I604 (st), I5I9 (st),
I455 (st), I324 (st), I290 (st), II64 (st), 115I (st). MS (APIES): m/z 485 [M-Hr (100%), HRMS (API-ES) m/z found
485.0935 [M-H].
The following compounds were prepared according to
Scheme 5.
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:::::J a
:::::J a

47,
48,
49,
50,

R
R
R
R

~Ph,

R1 ~ H, R1 ~ C02Et
2-Np, R1 ~ H, R1 ~ C02Et
~ 2-Np R1 ~ OBn, R1 ~ C02Me
~ 4-ClPh, R1 ~ OBn, R1 ~ C02Me
~

51, R
52, R
53, R
54, R

R1 ~ H, R1 ~ C02Et
~ 2-Np, R1 ~ H, R1 ~ C02Et
~ 2-Np, R1 ~ OBn, R1 ~ C02Me
~ 4-ClPh, R 1 ~ OBn, R2 ~ C02Me
~Ph,

-f

59, R
60, R
61, R
62, R
65, R
68, R

~Ph,

R1 ~ H, R1 ~ C02Et, R3 ~ CH3
R1 ~ H, R1 ~ C02H, R3 ~ OC6Hs
~ 2-Np R1 ~ H, R1 ~ C02H, R3 ~ OC6Hs
~ 2-Np, R1 ~ H, R1 ~ C02H, R3 ~ CH3
~ 2-Np, R1 ~ H, R1 ~ C02H, R3 ~ OC6Hs
~ 4-ClPh, R1 ~OH, R1 ~ C02H, R3 ~ OC6Hs
~Ph,

Key:
a benzyl bromide, DMF, K 2 C0 3 , rt, Ar, overnight;
b DBU, CH3 N02' mw, 100° C., 15 min;
c NiC12' NaBJ4, MeOH, 0° C., 20 min;
d 4-phenoxybenzenesulfor chloride or tosyl chloride, K 2 C0 3 , dioxane, H 2 0, rt, 2-3 h;
e ammonium formate, Me OH, 10% Pd/C, rt, Ar, 2 days;
f THF, MeOH, NaOH lM, rt, overnight Abbreviation Ph= phenyl, Np= naphthyl.

55, R ~Ph, R1 ~ H, R1 ~ C02Et, R3 ~ CH3
56, R ~Ph, R1 ~ H, R1 ~ C02Et, R3 ~ OC6Hs
57, R ~ 2-Np, R1 ~ H, R1 ~ C02Et, R3 ~ OC6Hs
58, R ~ 2-Np, R1 ~ H, R1 ~ C02Et, R3 ~ CH3
63, R ~ 2-Np, R1 ~ OBn, R1 ~ C02Me, R3 ~ OC6Hs
64, R ~ 2-Np, R1 ~OH, R1 ~ C02Me, R3 ~ OC6Hs
66, R ~ 4-ClPh, R1 ~ OBn, R1 ~ C02Me, R3 ~ OC6Hs
67, R ~ 4-ClPh, R1 ~OH, R1 ~ C02Me, R3 ~ OC6Hs

:::::J e
:::::J e
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4-(3-( 4-Chlorophenyl)-4-( 4-phenoxyphenylsulfonamido)
butanamido )benzoic acid (40). A solution of ester 38 (0.06S
g, O.I07 mmol) in methanol (l.S ml) and THF (l.S ml) was
stirred in presence ofNaOH IM (I ml) for 2 hat 80° C. After
cooling to rt, the solution remaining was concentrated in
vacuo. HCl IM (l.S ml) was addedand the formed white solid
was filtered, washed with water (IO ml) and dried. The pure
acid 40 was obtained without further need for purification
1
(O.OSO g, 0.088 mmol, 83% ), mp I I9-I2I ° C. H NMR (400
MHz, CD30D) o 2.6I (IH, dd, J 8.4, I 4 ·8 Hz, H--CHCO),
2.82 (IH, dd, l 6.0, I4.8 Hz, H--CHCO), 3 .o 9 (lH, dd, 17 ·8 ,
I3.4 Hz, -H--CHNH), 3.fD (lH, dd, J 6.4, I3.2 Hz,
H-CHNH), 6.99 (2H, d, J 9.2 Hz), 7.06-7.08 (2H, m), 7.I 7T.24 (SH, m), 7.47.44 (2H, m), 7.S4 (2H, d, J 9.2 Hz), 7. 72
13CNMR(400MH
(2H ' d ' J88H)
. z' 79I(2H
.
' d ' J92H)
. z.
z,
CD 30D) o. v max (pure sample)/(cm-1) 33S9 (st) (OH), I686
(st) (C=O), IS9S (st) (C=O), IS30 (st), I487 (st), I4IO
(md), 13I8 (md), I246 (st), IISO (st) I092 (md). MS (APIES): m/z S63 [M+Ht (100%), HRMS (API-ES) m/z found
S63.I0436 [M-Hr.
Ethyl 4-(3-naphthalen-2-yl-acryloylamino )benzoate (42).
Anhydrous pyridine (0.33I g, 4.2 mmol, 1.2 eq) and ethyl
4-aminobenzoate (O.S77 g, 3.SO mmol) were added to a solution of (E)-3-(2-naphthyl)propenoyl chloride (prepared from
its corresponding acid) (0.7S7 g, 3.SO mmo) in anhydrous
DCM (IS ml) under Ar. After stirring overnight at room
temperature, the white precipitate was filtered, washed with
DCM (IO ml) and dried under vacuum to give the amide 42
(0.960 g, 2.78 mmol, 80%) as a white solid, mp I73-I 7S° C.
1
HNMR(400MHz, DMSO-d 6 ) o 1.30(3H, t,J7.2Hz), 4.28
(2H, t, J 7.2 Hz), 6.97 (lH, d, J IS.4 Hz), 7.S4-7.S7 (2H, m),
7.7 (lH, d, J IS.4 Hz), 7.77 (lH, dd, J 1.6, 9.2 Hz), 7.84 (2H,
d, J 8.8 Hz), 7.93-7.97 (SH, m), 8.IS (lH, s), IO.S8 (lH, bs).
13
C NMR (100 MHz, DMSO-d6 ) o I4.88, 61.09, I I9.30,
I22.9I, I24.I8, I24.99, I27.47, I27.83, I28.38, I29.0 9,
I 29 .36, I 30.0S, I 30.98, I 32.82, I 33 .68, I 34.26, I 41.64,
I44.33, I64.69, I66.01. vmax (solid)/(cm-1) 33S7, I 702,
I660, I6I9, I607, IS9I, IS2I, I403, I282. MS (API-ES):
m/z 346 [M+Ht (100%), HRMS (API-ES) m/z found
346.I443 [M+Ht.
Methyl 4-(3-phenylacryloylamino)benzoate (4I). This
was obtained as a white solid from cinnamoyl chloride (1. I g,
6.62 mmol) and ethyl 4-aminobenzoate (1.10 g, 6.62 mmol)
in a similar manner as described for preparation of 42. The
reaction mixture was stirred at room temperature overnight
and the mixture was poured in HCl (aq, 2N, 20 ml). The
product was extracted with DCM (2x20 ml), dried over
Na 2 S04 andthesolventremovedunderreducedpressure.The
crude amide 4I was used in the next step without further
purification.
Methyl 2-hydroxy-4-(3-naphthalen-2-yl-acryloylamino)
benzoate (43). This was obtained from (E)-3-(2-naphthyl)
propenoyl chloride (0.320 g, 1.48 mmol) and methyl
4-amino-2-hydroxybenzoate (0.247 g, I .48 mmol) in a similar manner as described for preparation of 42. After stirring
overnight at room temperature, the white solid was filtered,
washed with DCM (ml) and dried under vacuum to give the
amide 43 (0.400 g, I.IS mmol, 79%) as an off-white solid, mp
2I0-2I2° C. 1H NMR (400 MHz, DMSO-d6 ) o 3.86 (3H, s,
OCH 3), 6.3I (lH, d, J IS.6 Hz, CH), 7.I7 (lH, dd, J 1.8, 8.8
Hz, H-6'), 7.S3 (lH, d, J 1.8 Hz, H-2'), 7.S4-7.S7 (2H, m,
2xCH, Ar), 7.74-7.79 (3H, m, 3xCH, Ar), 7.92-7.99 (3H, m,
3xCH, Ar), 8.IS (lH, s, CH, Ar), IO.S4 (lH, s, NH), I0.6S
(lH, s, NH). 13 C NMR (100 MHz, DMSO-d 6 ) o S2.0I (s)
(OCH 3), I06.9S (s) (CH, Ar), I08.27 (s) (C, Ar), I I 1.30 (s)
(CH, Ar), I22.78 (s) (CH), I24.2I (s) (CH, Ar), I27.S4 (s)
(CH,Ar), I27.92 (s) (CH,Ar), I28.40 (s) (CH,Ar), I29.I2 (s)

(CH,Ar), I29.39 (s) (CH,Ar), 130.I2 (s) (CH,Ar), I31.S6 (s)
(CH,Ar), I32.76 (s) (C,Ar), I33.67 (s)(C,Ar), 134.30 (s) (C,
Ar), I41.9I (s) (CH), I46.3S (s) (C, Ar), I61.9I (s) (C, Ar),
I 64.84 (s) (C=O), I 69.70 (s) (C=O). v max (solid)/(cm- 1)
33S2 (st), I692 (st), I662 (st), I622 (st), IS97 (st), IS07 (st),
I44S (st), I362 (st), I26S (st), I I88 (st), I I43 (st), I09S (st).
MS (API-ES): m/z 346 [M-Hr (100%), HRMS (API-ES)
m/z found 346.I088 [M-Hr.
Methyl 4 _[ 3 -( 4-chlorophenyl)acryloylamino ]-2-hydroxybenzoate (4S). This was obtained from 4-chlorocinnamoyl
chloride (I .80 g, 9.47 mmol) and methyl 4-amino-2-hydroxyb enzoate (I .S g, . mmo l) ma
· s1m1
· . ar manner as descn·b ed
8 9 47
1
for preparation of 42. After stirring for 2 hat room temperature,thewhiteprecipitatewasfiltered,washedwithDCM(IO
ml) anddried under vacuum to give the amide 4S (2.4I g, 7.SO
1
mmol, 80%) as an off-white solid, mp 208-2I0° C. H NMR
(400MHz,DMSO-d 6 )3.8S(3H,s,OCH3),6.80(lH,d,JIS.8
Hz, CH), 7.13 (lH, dd, J 2.4, 8.8 Hz, H-6'), 7.49 (lH, d, J 2.4
Hz,H-2'), 7.S0(2H,d,J8.4Hz,2xCH,Ar), 7.60(1H,d,J IS.8
Hz, CH), 7 .6S (2H, s, J 8.4 Hz, 2xCH, Ar), 7 .74 (lH, s, J 8.8
Hz, H-S'), IO.SO (IH, s, NH), I0.63 (lH, s, OH). 13 C NMR
(100 MHz, DMSO-d6 ) o S2.89 (s) (OCH 3), I06.97 (s) (CH,
Ar), I08.32 (s) (C, Ar), I I 1.28 (s) (CH, Ar), I23.20 (s) (CH),
I29.7S (s) (2xCH, Ar), I30.20 (s) (2xCH, Ar), 13I.47 (s)
(CH,Ar), I34.IS (s) (C,Ar), I3S.I4 (s) (C,Ar), I40.47 (s) (C,
Ar), I46.24 (s) (CH), I61.92 (s) (C, Ar), I64.S8 (s) (C=O),
I69.70 (s) (C=O). vmax (solid)/(cm- 1) 3346 (st), I693 (st),
I660 (st), I628 (st), IS97 (st), IS07 (st), I442 (st), I269 (st),
II 89 (st). MS (API-ES): m/z330 [M 3sCI-Hr (100%), 332
[M 37CI-Hp 32 (3 S%). HRMS (API-ES) m/z found
330.0SS2 [M-Hr.
Eh l ( .
h
lb
l · )b
(47) A
t y 4- 4 -mtro- 3 -p eny - utyry ammo enzoate
.
mixture of 4I (1.340 g, 4.44 mmol) in nitromethane (4 ml)
was heated a microwave reactor (Biotage Initiator) at I 00° C.
for IS minin presence ofDBU (0.811 g, S.328 mmol, 1.2 eq).
Aftercoolingtoroomtemperature,thereactionmixturewas
pouredintoHCl IM(IOml). Theproductextractedwithethyl
acetate (2xIS ml). The organic extracts were collected, dried
over Na 2 S04 and the solvent removed under reduced pressure. Chromatography on silica gel (7:3 hexanes/ethyl
acetate, Rf0.20) afforded 47 (0.980 g, 2.7S mmol, 62%) as a
yellow oil. 1H NMR (400 MHz, CDC1 3) o 1.37 (3H, t, J 7.6
Hz), 2.79 (IH, dd, J 7.2, IS.2 Hz), 2.86 (IH, dd, J 7.2, IS.2
Hz), 4.07 (IH, quint, J 7.2 Hz), 4.34 (2H, q, J 7.2 Hz), 4.72
(IH, dd, J 7.8, I2.6 Hz), 4.83 (lH, dd, J 6.4, I2.4 Hz), 6.63
(IH, d, J I6 Hz), 7.II (IH, t, J 7.6 Hz), 7.24-7.26 (2H, m),
7.27-7.36 (2H, m), 7.4S (IH, s), 7.47 (2H, d, J 8.8 Hz), 7.96
(2H, d, J 8.8 Hz). 13 C NMR (400 MHz, CDC1 3) o I4.SS,
40.67, 40.93, 61.20, 79.SO, I I9.I 7, I26.S4, I27.S3, I28.4S,
I29.48, I30.98, I38.SI, I41.60, I66.30, I68.39. MS (APIES): m/z found 3S7 [M+Ht (100%), HRMS (API-ES) m/z
found 3S7.I344 [M+Ht.
Ethyl
4-(3-naphthalen-2-yl-4-nitro-butyrylamino)benzoate (48). This was prepared from corresponding amide 42
(0.99S g, 2.88 mmol) in a similar manner as described for
preparation of 47. Chromatography on silica gel performed
using a FlashMaster 3 purification station (7S:2S hexanes/
ethyl acetate, Rf0.20) afforded 48 (0.8I9 g, 2.017 mmol,
70%) as a yellow oil. 1H NMR (400 MHz, DMSO-d6 ) o 1.26
(3H, t, 17.6 Hz), 2.8S-2.93 (2H,m), 4.IO (lH, quint, J8.0Hz),
4.23 (lH, q, J 7.2 Hz), S.02-S.IO (2H, m), 7.4S-7.48 (2H, m),
7.S4 (lH, dd, J 1.6, 8.8 Hz), 7.62 (2H, d, J 8.8 Hz), 7.82-7.87
(6H, m). 13 C NMR (400 MHz, CDC1 3) o I4.S2, 40.7S, 40.79,
61.2I, 79.48, I I9.2I, I24.97, I26.43, I26.6S, I26.78,
I26.87, I27.92, I28.04, I29.37, 130.94, 133.I I, 133.S9,
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I35.89, I41.68, I66.37, I68.54. MS (API-ES): m/z found
407 [M+Hr (100%), HRMS (API-ES) m/z 407.I607
[M+Ht.
Methyl 2-(benzyloxy)-4-(3-(naphthalen-2-yl)-4-nitrobutanamido )benzoate (49). Benzyl bromide (0.236 g, 1.38
mmol) and K 2 C0 3 (O.I90 g, 1.38 mmol) were added to a
stirred solution of 43 (0.400 g, 1.15 mmol) in anhydrous DMF
(7 ml) under Ar. The reaction mixture was stirred at room
temperature overnight and the mixture was poured in water
(IS ml). The product was extracted with ethyl acetate (2xI5
ml), dried over Na2 S04 and the solvent removed under
reduced pressure. The resultant product 44 was stirred in the
microwave reactor in presence ofDBU (O.I 92 g, I .27 mmol),
and nitromethane (7 ml) in the microwave), at I 00° C. for I 5
min. After cooling to room temperature, the reaction mixture
was poured into HCl IM (10 ml). The product was extracted
with ethyl acetate (2xI5 ml), dried over Na2 S04 and the
solvent removed under reduced pressure. Chromatography
on silica gel (60: 40 hexanes/ ethy1acetate) afforded 4 9 (0 .413
g, 0.83 mmol, 72%) as a yellow oil. 1 H NMR (400 MHz,
CDC1 3 ) o 2.88 (lH, dd, l 6.8, I5.6 Hz), 2.96 (lH, dd, l 7.2,
I5.2 Hz), 3.86 (3H, s), 4.26 (lH, quint, l 7.I Hz), 4.83 (lH,
dd, l 7.4, I2.6 Hz), 4.93 (lH, dd, l 6.8, I2.4 Hz), 5.IO (2H, s),
6.7I (lH, dd, l 2.0, 8.8 Hz), 7.13 (lH, bs), 7.28-7.32 (lH, m),
7.36-7.39 (3H, m), 7.47-7.52 (SH, m), 7.7I (lH, bs), 7.777.86 (4H, m). 13 C NMR (400 MHz, CDC1 3 ) o 40.68, 40.8I,
52.IS, 70.70, 79.44, IOl.39, IIl.15, II5.9I, I24.94, I26.67,
I26.79, I26.89, I27.22, I27.93, I28.05, I28.79, I28.72,
I29.39, I33.11, I33.60, I35.89, I36.54, I42.68, I59.6I,
I66.42, I68.57. MS (API-ES): m/z found 499 [M+Hr
(100%), HRMS (API-ES) m/z 499.I862 [M+Hr.
Methy1 2-(benzy loxy)-4-(3-(4-chloropheny1)-4-nitrobutanamido) benzoate (50). Benzyl bromide (0.575 g, 3.36
mmol) and K 2 C0 3 (0.77 g, 5 .60 mmol) were added to a stirred
solution of 45 (0.9 g, 2.80 mmol) in anhydrous DMF (20 ml)
under Ar. The reaction mixture was stirred at room temperature overnight and the mixture was poured in water (20 ml).
The product was extracted with ethyl acetate (2x20 ml), dried
over Na2 S04 and the solvent removed under reduced pressure. The resultant crude 46 was stirred in the microwave
reactor in presence of DBU (0.468 g, 3.08 mmol), and
nitromethane (IO mL in the microwave), at I00° C. for IS
min. After cooling to room temperature, the reaction mixture
was poured into HCl IM (IS ml). The product was extracted
with ethyl acetate (2x20 ml), dried over Na2 S04 and the
solvent removed under reduced pressure. Chromatography
on silica gel (80:20, hexanes/ethyl acetate) afforded SO (0.52I
g, 1.10 mmol, 40%) as a white solid, mp 8I-83° C. 1 H NMR
(400 MHz, CDC1 3 ) o2.75 (lH, dd, l 6.6, I5.4 Hz), 2.85 (lH,
dd, l 7.6, I5.6 Hz), 3.87 (3H, s), 4.07 (lH, quint, l 6.8 Hz),
4.70 (lH, dd, l 7.8, 13.0 Hz), 4.83 (lH, dd, l 6.4, I2.8 Hz),
5.I7 (2H, s), 6.77 (lH, dd, l 2.0, 8.4 Hz), 7.I9 (3H, d, l 8.0
Hz), 7 .32 (3H, d, l 8.8 Hz), 7 .39 (2H, t, l 8.0 Hz), 7 .5 I (2H, d,
17.2 Hz), 7.55 (lH, bs), 7.82 (lH, d, l 8.0Hz). 13 CNMR (IOO
MHz, CDC1 3 ) 039.89, 40.59, 52.I8, 70.79, 79.25, I04.96,
I I 1.08, I I6.I4, I27.20, I28.I I, I28.76, I28.92, I29.6I,
I33.I7, I34.28, I36.56, I37.04, I42.50, I59.65, I66.36,
I68.I7. vmax (pure sample)/(cm- 1 ) 3329, I695, I59I, I549,
I530, I245, I090. MS (API-ES): m/z 483 [M+Hr (100%),
HRMS (API-ES) m/z found 483.I236 [M+Hr.
Ethyl 4-( 4-amino-3-phenylbutanamido)benzoate (5 I).
Ref. J. Org. Chem., 2000, 65, 8001. To a stirred solution of
nitro compound 47 (0.749 g, 2.IO mmol) and NiC1 2 .6H 2 0
(1.99 g, 8.40 mmol) in methanol (IO ml) NaBH4 (0.7I9 g,
I8.93 mmol) was added portionwise over 20 min at 0° C.
After stirring for I 5 at room temperature, the solvent was
removed under reduced pressure. Water (20 ml) and ethyl

acetate (40 ml) were added to the solid residue. The resulting
mixture was filtered through a celite bed which was washed
with ethyl acetate (20 ml). After collecting the filtrate, the
organic phase was separated, dried over Na 2 S04 and the
solvent removed under reduced pressure to afford amine 5 I as
an off white solid (0.596 g, I.83 mmol, 87%). The amine was
used in the next step without further purification.
Ethyl 4-(4-amino-3-(naphthalen-2-yl)butanamido)benzoate (52). This was obtained as a yellow solid(0.8I9 g, 2.I 78
mmol, 89%) from nitro compound 48 (0.995 g, 2.450 mmol)
in a similar manner as described for preparation of 51. The
product amine 52 used in the next step without further purification.
Methyl 4-(4-amino-3-(naphthalen-2-yl)butanamido )-2(benzyloxy)benzoate (53). This was obtained as a white solid
(0.023 g, 0.033 mmol, 36%) from nitro compound 49 (0.043
g, 0.09 I mmol) a similar manner as described for preparation
of 5 I. The product amine 53 was taken to the next step without
further purification.
Methyl
4-( 4-amino-3-( 4-chlorophenyl)butanamido )-2(benzyloxy)benzoate (54). This was obtained as yellow solid
(0.349 g, 0.79 mmol, 77%) from nitro compound 50 (0.488 g,
I .033 mmol) a similar manner as described for preparation of
51. The crude amine 54 was taken to the next step without
further purification.
Ethyl
4-( 4-(4-methylphenylsulfonamido )-3-phenylbutanamido )benzoate (55). Potassium carbonate (0.325 g, 2.35
mmol) was added to a solution of 5 I (O. I28 g, 0.392 mmol) in
I,4-dioxane/H 2 0 1:1 (5 mL) and followed by tosyl chloride
(0.074 g, 0.392 mmol) at room temperature. After stirring for
2 hat room temperature, the resulting mixture was evaporated
in vacuo to dryness. Water (IO ml) was added and the resulting white solid was separated by filtration and dried in vacuo.
Pure 55 was obtained as an off-white solid (O.I22 g, 0.254
mmol, 65%) without further purification, mp I35-I37° C. 1 H
NMR (400MHz, CD 3 0D) 1.36 (3H, t, 17.2 Hz), 2.39 (3H, s),
2.63 (lH, dd, l 8.6, I4.6 Hz), 2.85 (lH, dd, l 6.2, IS.O Hz),
3.05 (lH, dd, l 7.4, I3.0 Hz), 3.I2 (lH, dd, l 6.8, Il.8 Hz),
4.32 (2H, q, l 7.2 Hz), 7.I 7-7.I9 (3H, m), 7.23-7.27 (2H, m),
7.3I (2H, d, l 8.0 Hz), 7.54 (2H, d, l 8.4 Hz), 7.65 (2H, d, l 8.4
Hz), 7.90 (2H, d, l 8.8 Hz). 13 C NMR (100 MHz, CDC1 3 )
I4.57, 21.73, 40.65, 42.04, 47.77, 61.07, II9.I5, I27.I4,
I27.75, I27.77, I29.29, I30.07, 130.94, 136.79, I40.74,
I42.I2, I43.97, I66.36, I70.24. vmax (solid)/(cm- 1 ) 3324,
3I9I, I707, I675, I597, I534, I270, II57, 1105. MS (APIES): m/z 48I [M+Ht (100%), HRMS (API-ES) m/z found
481.180I [M+Ht.
Ethyl 4-( 4-(4-phenoxyphenylsulfonamido )-3-phenylbutanamido )benzoate (56). This was obtained as an off white
solid (O.I82 g, 0.326 mmol, 77%) from SI (0.137 g, 0.420
mmol) and 4-phenoxybenzenesulfonyl chloride (O.I I2 g,
0.420 mmol) in a similar manner as described for preparation
of55, mp I47-I49° C. 1 H NMR (400 MHz, CD 3 0D) o 1.36
(3H, t, l 7.6 Hz), 2.63 (lH, dd, l 8.4, I4.8 Hz), 2.84 (lH, dd,
l 7.4, I3.2 Hz), 3.09 (lH, dd, l 7.2, I2.8 Hz), 3.I6 (lH, dd, l
7.2, I2.4 Hz), 4.3I (2H, q, l 6.8 Hz), 7.00 (2H, d, l 7.2 Hz),
7.06 (2H, dd, J0.8, 8.8 Hz), 7.I8-7.22 (3H, m), 7.23-7.26 (3H,
m), 7.39-74I (2H, m), 7.73 (2H, d, 18.8 Hz), 7.89 (2H, d, 18.8
Hz). 13 C NMR (100 MHz, CDC1 3 ) I4.57, 40.73, 42.06,
47.80, 61.07, II7.92, II9.I5, I20.52, I25.25, I27.75,
I27.80, I29.32, I29.35, I30.4I, 130.95, 133.27, I40.74,
I42.08, I55.23, I61.95, I66.34, I70.20. vmax (solid)/(cm- 1 )
3322,I702,I596,I532,I487,I407,I274,I243,II5I,II04,
695. MS (API-ES): m/z 559[M+Hr (100%), HRMS (APIES) m/z found 559.I906[M+Ht.
Ethyl 4-(4-( 4-methylphenylsulfonamido )-3-(naphthalen2-yl)butanamido )benzoate (57). This was obtained as an off
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white solid (0.058 g, O.I09 mmol) from 52 (O.I38 g, 0.375
mmol) in a similar manner as described for preparation of 55.
1
H NMR (400 MHz, CD 3 0D) o 1.34 (3H, t, J 7.2 Hz), 2.34
(3H, s), 2.73 (lH, dd, J 8.2, I4.6 Hz), 2.92 (lH, dd, J 6.4, I4.8
Hz), 3.I 7-3.28 (2H, m), 3.47-3.52 (lH, m), 4.30 (2H, q, J 7.2
Hz, CH 2 CH 3 ), 7.I9 (2H, d, J 8.0 Hz), 7.32 (lH, dd, J I.4, 8.6
Hz), 7.40-7.45 (2H, m), 7.5I (2H, d, J 8.4 Hz), 7.59 (2H, d, J
8.8 Hz), 7.60 (lH, s), 7.73-7.79 (3H, m), 7.90 (2H, d, J 9.2
Hz).vmaxCsolid)/(cm- 1 )2958, I706, I596, I53I, I273, II7I,
II52, 1105, I020. MS (API-ES): rn/z 53I [M+Hr (100%),
HRMS (API-ES) rn/z found 531.1962[M+Hr.
Ethyl
4-(3-(naphthalen-2-yl)-4-( 4-phenoxyphenylsulfonamido )butanamido )benzoate (58). The compound was
obtained as a white solid in (O.IOO g, O.I64 mmol, 73%) from
52 in a similar manner as described for preparation of 55, mp
I4I-I43° C. 1 HNMR(400MHz, CD 3 0D) o1.34 (3H, t, 17.2
Hz), 2.75 (lH, dd, J 8.4, I4.8 Hz), 2.92 (lH, dd, J 6.6, I5.0
Hz), 3.25-3.29 (2H, m), 3.34-3.53 (lH, m) 4.30 (2H, q, J 7.2
Hz), 6.6I (2H, d, J 9.2 Hz), 7.05 (2H, dd, J 1.2, 8.8 Hz),
7 .20-7 .23 (lH, m), 7 .34 (lH, dd, JI .4, 8.6 Hz), 7.40-7.45 (4H,
m), 7.54 (2H, d, J 8.8 Hz), 6.64 (lH, bs), 7.67 (2H, d, J 8.8
Hz), 7.75-7.90 (3H,m), 7.87 (2H, d, J 9.2 Hz). 13 CNMR (IOO
MHz, CDC1 3 ) I4.55, 40.68, 42.I2, 47.84, 61.05, II7.89,
I I9.I9, I20.5I, I25.22, I25.67, I26.2I, I26.35, I26.53,
I26.73, I27.85, I27.96, I29.09, I29.83, I30.39, I30.90,
I32.85, I33.27, I33.6I, I38.I6, I42.I3, I55.24, I61.90,
I66.34, I70.26.vmax(solid)/(cm- 1 ) I707, I596, I53I, I486,
I275, I243, II5I, I098. MS (API-ES): rn/z 609 [M+Hr
(100%), HRMS (API-ES) rn/z found 609.2058 [M+Hr.
4-(4-( 4-methylphenylsulfonamido )-3-phenylbutanamido)
benzoic acid (59). A solution of the ester 55 (O.I06 g, 0.220
mmol) in methanol (3 ml) and THF (3 ml) was stirred in
presence ofNaOH (aq, IM, I ml) at room temperature overnight. The solvent was removed under reduced pressure. HCl
(aq, IM, 1.5 ml) was added and the white precipitate was
filtered, washed with water (5 ml) and dried under vacuum.
Pure 59 was obtained as a white solid (0.085 g, O.I88 mmol,
85%) without further purification, mp 225-227° C. 1 H NMR
(400 MHz, CD 3 0D) 02.39 (3H, s), 2.62 (lH, dd, J 8.4, I4.8
Hz), 2.35 (lH, dd, J 6.6, I4.6 Hz), 3.05 (lH, dd, J 8.0, 13.0
Hz), 3.I2 (lH, dd, J 7.2, I2.8 Hz), 7.I6-7.I9 (3H, m), 7.247.27 (2H, m), 7.30 (2H, d, J 7.6 Hz), 7.53 (2H, d, J 8.4 Hz),
7.65 (2H, d, J 8.4 Hz), 7.9I (2H, d, J 9.2 Hz). 13 C NMR (100
MHz, DMSO-d3 ) o 21.6I, 40.65, 42.32, 48.33, I I8.95,
I25.6I, I27.I8), I27.26, I28.38, I28.96, I30.02, I30.98,
138.09, I42.47, I43.22, I43.72, I67.55, I70.64.vmax(solid)/
(cm- 1 ) 33I6, 3277), I668, I595, I53I, I408, I3I7, I254,
I I52. MS (API-ES): m/z 45I[M-Hr (100%), HRMS (APIES) rn/z found 451.1334 [M-Hr.
4-(4-( 4-phenoxyphenylsulfonamido )-3-phenylbutanamido )benzoic acid (60). This was obtained as a white solid
(O.I20 g, 0.226 mmol, 83%) from the ester 56 (O.I52, 0.272
mmol) in a similar manner as described for preparation of 59,
mp I87-I89°C. 1 HNMR(400MHz,CD 3 0D) 02.63 (lH,dd,
J 8.8, I4.8 Hz), 2.84 (lH, dd, J 6.6, I4.6 Hz), 3.09 (lH, dd, J
7.8, I3.0 Hz), 3.I6 (lH, dd, J 6.8, I2.8 Hz), 7.00 (2H, d, J 9.2
Hz), 7.06 (2H, dd, J 1.2, 8.4 Hz), 7.I6-7.28 (6H, m), 7.39-743
(2H, m), 7.53 (2H, d, J 8.4 Hz), 7.73 (2H, d, J 8.4 Hz), 7.90
(2H, d, J 8.4 Hz). 13 C NMR (100 MHz, CD 3 0D) 40.86,
42.63, 47.85, II7.47, II9.00, I20.09, I24.77, I25.74,
I26.70, I27.66, I28.46, I29.I2, 130.IO, I30.49, I34.36,
I41.39, I42.9I, I55.62, I61.59, I68.23, I 7I .43. V max (solid)/
(cm- 1 ) 3060, I68I, I596, I585, I487, 13I8, I294, I25I,
II5Il. MS (API-ES): rn/z found 529 [M-H]- (100%),
HRMS (API-ES) rn/z found 529.I433 [M-Hr.

4-(3-(naphthalen-2-y1)-4-(4-phenoxyphenylsulfonamido)
butanamido )benzoic acid (6I ). This was obtained as a white
solid (0.052 g, 0.090 mmol, 70%) from 57 (0.079 g, O.I29
mmol) in a similar manner as described for preparation of 59,
mp I83-I84°C. 1 HNMR(400MHz,CD 3 0D) 02.65 (lH,dd,
J 8.4, I4.8 Hz), 2.82 (lH, dd, J 6.8, I4.8 Hz), 3.I I-3.20 (2H,
m), 3.40-3.44 (lH, m), 6.8I (2H, d, J 8.4 Hz), 6.94-6.96 (2H,
m), 7.I0-7.I4 (lH, m), 7.25 (lH, dd, J 1.6, 8.8 Hz), 7.29-7.35
(4H, m), 7.4I (2H, d, J 8.8 Hz), 7.54 (lH, bs), 7.58 (2H, d, J
8.8 Hz), 7.65-7.68 (3H, m), 7.78 (2H, d, J 8.4 Hz). 13 C NMR
(100 MHz, CD 3 0D) 40.82, 42.70, 47.90, I I 7.34, 119.00,
I20.II5, I24.76, I25.53, I25.66, I25.9I, I26.54, I27.39,
I27.53, I28.I2, I29.06, I30.09, 130.5I, 132.92, 133.74,
I34.38, I38.80, I42.80, I55.55, I61.50, I 71.36. vmax (solid)/
(cm- 1 ) 306I, I683, I599, I584, I5I4, I486, I304, I240,
I I47. MS (API-ES): rn/z found 579 [M-Hr (100%), HRMS
(API-ES) rn/z found 579.I585 [M-Hr.
4-(4-( 4-methylphenylsulfonamido )-3-(naphthalen-2-yl)
butanamido )benzoic acid (62). This was obtained as a white
solid (0.02I g, 0.042 mmol, 65%) from 58 (0.034 g, 0.064
mmol) in a similar manner as described for preparation of 59,
mp. 1 H NMR (400 MHz, CD 3 0D) o 2.34 (3H, s), 2.73 (lH,
dd, J 8.2, I4.6 Hz), 2.9I (lH, dd, J 6.4, I4.8 Hz), 3.20 (lH, dd,
J 7.6, I2.8 Hz), 3.25-3.29 (lH, m), 3.47-3.53 (lH, m), 7.I9
(2H, d, J 8.0 Hz), 7.32 (lH, dd, J 1.6, 8.8 Hz), 7.39-7.45 (2H,
m), 7.5I (2H, d, J 9.2 Hz), 7.59 (2H, d, J 8.8 Hz), 7.60 (lH, s),
7.73-7.79 (3H, m), 7.88 (2H, d, J 9.2 Hz). 13 C NMR (100
MHz, DMSO-d 6 ) 21.60, 42.52, 48.3I, I I8.92, I25.73,
I26.20, I26.65, I26.88, I26.95, I27.I3, I28.09, I28.20,
I28.4I, I30.I8, I30.95, I32.73, 133.62, 138.I6, I40.03,
I43.I5, I43.67, I67.57, I70.61. vmax (solid)/(cm- 1 ) I680,
I595, I530, I408, 1305, I252, I I52. MS (API-ES): rn/z 50I9
[M-Hr (100%), HRMS (API-ES) rn/z found 501.1483I
[M-H]-.
Methyl 2-(benzyloxy )-4-(3-(naphthalen-2-yl)-4-( 4-phenoxyphenylsulfonamido )butanamido )benzoate (63). This
was obtained as an off white solid (0.023 g, 0.032 mmol,
36%) from amine 53 (0.043 g, 0.09I mmol) in a similar
manner as described for preparation of 55. The crude ester
was used in the next step without further purification.
Methy1 2-hydroxy-4-(3-(naphthalen-2-yl )-4-(4-phenoxypheny lsulfonamido )butanamido) benzoate (64). A solution
of 63 (0.023 g, 0.032 mmol) in methanol (I ml) was stirred in
presence of ammonium formate (0.089 g) and IO% Pd/C
(0.023 g), under H 2 , at room temperature for 2 days. The
solution was then filtered through a celite bed and the solvent
removed under reduced pressure to afford ester 64 (O.OI4 g,
0.0230 mmol, 70%) as yellow solid, which was used in the
next step without further purification.
2-hydroxy-4-(3-(naphthalen-2-yl)-4-(4-phenoxyphenylsulfonamido)butanamido)benzoic acid (65). This was
obtained as an off-white solid (0.0063 g, O.OI I mmol, 50%)
ester 64 (O.OI3 g, 0.02I mmol) in a similar manner as
described for preparation of 59. mp I53-I55° C. 1 H NMR
(400 MHz, CD 3 0D) o2.63 (lH, dd, J I4.6, 8.2 Hz), 2.86 (lH,
dd, J I5.0, 6.6 Hz), 3.I3 (lH, dd, J I3.2, 7.6 Hz), 3.I6-3.20
(lH, m), 3.37-3.48 (lH, m), 6.77-6.83 (3H, m), 6.94-6.96
(2H, m), 7.08-7.I4 (2H, m), 7.24 (lH, dd, J 8.4, 1.66 Hz),
7.29-7.35 (4H, m), 7.53 (lH, bs), 7.57-7.60 (lH, m), 7.667.69 (3H, m), 9.80 (lH, bs). MS (API-ES): rn/z 595 [M-Hr
(100%), HRMS (API-ES) rn/z found 595.I537 [M-Hr.
Methyl 2-(benzyloxy)-4-(3-( 4-chlorophenyl)-4-( 4-phenoxyphenylsulfonamido )butanamido )benzoate (66). This
was obtained as an off-white solid (0.205 g, 0.304 mmol,
78%) from the amine 54 (0.137 g, 0.39I mmol) in a similar
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manner as described for preparation of 5 5. The crude product
sulfonamide was taken to the next step without further purification.
Methyl 4-(3-(4-chlorophenyl)-4-( 4-phenoxyphenylsulfonamido )butanamido )-2-hydroxybenzoate (67). This was
obtained as an off-white solid (0.106 g, 0.181 mmol, 67%)
from benzyl ether 66 (0.183 g, 0.27 mmol) in a similar manner as described for preparation of 64. The crude ester 67 was
taken to the next step without further purification.
4-(3-( 4-Chlorophenyl)-4-( 4-phenoxyphenylsulfonamido)
butanamido )-2-hydroxybenzoic acid (68). This was obtained
as an off-white solid (0.047 g, 0.082 mmol, 67%) from the
ester 67 (0.076 g, 0.130 mmol) in a similar manner as
described for preparation of 59. The crude acid 68 was taken
to the next step without further purification. 1 H NMR (400
MHz, CDC1 3 ) o2.59 (lH, dd, J 14.8, 8.8 Hz), 2.80 (lH, dd, J
14.8, 6.8 Hz), 3.12 (2H, m), 6.90 (lH, dd, J 10.4, 2.0 Hz), 6.99
(2H, d, J 9.2 Hz), 7.07 (2H, d, J 9.2 Hz), 7.16-7.27 (6H, m),
7.40-7.44 (2H, m), 7.69-7.74 (3H,m). MS (API-ES): m/z 579
[M-Hr (100%), HRMS (API-ES) m/z found 579.1000
[M-H]-.
Ethyl 4-(3-(naphthalen-2-yl)propanamido )benzoate (69).
Ref. J. ofOrg. Chem., 2000, 65, 8001. To a stirred solution of
amide 42 (0.086 g, 0.249 mmol) and NiC1 2 6H 2 0 (0.118 g,
0.498 mmol, 2 eq) in methanol (8 ml) and THF (4 ml) NaBH4
(0.028 g, 0.749 mmol, 4 eq) was added portionwise over 20
min at 0° C. After stirring for 1 h at room temperature, the
solvent was distilled off under reduced pressure. Water (10
ml) and ethyl acetate (10 ml) was added. The resulting mixture was filtered through a celite bed which was washed with
ethyl acetate (20 ml). After collecting the filtrate, the organic
phase was separated, dried over Na2 S04 and the solvent was
distilled off under reduced pressure to give the pure product
69asawhitesolid(0.066g,0.190mmol, 79%),mp 119-121°
C. 1 H NMR (400 MHz, CDC1 3 ) o 1.38 (3H, t, J 7 .2 Hz, CH 2 C
H3 ) 2.75 (2H, t, J 7.2 Hz, CH 2 CO), 3.23 (2H, t, J 7.2 Hz, C
H;-Ar), 4.35 (2H, q, J 7.2 Hz, CH 2 CH 3 ), 7.12 (lH, bs, NH), 7.37 (lH, dd, J 1.6, 8.4 Hz, CH, Ar), 7.42-7.50 (4H, m,
4xCH, Ar), 7.69 (lH, bs, CH, Ar), 7.76-7.82 (3H, m, 3xCH,
Ar), 7.97 (2H, d, J 9.2 Hz, 2xCH,Ar). MS (API-ES): m/z348
[M+Hr (100%), HRMS (API-ES) m/z found 348.1602
[M+Ht.
Ethyl 4-(3-phenylpropanamido )benzoate (70). This was as
obtained from 41 in a similar manner as described for preparation of 69. The crude product 70 was taken to the next step
without further purification, mp 109-111 ° C. 1 H NMR (400
MHz, CDC1 3 ) o(3H, t, J Hz, CH 2 CH 3 ), (2H, t, J Hz, CH 2 CO),
(2H, t, J Hz, CH 2 -Ar), (2H, q, TTI-Iz, CH 2 CH 3 ), (IH, bs,
N-H), 7.37 (111, dd, J 1.6, 8.4 Hz, CH, ArT,7.42-7.50 (4H,
m, 4XCH, Ar), 7.69 (lH, bs, CH, Ar), 7.76-7.82 (3H, m,
3xCH, Ar), 7.97 (2H, d, J 9.2 Hz, 2xCH, Ar). MS (API-ES):
m/z 298 [M-Hr (100%), HRMS (API-ES) m/z found
298.1444 [M-H]-.
4-(3-(Naphthalen-2-yl)propanamido )benzoic acid (71 ).
The pure compound was obtained as a white solid in 73%
yield from 69 in a similar marmer as described for preparation
of 59, mp 255-257° C. 1 H NMR (400 MHz, CD 3 0D) o 2.69
(2H, t, J 7.2 Hz, CH 2 CO), 3.07 (2H, t, J 7.6 Hz, CH 2 -Ar),
7.28-7.35 (3H, m, 1XCH, Ar), 7.53 (2H, d, J 8.4 rrz;--2xCH,
Ar), 7.61 (lH, bs,CH,Ar), 7.66-7.71(3H,m,3xCH,Ar),7.84
(2H, d,J9.2Hz, 2xCH,Ar). 13 CNMR(400MHz, DMSO-d 6 )
o31.53 (s) (CH 2 CO), 38.60 (s) (CH 2 Ar), 118.95 (s) (2xCH,
Ar), 125.99 (S) (CH,Ar), 126.71(S)(CH,Ar),126.80 (s) (CH,
Ar), 127.91 (s) (CH,Ar), 127.98 (s) (CH,Ar), 128.15 (s) (CH,
Ar), 128.46 (s) (CH, Ar), 131.03 (s) (2xCH, Ar), 132.34 (s)
(C,Ar), 133.82 (s) (C,Ar), 139.41 (s) (C,Ar), 143.85 (s) (C,
Ar), 167.65 (s) (C=O), 171.62 (s) (C=O). vmax (pure
sample)/(cm- 1 ) 3298 (st) (OH), 1701 (md) (C=O), 1674 (st)
(C=O) 1607 (md), 1595 (md), 1530 (st), 1429, 1405, 1293.

MS (API-ES): m/z 318 [M-Hr (100%), HRMS (API-ES)
mlz found 318.11327 [M-Hr.
4-(3-Phenylpropanamido )benzoic acid (72). This was
obtained pure as a white solid in 76% yield from 69 in a
similar marmer as described for preparation of 59. 1 H NMR
(400 MHz, CD 3 0D) o2.68 (2H, t, J 7.6 Hz), 2.99 (2H, t, J 8.4
Hz), 7.16-7.19 (lH, m), 7.23-7.26 (4H, m), 7.63 (2H, d, J 8.4
Hz), 7.94 (2H, d, J 8.4 Hz). vmax (pure sample)/(cm- 1 ) 3310,
1666, 1607 (md), 1593, 1522, 1428, 1404, 1318. MS (APIES): m/z 268 [M-Hr (100%), HRMS (API-ES) m/z
268.0979 [M-Hr.
4-(3-Phenylpropanamido )-2-hydroxybenzoic acid (73). A
solution of the chlorocinnamide 45 (0.118 g, 0.367 mmol) in
methanol (6 ml) and THF (6 ml) was stirred in presence of
ammonium formate (0.231 g) and 10% Pd/C (0.010 g) at
room temperature under Ar. After stirring overnight, the solution was filtered through a celite bed and the solvent removed
under reduced pressure to afford an off-white solid. The solution of the crude compound in methanol (10 ml) and THF (4
ml) was stirredinpresenceofNaOH (aq, 1M,3 ml) at 100°
C. for 2 h. After cooling to room temperature, the solvent was
removed under reduced pressure, and the resulting aqueous
solution acidified with HCl (aq, 1 M) until pH 1. The precipitate was collected by filtration, washed with H 2 0 (3 ml) and
dried in vacuo. Pure 22 was obtained as an off-white solid
without further purification (0.045 g, 0.165 mmol, 45% ), mp
165-167° C. 1 H NMR (400 MHz, DMSO-d 6 ) o2.61 (2H, t, J
8.0 Hz), 2.88 (2H, t, J 8.0 Hz), 7.00 (lH, dd, J 8.8, 2.4 Hz),
7.21-7.33 (SH, m), 7.67 (2H, d, J 8.8 Hz), MS (API-ES): m/z
284 [M-Hr (100%), HRMS (API-ES) m/z found
284.097194 [M-Hr.
The following compounds were prepared according to
Scheme 6.
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6-(Methoxycarbonyl)-2-naphthoic acid (74). A solution of
KOH (0.459 g, 8.18mmol) in methanol (1.5 ml) was added to
a suspension of dimethyl 2,6-naphthlene dicarboxylate (2.0
g, 8.18 mmol) in dioxane (20 ml). The reaction mixture was
stirred at 80° C. for 4 h, cooled to room temperature and a
solid residue was rinsed with diethyl ether (10 ml). The solid
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was dissolved in water and treated with HCI (aq, 2M) to pH 3.
The precipitate was filtered, washed with water, dried under
vacuum to provide pure 74 as a white solid (1.55 g, 6.72
mmol, 82%). 1 HNMR(400MHz, DMSO-d6 ) o3.91 (3H, s),
8.02 (2H, dd, J 8.4 Hz), 8.22 (2H, dd, J 8.4 Hz), 8.66 (2H, dd,
J 10.4 Hz).
4-hydroxy-3-( 6-(methoxycarbony1)-2-naphthamido )benzoic acid (75). A solution of3-amino-4-hydroxybenzoic acid
(0.142 g, 0.927 mmol) and the acyl chloride prepared from
acid 74 (in 84% yield) (0.259 g, 1.019 mmol) in DCM (5 ml)
and pyridine ( 6 ml) was stirred at room temperature for under
at for 24 h. The solvent was removed under reduced pressure.
HCI (aq, 4 M, 6 ml) was added and the precipitate was filtered,
washed with water (10 ml) and dried under vacuum. Trituration with methanol (15 ml) and acetone (10 ml) afforded 75 as
an off-white solid (0.084 g, 0.230 mm!, 25% ). 1 H NMR (400
MHz, DMSO-d6 ) o3.92 (3H, s), 7.00 (lH, d, J 8.4 Hz), 7.67
(lH, d, J 8.8 Hz), 8.04-8.10 (2H, m), 8.16-8.27 (2H, m), 8.33
(lH, s), 8.70-8.66 (2H, m), 9.80 (lH, s), 10.55 (lH, bs). 13 C
NMR (100 MHz, DMSO-d 6 ) o 53.09, 116.18, 122.59,
125.94, 126.45, 126.26, 126.80, 128.45, 128.48, 129.19,
130.35, 130.40, 130.93, 134.13, 134.66, 134.94, 154.61,
165.85, 166.84, 167.73. vmax (solid)/(cm- 1 ) 3059, 1716,
1666, 1592, 1541, 1283, 1247, 1132, 759.

2,392 3D structures for the Diversity Set and 150,829 3D
structures for the Plated Set. These structures were docked
using GLIDE 2.7 in SP (Standard Precision) mode into the
pTyrpeptide binding site within the SH2 domain of the monomer employed. The best scoring compounds (74 compounds
selected via visual inspection from the top 100 compounds
with the best score from the Diversity Set and the top 200
compounds from the Plated Set that then were filtered by MW
(<700) and computed logs (>-10) to yield 122 compounds)
were selected for evaluation in in vitro Stat3 DNA-binding
assay. Nuclear extracts containing activated STATs were
incubated for 30 minutes with or without increasing concentrations of compounds prior to incubation with radiolabeled
hSIE probe that binds to Stat! and Stat3 or MGFe probe that
binds Stat! and Stat5 and subjected to EMSA analysis.
Results for a representative number of compounds show differential inhibition of DNA binding activity of Stat3 following preincubation of nuclear extracts with compounds (Table
4) (data not shown for the remainder of the 194 compounds
evaluated in the DNA-binding assay). Potent inhibition of
Stat3 DNA-binding activity by the NCI Plated Set compounds, NSC 42067, NSC 59263, NSC 74859, and NSC
7 5912, was observed. Other notable potent inhibitors of Stat3
DNA-binding activity from the Plated Set include NSC
11421, NSC 91529, and NSC 263435 (Table 4). A few compounds with weak inhibitory activity were also identified
from the NCI Diversity Set (data not shown). To determine
selectivity against other STAT family members, selected
active compounds were evaluated in in vitro DNA-binding
assay of the three STAT proteins, Stat!, Stat3, and Stat5, in
nuclear extracts prepared from EGF-stimulated NIH3T3/
hEGFR fibroblasts that activates all three STATs. EMSA
analyses of the DNA-binding activities of STAT proteins
show that of the representative compounds, NSC 74859 preferentially inhibits Stat3 over Stat! or Stat5 DNA-binding
activity (Table 4), while NSC 42067 and NSC 59263 preferentially inhibit Stat3 and Stat5 over that of Stat! (Table 4 ). In
recognition of the role of constitutive Stat5 in hematological
and other cancers, the inhibition of Stat5 DNA-binding activity could have clinical implications. Where Stat! DNA-binding activity was inhibited, as with NSC 42067 and NSC
59263, it occurred at concentrations 3-4 times higher than
concentrations that inhibited Stat3 or Stat5 (Table 4). In contrast, NSC 75912 preferentially inhibits Stat! over Stat3 or
Stat5 (Table 4). For the remaining compounds, no appreciable
pattern of specificity of inhibition of the STAT family members was observed (Table 4 and data not shown). These studies identify NSC 42067, NSC 59263, and NSC 74859 from
the NCI chemical libraries as binders within the SH2 domain
ofStat3 and which potently inhibit Stat3 DNA-binding activity. The best of these compounds is NSC 74859 (re-synthesized as a pure sample named BG2065p or S3I-201).

Example 12

5

10

15

20

25

Effects of Compounds on Activation of STATs, She,
and Erks
The following experiments and results are described and
shown in Siddiquee, K. et al., PNAS USA, 2007, May, 104
(18):7391-7396, Epub 2007 Apr. 26, which is incorporated by
reference herein in its entirety. Nuclear extracts containing
activated Stat!, Stat3, and Stat5 proteins were pre-incubated
with increasing concentrations of compounds for 30 minutes
at room temperature prior to incubation with radiolabeled
hSIE probe that binds Stat! and Stat3 or MGFe probe that
binds Stat! and Stat5 and subjecting to EMSA analysis. Cell
lysates containing activated Stat3 were pre-incubated with
NSC 7 4859 in the presence and absence ofincreasing amount
of cell lysates containing inactive Stat3 protein (monomer)
prior to incubation with radiolabeledhSIE probe and subjecting to EMSA analysis. Nuclear extract preparations from
v-Src-transformed NIH3T3/v-Src fibroblasts treated for the
times indicated in FIG. 2 of Siddiquee, K et al. (2007) or
human breast cancer MDA-MB-231 and MDA-MB-468
treated for 48 hours with 100 µM NSC 7 4859 were incubated
with radiolabeled hSIE probe and subjected to EMSA analysis. SDS-PAGE and Western blot analysis of whole-cell
lysates from NIH3T3/v-Src fibroblasts treated with or withoutNSC 74859 (100 µM, 48 hours) forpTyr705Stat3 orStat3.
SDS-PAGE and Western blot analysis of cell lysates prepared
from NIH3T3/v-Src or EGF-stimulated NIH3T3/hEGFR
was carried out using antibodies against pShc, pErkl/2 (pp42/
pp44), Erk, or ~-actin, or antiphosphotyrosine antibody,
clone 4G 10. Controls included nuclear extracts untreated
with compounds, and nuclear extracts or lysates prepared
from untreated cells.
Virtual high throughput screening relied upon computational modeling of the native pTyr peptide sequence
(APY*LKT; SEQ ID NO: 1) from one Stat3 monomer bound
within the SH2 domain of the second Stat3 monomer, as
observed for the Stat3 dimer protein bound to DNA (Becker,
S. et al. Nature, 1998, 394:145-151). For the docking studies,
DNA was removed and only one of the two monomers was
employed. The approach was used to evaluate the NCI Diversity Set and Plated Set chemical libraries. Three-dimensional
structures for compounds from the NCI Diversity Set and
NCI Plated Set were downloaded from NCI's DTP website
(presented in Siddiquee, K. et al. (2007)), processed with
LigPrep (36; available from Schriidinger, L.L.C.) to produce
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TABLE4
IC, 0 values for the inhibition of STATs DNA-binding activity in vitro
IC

55

60

65

M

NSC#

Stat3:3

Stat1:3

Stall :1

Stat5:5

11421
24056
26685
42067
51926
59263
71906
74859
75912
75914
87849

80
245
85
65
292
72
295
86
160
276
>300

145
256
68
86
300
89
258
160
104
263
>300

105
267
95
197
300
226
225
>300
72
113
>300

221
235
125
88
>300
69
285
166
>300
>300
>300
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TABLE 4-continued

TABLE 5-continued

IC, 0 values for the inhibition of STATs DNA-binding activity in vitro

Inhibition of STAT3 dimerization

IC

Compound
Compound # Identifier

NSC#

Stat3:3

Stall :3

Stall :1

Stat5:5

90438
91529
101595
117907
205965
216360
263435
645885
647608

>300
95
275
202
225
220
25
245
295

>300
85
>300
292
256
290
40
250
>300

>300
155
>300
>300
253
>300
50
205
>300

>300
85
288
>300
255
>300
25
250
>300

10

15

Example 13
Inhibition of STAT3 Dimerization
20

Table 5 shows half maximal inhibitory concentration
(IC 50 ) for inhibition of STAT3 dimerization, as measured by
the EMSA asay (Yu, C. L. et al. Science, 1995, 269:81-83;
Garcia, R. et al. Oncogene, 2001, 20:2499-2513; Turkson, J.
et al. Mal. Cell. Biol., 1998, 18:2545-2552).
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TABLES
Inhibition of STAT3 dimerization
Compound
Compound# Identifier

2
7
11
15
19

NSC-74859
BG2066
BG3006A
BG3006B
BG3006D
BG2069-1
BG2074
BG3004

Figure

IC 50 for the inhibition of STAT3
dimerization

7
28
31
32
33
23
29
30

<500
>500
>500
>500
>500
>500
>500
>500

µM
µM
µM
µM
µM
µM
µM
µM

30

35

20
21
22
23
24
25
27
28
29
30
31
32
36
38
39
55
59
37
40
56
60
57
61
58
62
65
45
73
70
72
69
71
68
75

<160> NUMBER OF SEQ ID NOS, 4
SEQ ID NO 1
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, pTyr-peptide
FEATURE,
NAME/KEY, MISC_FEATURE
LOCATION, (3) .. (3)
OTHER INFORMATION, phosphorylation

<400> SEQUENCE, 1
Ala Pro Tyr Leu Lys Thr
1
5

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>

34
13
14
15
16
17
19
22
24
25
26
27
35
35
35
36
36
37
37
38
38
39
39
40
40
41
42
43
44
44
45
45
46
47

IC 50 for the inhibition of STAT3
dimerization
>500
>500
>500
>500
<500
<500
>500
>500
>500
>500
>500
>500
<500
<500
<500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
>500
<500

µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM
µM

All patents, patent applications, provisional applications,
and publications referred to or cited herein, supra or infra, are
incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the
explicit teachings of this specification.

SEQUENCE LISTING

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>

BG3009
HL2-006-1
HL2-006-2
HL2-006-3
HL2-006-4
HL2-006-5
HL2-011-2
HL2-011-5
HL2-011-6
HL2-011-6
HL2-005
HL2-003
RPM381
RPM384
RPM385
RPM405
RPM411
RPM407
RPM412
RPM408
RPM410
RPM415
RPM416
RPM418
RPM418-A
RPM427
RPM431
RPM431
RPM444
RPM448
RPM445
RPM447
RPM452
RPM202

Figure

SEQ ID NO 2
LENGTH, 9
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, biotinylated conjugate pTyr-peptide
FEATURE,
NAME/KEY, MISC_FEATURE

US 7,960,434 B2
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70
-continued

<222> LOCATION, (4) .. (4)
<223> OTHER INFORMATION, phosphorylation
<400> SEQUENCE, 2
Glu Pro Gln Tyr Glu Glu Ile Glu Leu
1

5

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 24
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, hSIE oligonucleotide probe

<400> SEQUENCE, 3
24

agcttcattt cccgtaaatc ccta

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 18
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, MGFe oligonucleotide probe

<400> SEQUENCE, 4
agatttctag gaattcaa

18

We claim:

30

-continued
FormulaD

1. A method of treating a subject that has a proliferation

disorder, comprising administering an effective amount of an
isolated compound to a subject, wherein the isolated compound is at least one compound selected from
35

NSC-74859

o\,,(Y

40

Phosphotyrosine mimic

I

FormulaE

):~

45

A
Y'OH

50

Phosphotyrosine mimic

FormulaF

C02H

55
Formula C

60

65

Phosphotyrosine mimic

Phosphotyrosine mimic

wherein for the compound of formula C, formula D, formula E, or formula F:
R 1 is an aliphatic or aromatic group;
R 2 is an aliphatic or aromatic group;
each X is independently CO, S0 2 , CONH, or alkyl; and
Z is alkyl; and

US 7,960,434 B2
72

71
the phosphotyrosine mimic is C0 2 H, S03 H, P0 3 H, N0 2 ,
CH 2 C0 2 H, or CF 2 C0 2 H
or a pharmaceutically acceptable salt or analog of any of
the foregoing.
2. The method of claim 1, wherein the proliferation disorder is cancer.
3. The method of claim 2, wherein the compound is administered locally at the site of a tumor.
4. The method of claim 1, wherein the proliferation disorder is cancer, and wherein the subject is suffering from a
tumor and the compound inhibits growth of the tumor.
5. The method of claim 1, wherein the proliferation disorder is a non-malignant disease characterized by aberrant Stat3
activation of cells.
6. The method of claim 1, wherein the compound is administered locally at the site of the proliferation disorder.
7. The method of claim 1, wherein the route of administration is selected from the group consisting of intravenous,
intramuscular, oral, and intra-nasal.
8. The method of claim 1, wherein the subject is human.
9. The method of claim 1, wherein the subject is a nonhuman mammal.
10. The method of claim 1, further comprising identifying
the subject as one suffering from the proliferation disorder.
11. The method of claim 1, wherein the subject is suffering
from a tumor and wherein said administering comprises
administering at the site of the tumor the compound:

12. The method according to claim 1, wherein for the

5

10

15

20

compound of any of formula C, formula D, formula E, or
formula F, the R 1 group is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, or aryl,
any of which may be optionally substituted.
13. The method according to claim 1, wherein for the
compound of any of formula C, formula D, formula E, or
formula F, the R 2 group is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, cylcoalkenyl, heterocycloalkenyl, acyl, or aryl,
any of which may be optionally substituted.
14. The method according to claim 1, wherein for the
compound of any of formula C, formula D, formula E, or
formula F, the R 1 group is aryl, substituted aryl, heteroaryl, or
alkyl.
15. The method according to claim 1, wherein for the
compound of any of formula C, formula D, formula E, or
formula F, the R 2 group is aryl, substituted aryl, heteroaryl, or
alkyl.
16. The method of claim 1, wherein the compound is

NSC-74859
25

NSC-74859

o\,()
):~
I

30

35

A
Y'OH
C02H

40

or a pharmaceutically acceptable salt or analog thereof.

or a pharmaceutically acceptable salt or analog thereof.

* * * * *
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